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Abstract
Abelson Kinase Based Regulation of HNSCC Tumor Cell Invasion

Karen E. Hayes
Nearly 40,000 new cases of head and neck squamous cell carcinoma (HNSCC) are
annually diagnosed in the United States. The current standard of care for HNSCC
patients consists of chemoradiation often combined with targeted therapeutic agents.
However, the five-year survival rate for patients that relapse is < 50%. Patients with
recurrent or metastatic disease have a very poor prognosis and typical survive < 12
months due to therapeutic resistance and loco-regional invasive spread. HNSCC
invasion is mediated in part by lamellipodia and invadopodia, two actin-based structures
responsible for facilitating invasive movement. Key signaling pathways that govern
lamellipodia and invadopodia production are hyperactivated or overexpressed in
HNSCC, including EGFR, Src, Erk 1/2, and cortactin. The overall goal of this
dissertation is to determine how these signaling components regulate lamellipodia and
invadopodia production and function in HNSCC. Three studies were completed that
address these issues. Study One reveals an anti-invasive function for Abl in
invadopodia regulation in HNSCC, results that are contrary to the pro-invasive influence
Abl has in breast and other cancer types. Study Two establishes a fundamental role for
Src has in HNSCC invasion and metastasis through the use of the dual Src/Abl inhibitor
saracatinib. In Study Three we determine the expression and activation levels of Erk 1/2
in HNSCC patient samples and the role of Erk 1/2 cortactin phosphorylation in HNSCC
adhesion, migration and lamellipodia persistence. Collectively these studies shed new
light into the fundamental mechanisms utilized during various steps in HNSCC invasion,
providing the potential for refinement and development of new avenues for therapeutic
intervention.
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Literature Review
Head and neck squamous cell carcinoma.
Head and neck squamous cell carcinoma (HNSCC) arises in the mucosal epithelial
linings of the oral cavity, oropharynx, nasopharynx, larynx and hypopharynx (1,2). In
the United States approximately 40,000 patients are diagnosed with HNSCC each year,
comprising 3% to 5% of all cancer patients (3). HNSCC can be classified as human
papilloma virus (HPV)-positive or HPV-negative.

The major risk factors of HPV-

negative HNSCC are sustained tobacco and alcohol use, with 90% of HNSCC cases
having a positive correlation. Recently tobacco-associated HNSCC diagnoses have
declined, likely due to the decrease in tobacco consumption in the United States over
the last eleven years.

Conversely, the number of HPV-positive HNSCC patients

continues to increase. (3-5).
Presently, HPV-positive (predominantly HPV type-16) HNSCC patients comprise
approximately 20% of all HNSCC cases, of which 60% to 80% are oropharyngeal-based
cancers (5). HPV is a small circular double stranded DNA virus encoding sequences for
early proteins E1, E2 and E4-E7 and late proteins L1 and L2. HPV transforms epithelial
cells via E6- and E7-mediated regulation of tumor suppressors, p53 and Rb and other
key components while E5 modulates epidermal growth factor receptor (EGFR) and
platelet-derived growth factor receptor (PDGFR) internalization (5,6). In general, HPVpositive HNSCC primary tumors are smaller, poorly differentiated and have a 5-year
survival rate between 70-80%. This survival rate is significantly better than the 5-year
rate for HPV-negative HNSCC, which is less than 50%.

Both HNSCC sub-types

receive the same standard treatment consisting of tumor resection, post-operative
irradiation therapy and/or platinum-based chemotherapy (3,4,7). Regardless of HPV
designation, recurrent and/or metastatic HNSCC patients have an abysmally poor
prognosis with a median survival rate of less than one year despite the addition of
concomitant treatment with the EGFR-targeted pharmacological agent cetuximab (4,8).
In general HNSCC presents as a locoregional disease involving metastasis to cervical
lymph nodes, but distant metastases arise occasionally in lungs, bone, or liver of
1

HNSCC patients (9).

Metastasis is a multi-faceted processes, involving invasion

through the basement membrane and extracellular matrix (ECM), intravasation and
extravasion through vascular endothelial layers, and colonization at distant sites (9,10).
The heterogeneity of tumors and the complexity of the microenvironment perpetuate a
multitude of proposed modes of cell invasion, from collective to single cell
amoeboid/mesenchymal phenotypes (Figure 1) (11).
Methods of cancer cell motility and invasion.
Amoeboid invasion (blebbing or pseudopodal) is generated though physical force that
permits rounded, poorly attached individual tumor cells to push through gaps in loose
connective tissue and induce non-proteolytic deformation of the extracellular matrix.
Amoeboid invasion utilizes bleb-like membrane protrusions, pseudopodia (Rac GTPase
induced cylindrical actin-network based membrane protrusions), or filopodia (Cdc42
GTPase mediated slender membrane protrusions containing cross-linked parallel
filamentous (F)-actin bundles at the leading edge of polarized motile cells.

These

structures assist in mediating the speed and trajectory of the cell during amoeboid

Figure 1
Plasticity of tumor cell
migration. Modes of tumor cell migration
are classified by cellular morphology and
proteolytic activity.
Individual cell
movements: amoeboid mediated by
protease independent and contractile
forces pushing through loose connective
tissue, or mesenchymal mediated by
protease-dependent
degradation
of
extracellular matrix.
Collective cell
movements:
multicellular streaming
mediated by chemotactic signaling and
pathways
generated
by
matrix
remodeling, or collective movement
reliant focalized ECM degradation and
cell-to-cell
contacts
to
generate
directionality.
Friedl, P. and Wolf, K. (2010) J. Cell.
Biol., 188(1), 11-19 (modified).
2

movement (11-13). The myosin II influenced contractile forces utilized to push the cell
forward

are

generated

via

Rho-mediated

activation

of

the

Rho-associated

serine/threonine kinase (ROCK), resulting in simultaneous inactivating phosphorylation
of myosin phosphatase and subsequent persistent phosphorylation of myosin light chain
on threonine 18 and serine 19 to collectively drive cell contraction (14,15).
Mesenchymal motility is a multi-step process dependent on proteolytic activity to
remodel connective tissue. Spindle shaped cells in response to spatial and temporal
signaling extend actin-based protrusion classified as invadopodia.

Invadopodia are

proteolytic actin-rich structures that degrade the ECM or basement membrane.
Invadopodia-generated motility occurs via actomysin-mediated contraction that propels
the cell forward along with retraction of cell posterior (16,17). The plasticity of tumor
cells allows transition from amoeboid and mesenchymal invasion (and vice versa)
based on microenvironment conditions as well as intra- and extracellular signaling cues
(11,18).
Collective cell movement encompasses invading cellular streams and cellular sheets
that maintain cell-cell contact with each other and possess focalized degradation of
ECM at the invasive front.

Cellular stream invasion utilizes cancer associated

fibroblasts (CAF) or mesenchymal tumor cells to generate microtracks in connective
tissue, permitting chain-like migration (19). The intercellular signaling generated from
the cell-cell contact directs cellular collective movement (20). Collective invasion is the
primary invasion mode utilized by HNSCC (18).
This dissertation focuses on two actin-generated organelles, lamellipodia and
invadopodia, that are necessary for these modes of invasion. Lamellipodial-based 2D
invasion occurs at the leading edge of motile cells and possess little to no proteolytic
activity. Lamellipodia are dynamic structures that last only minutes in vitro; they are
responsible for facilitating rapid directional movement. Conversely, invadopodial-based
2D invasion is mediated by proteolytic degradation of ECM on the ventral surface of the
cell. Invasion occurring via invadopodia is generally slow, with invadopodia structures
lasting up to several hours (21). Lamellipodia (or pseudopodia; the 3D equivalent) are
thin sheet-like membrane protrusions induced by extrinsic chemokines or adhesion
3

signaling that function by attaching to the ECM and pulling the cell forward.

The

prototypical Rho-family GTPases Rac1, RhoA and Cdc42, as well as receptor tyrosine
kinases and phospholipids propagate cytoplasmic signaling responsible for stimulating
branched actin-based cytoskeletal networks generating the force required to extend the
membrane (22,23).

Actin nucleating promoting factors (NPFs) are responsible for

lamellipodia extension, where the actin-related protein 2/3 (Arp 2/3) complex forms
branched actin networks, while NPFs of the formin family (e.g.; mDia1), and Spire
(Cordon Blue) facilitate straight actin filament formation that serves as the basis for
subsequent branched Arp2/3-produced networks (24,25).
First observed by Chen et. al., invadopodia are protrusive invasive structures that have
focalized matrix proteolytic activity (26,27).

Invadopodia utilize many of the same

regulatory and actin-nucleating proteins observed in lamellipodia. However, invadopodia
also require the components needed to form microtubules and secrete matrix
metalloproteases to facilitate ECM degradation. This collective activity allows resulting
membrane protrusions to penetrate the basement membrane in order to remodel ECM
(28-30). Invadopodia are complex structures comprising of a central Arp 2/3-generated
F-actin core. Key actin polymerization regulators, including Arp 2/3, cortactin, Tks 5 and
N-WASp localize to the core region and are required for invadopodia formation (30-34).
Invadopodia are produced following stimulation by extracellular cues, where Ras family
GTPases, such as CDC42/CDC42 GEF (Fgd1), non-receptor and receptor tyrosine
kinases (RTKs) are activated (18,21,32,35-38). Src-phosphorylated Tsk5 binds and
recruits the adaptor proteins Nck, cortactin and N-WASp to pre-invadopodia sites
(34,39,40). WIP, Nck, and N-WASp bind Src or Abl/Arg tyrosine kinases, which in turn
tyrosine-phosphorylate cortactin to create docking sites for multimeric protein
complexes (see below for details) that amplify Arp 2/3-mediated actin branching and
subsequent invadopodial membrane protrusion (30,36,37,41). Additional actin binding
proteins assist in modulating invadopodia activity.

For example, the actin binding

protein cofilin regulates invadopodia assembly/disassembly by inducing barbed-end
generation, Arp2/3 filament debranching and actin turnover (32,37,42). Microtubules
and intermediate filaments extend into nascent invadopodia and are essential for
4

elongation (43). Invadopodia also contain radial, unbranched, bundled actin filaments
that are polymerized by formins, where filament ends are uncapped by Ena/Vasp
proteins to facilitate direct actin filament elongation by allowing preferential monomer
addition at the “plus” end near the invadopodia tip (43-46). Parallel actin filaments are
bundled by the proteins fascin, α-actinin and caldesmon to provide structural integrity to
the actin core (43,47-49).

The adhesion proteins talin and paxillin localize to

invadopodia and mediate integrin-based contact with ECM, but oddly the adhesion
proteins focal adhesion kinase (FAK) and vinculin are not found in invadopodia (49-51).
On a cellular level, adhesion and ECM degradation are inversely but tightly regulated;
where degradation of matrix at sites of adhesion is counterproductive to adhesionbased force generation (16,18,52).
Focalized ECM degradation occurs at tips and branch points of elongated invadopodia
(16,18,52,53).

Several proteinases localize to invadopodia that are responsible for

facilitating ECM degradation.

These include matrix metalloproteinases MT1-MMP

(MMP14), MMP2, MMP9, ADAM-family sheddases, cathepsin, seprase, and urokinase
type plasminogen activator (uPAR)) (21,29,54-59). MT1-MMP is widely considered the
major and essential zinc-dependent membrane-bound MMP in regulating and enabling
invadopodia proteolytic activity (the last stage in functional invadopodia maturation), as
manipulation of MT1-MMP expression or activity directly modulates matrix degradation
and invasion (29,57,60-62). MT1-MMP localization to invadopodia can occur through
clatherin-mediated endocytosis (63-66) or by exocytic membrane trafficking (67-69).
Although the majority of work imaging invadopodia has been performed in 2D settings,
invadopodia are believed to exist in vivo, since invadopodia forming cancer cell lines are
more invasive in xenografts models than lines that do not form invadopodia. Also,
primary cells from several tumor types, including HNSCC, bladder cancer and
glioblastomas form functional invadopodia in classic 2D gelatin matrix degradation
assays (70-73).

In addition, invadopodia-like structures have been imaged in

physiological relevant in vivo and ex vivo microenvironments containing key proteins
associated with invadopodia, including N-WASp, Tks5, cortactin and Arp 2/3 that result
in proteolysis of 3D ECM (69,74-77).

Finally, actin-rich protrusive degradative
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structures termed podosomes are related to invadopodia, but are found in nontransformed cell types where they are essential for homeostatic invasive processes
conducted by osteoclasts, macrophages, smooth muscle and endothelial cells (21,78).
Cortactin: A node of actin network regulation.
Wu and Parsons identified cortactin as a substrate of Src kinase that localizes to cortical
F-actin over 20 years ago (79). Cortactin is a NPF that simultaneously activates Arp 2/3
actin polymerization and also serves to stabilize resultant branched actin networks in
lamellipodia and invadopodia (80).

Cortactin is overexpressed in several different

cancer types, including HNSCC (30% of cases), breast (15% of cases), lung, and
bladder. Notably, cortactin overexpression in these and other tumor types is primarily
due to amplification of the cortactin (CTTN) gene on chromosome 11q13 (81-86), where
cortactin gene amplification has emerged as a prognostic marker for poor outcome,
corresponding with increased risk for tumor recurrence and lymph node metastasis
(84,87-90).
Cortactin is a multi-domain, rod-shaped protein that folds back onto itself to form a
“lollipop” shaped structure containing a globular region produced via intramolecular
interactions (80,91).

Cortactin consists of five domains: an amino-terminal acidic

domain (NTA), an F-actin binding domain (FAB), a helical region, a proline-rich region
(PRR), and a Src-homology 3 domain (SH3) (Figure 2) (92).

The NTA region of

cortactin binds Arp 2/3 via the highly conserved DDW amino acid sequence (amino
acids 20-22) found in other NPF proteins (93-96) that directly activates in vitro Arp 2/3
nucleation activity (97). Arp 2/3 activation by cortactin is enhanced through additional
indirect mechanisms that include the recruitment of cortactin binding proteins to other
cortactin domains (41,98-100). Adjacent to the NTA region, the F-actin binding domain
consists of six and a half 37 amino tandem repeats that bind directly bind F-actin
(79,101). F-actin binding is regulated by acetylation/deacetylation of lysine residues
within the repeats region.

The histone acetyltransferases pCAF/p300 and SIRT1

acetylate cortactin and prevent F-actin binding, whereas the histone deacetylase
HDAC6 deacetylates cortactin to facilitate F-actin re-binding (102-104).

Cortactin

binding to F-actin results in increased cell migration and is necessary for invadopodia
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formation and function (104-107). The helical region contains a calpain cleavage site
that results in impaired lamellipodia protrusion and increased migration when
proteolyzed by calpain 2 (108). The PRR and SH3 domains constitute regions that are
responsible for receiving upstream signaling inputs via phosphorylation and regulated
interaction of SH3 binding partners (Table 1) that ultimately govern downstream actinmediated cellular processes (21,80).

Figure 2.
Schematic diagram of cortactin
structure with adapter and signaling partners.
The N-terminal acidic domain (NTA) binds Arp2/3
via a conserved DDW sequence. Adjacent to NTA
domain, the F-actin binding repeat region (R1-R-6
and
1/2),
is
regulated
by
cycles
of
acetylation/deacetylation.
The helical domain
contains a calpain cleavage site.
Serine and
tyrosine residues in the proline-rich region (PRR) are
phosphorylated by Src family and MAPK kinases,
creating docking sites for SH2 domain proteins or
mediating conformational changes to allow ligand binding to the SH3 domain. The
carboxyl-terminal SH3 domain binds several proline-rich proteins regulating multiple
diverse cellular processes. Adaption from L. Kelley dissertation, 2010.
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Table 1. Table of cortactin SH3 binding proteins.
Cortactin SH3 Binding

Function

Reference

Phosphorylation of Y421, Y470, Y486 regulating dorsal waves, lamellipodia and

(110,111,310)

Protein

Abl/Arg

invadopodia

CBP90

A “brain specific” protein that bind cortactin at synaptosomal membrane,

(377)

function unknown

ZO-1

Tight junction adaptor, binds cortactin regulating cell adhesion and spreading

(378-380)

BPGAP1

RhoA-GAP, facilitates cortactin translocation to cell periphery increasing cell

(381,382)

migration

HIP1R

Caps barbed ends inhibiting actin polymerization mediating clatherin-mediated

(383)

endocytosis

BK channels

large conductance calcium- and voltage-activated potassium ion channels,

(384,385)

cortactin mediates Src regulation of BK channel function

ASAP1/AMAP1

Recycling endosomes focal adhesions, invadopodia podosomes/ ARF6 GAP

(386-390)

N-WASp

Neucleating promoting factor, enhances cortactin-based Arp2/3 nucleation

(32,37,100,121,391-

activity

393)

GTPase, cortactin links dynamin2 and actin filament facilitating dynamin2

(277,394-397)

Dynamin 2

remodeling of actin filaments, membrane trafficking

CortBP1/SHANK

Scaffold protein in postsynaptic sites, binds cortactin modulating actin

(398-400)

remodeling

FGD1

CDC42-GEF, enhances cortactin mediated Arp2/3 actin polymerization
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(401,402)

WIP

Forms complex with N-WASp and cortactin enhancing Arp2/3 mediated actin

(98,100,403)

polymerization

Myosin

Light

Chain

Cortactin/MLCK interaction enhances myosin light chain phosphorylation and

Kinase (MLCK)

positively regulates endothelial cell barriers

Missing in Metastasis

Enhances cortactin mediated Arp 2/3 actin polymerization increasing cortactin

(MIM)

induce motility. Src-mediated phosphorylation of cortactin is inhibited by MIM,

(404-407)

(408-410)

enhancing cilia formation

CD2AP

Cortactin binds/recruits CD2AP to lamellipodia, CD2AP recruits barbed end
capping protein (CP) to lamellipodia.

(411,412)

CD2AP binds cortactin and EGFR

regulating EGFR endocytosis

ACK

ACK1 phosphorylates cortactin; ACK1/cortactin interaction mediates EGFR

(413)

internalization

FAK

Non-receptor tyrosine kinase, FAK/Src complex binds and phosphorylates

(133-135)

cortactin stimulating focal adhesion turnover and cell motility and regulates
irradiation induced JAK activation.

The cortactin PRR contains three key tyrosine residues (Y421, Y470, and Y486 in
humans) that are phosphorylated by the Src family kinases Src, Fyn, Syk, and Fer, as
well as the Abl family kinases Abl and Arg (109-113).

Phosphorylation at these

residues creating binding sites for the Src homology 2 (SH2) domain containing
adaptors proteins Nck1 and Crk, as well as mediating Abl family kinase binding
(100,110,111,114).

In the case of Nck1, the Nck1 SH2 domain binds pY421 and

pY466, and recruits the Arp 2/3 NPF, N-WASp; N-WASp PRR domain binds cortacin
SH3 domain creating a ternary complex that amplifies cortactin-based Arp2/3 nucleation
activity indirectly through promoting N-WASp activation (41,100).

The net result of

cortactin tyrosine phosphorylation is increased invasion and metastasis by enhancing
lamellipodia persistence, dorsal wave formation and invadopodia ECM degradation
activity (37,41,110,111,115-119). Protein tyrosine phosphatase 1B (PTP1B) interacts

9

with and dephosphorylates cortactin, consequently reducing cortactin-mediated invasion
and metastasis (120).
Extracellular signal-regulated kinases Erk 1/2 (MAPK 3/1), are two related
serine/threonine kinases that phosphorylate S405 and S418 in the cortactin PPR. Erk
phosphorylation causes a characteristic shift in the Mr of cortactin from 80 to 85 kDa in
SDS-PAGE due to conformational alterations rather then simple addition of phosphate
moieties (121-123).

The close proximity of the targeted serine and tyrosine

phosphorylation sites (especially S418 and Y421) has led to proposals where interplay
between these two different phosphorylation events function in tandem to regulate
cortactin signaling inputs. Work by Martinez-Quilles et al. (2004) with various tyrosine
and serine cortactin phosphorylation mutants in in vitro biochemical assays indicated
that serine phosphorylation by Erk 1/2 enhanced cortactin SH3 domain binding to the NWASp, PRR, resulting in N-WASp activation and Arp 2/3 activation apart from the
tyrosine phosphorylation Nck1/N-WASp mechanism described above. Phosphorylation
by Src led to decreased N-WASp binding and reduced Arp 2/3 actin polymerization.
This group hypothesized that phosphorylation of cortactin serves as an on/off switch,
where serine phosphorylation disrupts the intra-molecular interactions holding cortactin
in a globular form to allow proline-rich proteins (e.g. N-WASp) to bind the exposed SH3
domain and become activated (the so-called “active” cortactin form).

Conversely,

tyrosine phosphorylation was proposed to promote the closed conformation by
permitting re-folding of cortactin into the globular “inactive” conformation. While the
precise mechanism of how Src-based tyrosine phosphorylation promotes cortactin
inactivation was unclear, it was proposed that the modes of the serine/tyrosine switch
function independently (121).

Our lab (Study 3) demonstrated through the use of

phosphospecific antibodies against cortactin Y421 and S418 that phosphorylation of
serine and tyrosine residues occur simultaneously in cells, in contrast to these earlier
findings

(123,124).

Collectively

these

results

suggest

that

cortactin

tyrosine

phosphorylation does not confer a closed “inactive” conformation proposed by the
“serine-tyrosine switch”.

10

In addition to Src-, Abl- and Erk-family kinases, cortactin is also targeted by a variety of
other

kinases.

The

serine/threonine

kinase

p21-associated

kinase

(PAK1)

phosphorylates S405/S418 following activation of Rac1 to regulate N-WASp-mediated
vesicle motility (125). Phosphorylation of cortactin S113 by PAK3 in the first tandem
repeat regulates cortactin binding to F-actin (126). Protein kinase D (PKD) targets
cortactin at S298/S348, inhibiting WAVE2/Arp2/3 mediated actin polymerization (127129). In addition to these examples, there are 15 additional cortactin phosphorylation
sites identified by mass spectroscopy that currently have unknown functions (130).
Moreover, integrin-mediated FAK modulation of cortactin activity has divergent effects in
Src-dependent and Src-independent manner.

The FAK/Src complex binds and

phosphorylates cortactin on Y421, Y470, and Y486 increasing focal adhesion turnover
and cell motility (131-134). Integrin engagement also confers radiation resistance via
FAK/cortactin downregulation of JNK in a Src-independent manner (135).
The carboxyl-terminal cortactin SH3 domain binds a multitude of different proteins
(Table 1). These binding partners mediate cortactin regulation of various actin-based
processes including cellular signaling (Fgd1, BPGAP1, Abl family kinases), actin
polymerization (N-WASp, WASp-interacting protein (WIP)), membrane deformation
(missing in metastatis, (MIM)), cell-cell and cell-substrate adhesion (ZO1 and FAK),
endocytic and exocytic membrane trafficking (ACK1, HIP1R, AMAP, dynamin2,
CortBP1/SHANK2, CD2AP), and actomyosin-based contraction (myosin light chain
kinase (MLCK) (80,136-138).

These processes are collectively involved in cell

migration and utilized in the organization invadopodia assembly. Several studies using
deletion mutants have clearly determined that the cortactin SH3 domain is essential for
proper invadopodia formation and function in cancer cell lines (37,125,139). These
results suggest cortactin creates a nexus for invadopodia regulation and subsequently
serves as a driver of cancer cell invasion.
EGFR: Signaling and significance in HNSCC.
Epidermal growth factor receptor (EGFR, HER1, ErbB1) is a transmembrane tyrosine
kinase that is a member of the ErbB family. Other members include ErbB2 (HER2),
ErbB3, and ErbB4 (140). EGFR contains an N-terminal extracellular ligand binding
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region (domains I-IV), a hydrophobic transmembrane region, and a C-terminal
cytoplasmic consisting of tyrosine kinase and autophosphorylation regions that
propagate “outside-in” signaling (Figure 3) (140,141). There are thirteen distinct ligands
that can bind one or more ErbB receptors, adding to the complexity of ErbB signaling
(142,143). ErbB ligands are produced in the “pro” form and then transported to the
plasma membrane, where they are inserted into the membrane or are exocytosed. In
HNSCC, the sheddases ADAMS 10 or 17 cleave the pro-ligand to create an autocrine
or paracrine signal (144,145).

Alternatively, the uncleaved EGFR ligand heparin

binding-epidermal growth factor (HB-EGF) can bind adjacent cells to generate a
juxtacrine signal (146). Epidermal growth factor (EGF), transforming growth factor α
(TGFα) and amphiregullin (AREG) are common ErbB ligands that preferentially bind
EGFR and are overexpressed in HNSCC, although other EGFR ligands also play lesser
roles in HNSCC progression (143,147,148).
Following ligand binding, ErbB receptors undergo a conformational change exposing a
“dimerization arm” in domain II of the receptor to permit hetero- or homo-dimerization
with a second ErbB receptor. Dimerization activates the tyrosine kinase domain,
facilitating cross autophosphorylation of ten tyrosine sites of dimerized ErbB receptor
cytoplasmic tail.

The phosphorylation pattern varies depending on the ErbB/ligand

combination (149,150). Phosphorylated tyrosines in the EGFR cytoplasmic region bind
SH2 domain-containing scaffold proteins (e.g. Shc, Crk, and Grb2) as well as
downstream signaling proteins (e.g. STAT, PLCγ, and Cbl). EGFR activation regulates
several

critical

signaling

pathways,

mainly

JAK2/STAT,

RAS/Raf/MAPK,

and

PLCγ/PI3K/Akt to govern cellular processes that include proliferation, survival, and
motility (Figure 3) (151-155).

EGFR signal attenuation occurs via clatherin-coated

mediated endocytosis, with the targeting of EGFR-containing endosomes for surface
recycling, degradation, or nuclear localization based on affinity of ligand and
phosphorylation status. ErbB receptors with weakly bound ligands (e.g.; EGFR/TGFα)
are recycled from early endosomes back to cell surface, whereas highly phosphorylated
ErbB receptors are targeted for lysosomal degradation via late endosomes.
Termination of EGFR signaling is assured through SH2 domain-mediated binding of the
E3 ubiquitinase Cbl to phosphorylated tyrosine 1045 on EGFR, leading to ubiquitination
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of EGFR to target it for proteosome-mediated degradation (156-159). EGFR is also
targeted to the nucleus through importin β retrograde transport (160,161), where it
regulates cell proliferation and DNA repair. Nuclear EGFR is also an indicator of poor
prognosis in cancer patients (162,163).

Figure 3. Schematic diagram of EGFR and conical MAPK signaling pathways.
Summary of EGFR-based signal transduction. EGFR extracellular region (domains (dm)
I-IV) binds ligand, dimerizes and cross-phosphorylates a second ErbB receptor.
Activated EGFR triggers three MAPK pathways: JAK/Stat, PI3K/Akt/mTOR, and
RAS/RAF/Erk1/2 signaling cascades regulating transcription of genes that modulate
cellular processes that induce tumorgenesis. Clatherin-mediated EGFR internalization is
regulated by adaptor protein Crk. E3 ubiquitin ligase Cbl targets EGFR for degradation.

In addition to elevated proliferation and survival, activated EGFR regulates cell motility
and invasion in HNSCC and other cancer types. EGFR activation stimulates activation
of Src and Abl family tyrosine kinases that in turn govern the downstream production of
13

lamellipodia and invadopodia (36,37,100,111,115,116,164-168). Invasion and motility
in HNSCC are directly inhibited with the small molecule EGFR targeting drug gefitinib
(115,169,170).

EGFR activation in HNSCC also enhances MMP9 expression and

activation (171,172). These studies suggest a correlation between EGFR activity and
pro-metastatic behavior in HNSCC.
The majority of stage III and IV HNSCC patients develop locoregional reoccurrences
and/or distant metastasis (4,141). EGFR overexpression occurs in >90% of all HPVnegative HNSCC, where it correlates with radiation resistant tumors and locoregional
failures (170,173). Up-regulation of EGFR signaling in HNSCC is further enhanced by
the expression of EGFR ligands. EGF is overexpressed in 65% of cases, TGFα in 90%
and AREG in 45% ((170,174,175).

Recent work indicates that EGFR expression and

activation levels are independent predictors of poor prognosis for HNSCC patients
(176). The observed high rate of elevated EGFR activation is likely not due to activating
point mutations, which rarely arise in HNSCC. However, a truncated version of EGFR
(EGFRVIII) with deletion of exons 2-7 occurs in 17 - 42% of the HNSCC cases (177179). Exon 2-7 deletion removes the extracellular domain, rendering it constitutively
active and resistant to monoclonal antibody-based therapeutic inhibition (177,180,181).
In addition to HNSCC, several other solid tumor types overexpress EGFR, including
non-small cell lung carcinoma (NSCLC, 62%), breast cancer (50-70%) and
glioblastomas (>50%) (182-184).
Multiple therapeutic EGFR inhibitors exist today designed to disrupt or ablate EGFR
dimerization or kinase activity. Prominent examples include cetuximab, panitumumab,
gefitinib, vandetanib, erlotinib and lapatinib. EGFR targeted therapy can be subdivided
into two categories; monoclonal antibodies or small molecule inhibitors (181,185).
Cetuximab is a monoclonal antibody that has been approved for concomitant therapy
with radiation or platinum-based chemotherapy for recurrent or metastatic HNSCC
based on the increased response rate in phase III trial (8,141,186,187). Gefitinib is a
small molecular EGFR inhibitor approved for patient treatment. However, combination
therapy

of

gefitinib

recurrent/metastatic

and

methotrexate

HNSCC

patients

did
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in

phase
not

III

improve

trial

of

overall

chemoresistant
response

rate

(181,188,189).

The high percentage of different solid tumor types combined with

sporadic success of targeted therapeutic approaches continues to keep EGFR in the
spotlight as an important molecular target in head and neck oncology.
Erk1/2: Effector proteins for EGFR signaling.
Extracellular signal-regulated kinase 1 and 2 (Erk 1/2, MAPK 3/1) were the first
discovered members of the mitogen-activated protein kinases (MAPK) kinase family
and are ubiquitously expressed. Erk 1/2 and other MAPK members including c-Jun Nterminal kinase (JNK), p38 MAPK, and Erk5 are serine/threonine kinases activated by
various extracellular cues (190,191). Erk 1/2 proteins are comprised of an N-terminal
domain that facilitates binding to ATP and a C-terminal catalytic domain containing a
conserved “TXY” amino acid sequence targeted by upstream kinases.

A channel

generated between the two terminal domains creates a binding pocket for Erk 1/2
substrates (192-194).
Erk 1/2 has approximately 180 substrates that impact proliferation, differentiation,
cellular survival/apoptosis, differentiation, motility, and invasion (195,196). Given the
complexity of Erk 1/2 signaling network, Erk activity is tightly regulated in a spatial and
temporal manner. The subcellular localization of Erk proteins is determined by several
factors, including binding of Erk 1/2 to the tethering proteins VDAC, SEF, or LSP1 at
mitochondria, Golgi, or the plasma membrane, respectively (195).

Erk 1/2

compartmentalization is also influenced by the duration and strength of upstream EGFR
signals, where strongly EGF-activated EGFR generates a transient cytoplasmic signal,
while weakly bound EGFR ligands initiate sustained Erk activation and relocation of Erk
kinases to the nucleus (140,195).
The mechanism of EGFR-mediated Erk 1/2 activation is well described.

Following

EGFR activation, Src homology 2 containing (Shc) protein binds to phosphorylated
tyrosines on the EGFR cytoplasmic domain. This in turn recruits growth factor bound
protein 2 (Grb2) and son of sevenless (SOS), a RAS guanine nucleotide exchange
factor (GEF). SOS activates one of three different RAS isoforms (H-RAS, N-RAS, or KRAS) by converting GDP-bound RAS to GTP-RAS (197). RAF (A-RAF, B-RAF, or C15

RAF) are a class serine/theronine kinases that localize to the plasma membrane and
are activated by GTP-RAS. Activated RAF in turn phosphorylates mitogen-activated
protein kinase kinase (MEK or MAP2K), resulting in MEK activation (191,195,198,199).
The RAF/MEK complex is stabilized by the scaffold protein kinase suppressor of Ras 1
(KSR1), which also recruits Erk 1/2 (200,201). Activated MEK in turn phosphorylates
Erk 1/2 on T183 and T185 to generate an active kinase (202,203). Once activated, the
protein complex disassociates and releases activate Erk 1/2, which either localizes to
the nucleus to regulate transcription, or to specific cytoplasmic compartments to
regulate other cellular processes (detailed in Figure 4) (191,195,198,199,204).
Since Erk 1/2 controls an array of cellular processes, its activation cycle is tightly
regulated. Erk 1/2 is inactivated by MAPK phosphatases (PP2A and PP2C) (205) and
dual specific phosphatase (DUSP) (206). Erk 1/2 itself also regulates several of the
factors involved in the RAS activation pathway.

SOS phosphorylation by Erk 1/2

disrupts the SOS/Grb2 interaction (207), Erk1/2-mediated phosphorylation of EGFR
Y669 increases EGFR phosphoryaltion and inhibits EGFR degradation, enhancing
EGFR activity (208) RAF and MEK are also inhibited by Erk 1/2 phosphorylation
(209,209,210). In addition, DUSP transcription is induced by Erk 1/2 phosphorylation of
transcription factor Ets (211).

Collectively, Erk 1/2 activation regulates several

feedback loops that converge at multiple levels to provide fine tuning of the Erk 1/2
signaling cascade (191,212,213).
In addition to EGFR, Erk 1/2 activation is facilitated by integrin signaling in a noncanonical manner. Integrin-mediated activation of FAK induces activation of Src, which
initiates Ras activation to increase Erk 1/2 activity (214-216). Erk activation stimulated
by integrin engagement imparts multiple effects that manifest in increased invasion and
metastasis in many tumor types. HNSCC cells plated on fibronectin enhances Erk 1/2
activation (217). FAK activity induced by αVβ3 integrin engagement enhances Erk and
Akt activation, increasing the aggressiveness of chronic myologenous leukemia (CML)
(218). The aforementioned Erk1/2-mediated serine phosphorylation of cortactin
regulates invadopodia proteolytic activity in HNSCC and melanoma cell lines
(115,123,139) and lamellipodia formation in breast cancer lines (123).
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Figure 4. Erk1/2 signaling cascade and regulation of cellular processes.
Summary of the RAS-RAF-MEK-ERK 1/2 activation cascade. Following EGFR
activation, the Grb2/Shc adapter complex activates SOS RAS-GEF activity, stimulating
RAS to activate RAF. RAF/MEK/Erk1/2 form a complex and signaling cascade, RAF
activating MEK, MEK activating Erk 1/2. Erk 1/2 regulates several cellular processes
in the nucleus via several transcription factors to modulate proliferation, differentiation,
cell survival, and migration. Cytoplasmic Erk 1/2 regulation of migration and invasion,
apoptosis, and Golgi fractionation is controlled in part by cytoplasmic location. Erk 1/2
activity is tightly regulated via several negative feedback loops mediated by Erk 1/2.
In HNSCC patient samples with EGFR and TGFα overexpression, Erk activation
correlates with more aggressive recurrent disease and regional lymph node metastasis
(219). Hyperactivation of Erk 1/2 can occur by activating mutations in kinases and
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regulators upstream of Erk activation cascade.

These include gain of function

mutations in RAS (typically K-RAS) that stimulate cell proliferation in 30% of all cancer
and 90% of pancreatic adenocarcinoma patients. Generally, mutations in the P loop
(G12) or catalytic region (Q61) of K-RAS renders K-RAS resistant to GAP inactivation.
Downstream from RAS, B-RAF is commonly mutated in melanoma (39%) and papillary
thyroid (38%) carcinomas. This results in hyperactivation of the closely related C-RAF
as described above. However, RAS and RAF-activating mutations are seldom seen in
HNSCC, suggesting Erk activation is more likely due to integrin engagement, EGFR
activation or other factors (220).
Given the central importance of Erk activity in human cancers, several pharmacological
agents targeting the Erk 1/2 signaling pathway have been generated to date.
Selumetinib (AZD6244, utilized in Study 3) inhibits Erk 1/2 via inhibition of MEK by
functioning as a non-competitive ATP-binding inhibitor. While well tolerated in early
phase I clinical trials, no significant benefit in progression free survival was observed in
colorectal or NSCLC patients treated with selumetinib in phase II trials (220-223). Other
MEK inhibitors in clinical or preclinical trials are CI 1040 (PD184-352) and U0126, which
demonstrate some efficacy in preclinical work, but to date but have not been extensively
tested in the clinic (220). Sorafenib, an inhibitor designed to target all major RAF
isoforms, has shown some efficacy in a phase II trial of hepatocellular carcinoma, but
did not increase the overall survival of patients in a phase III trial (220,224,225). The
overall ineffectiveness of MEK and RAF inhibitors in the clinic suggests that alternative
MAPK pathways are likely compensating to overcome Erk 1/2 inhibition, or Erk is being
activated by alternate mechanisms.
Src: The first oncogene.
Over a century ago, Peyton Rous discovered the first oncogene that caused cancer in
chickens (226). Termed v-Src, the human homolog c-Src was discovered years later
and was subsequently identified as a proto oncogene in human cancers (227). Src is
one member of a kinase family that incorporates a number of related non-receptor
tyrosine kinases including the closely homologous members Yes, and Fyn in epithelia.
Src modulates several cellular processes, including cytoskeletal organization, cell-cell
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interactions, cell-matrix adhesion, EMT, migration and invasion (228,229). Src has a
modular molecular structure, consisting of an N-terminal Src homology 4 (SH4) domain
that is myristolyated to allow membrane association (230-232). SH3 and SH2 domains
are adjacent to the SH4 domain and function to mediate inactivating intramolecular
interactions, as well as for binding to Src adapter and substrate proteins. The SH1
domain contains the catalytic region at the C-terminus (Figure 5) (229,231,233,234).
Within the C-terminal tail is a critical tyrosine residue (Y527) phosphorylated by Cterminal Src kinase (CSK). Phosphorylated (p)Y527 binds the SH2 domain to form a
stable interaction that maintains Src in an inactivate state (235,236). Inactivation is also
reinforced by SH2/SH1 and SH3/linker region interactions (237). Src activation is
accomplished through a multi-step process initiated by the binding of substrates and/or
scaffolding proteins to the SH2 or SH3 domain to disrupt intramolecular interactions
between the catalytic and linker regions. Activation is further achieved through the
action of the tyrosine phosphatases; PTP1B, SHP 1/2, PTPα, which dephosphorylates
Src pY527, fully releasing the C-terminal tail from the SH2 domain to allow “opening” of
Src into the active conformation (238-241). Full activation is achieved by subsequent
autophosphorylation of tyrosine 419 in the kinase domain (237). In cellular contexts,
integrin engagement stimulates formation of FAK/Src or p130CAS (CAS)/Src
complexes through Src SH2 domain binding, achieving similar opening of the kinase
and subsequent Src activation (242). Alternatively, Src activation occurs downstream of
G-coupled protein receptors (GCPR) or the receptor tyrosine kinases PDGFR, EGFR,
FGFR, c-Met, and HER (165,243-250).

Src phosphorylates and activates receptor

tyrosine kinases (e.g.; EGFR) and FAK, creating positive feedback loops that enhance
Src activity.
Src mediates cellular invasion and migration by phosphorylating several key
components involved in these processes. Phosphorylation of paxillin, p130CAS, and
FAK disrupt focal adhesions, enhancing adhesion turnover and subsequent migration
(242,251-254).

Src also hinders contractility by activation of p190RhoGAP (a Src

substrate), inhibiting RhoA/Rho kinase/myosin light chain II (MLC II) mediated
contraction (255-257). Alternately, Src induces RAS-activation to stimulate Erk 1/2
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activation and phosphorylation of myosin light chain kinase (MLCK)/MLC II, increasing
contractility and disassembly of focal adhesions (258,259).
Src phosphorylates several key proteins involved in invadopodia assembly, maturation,
and disassembly. Src phosphorylates and regulates AMAP1 (Arf6 effector protein) and
Tks 4/5, both events that serve to modulate invadopodia actin polymerization and
localization of proteins that initiate invadopodia assembly. AMAP1 binds and localizes
CIN85 and Cbl to invadopodia, increasing ECM degradation.

AMAP1 also binds

cortactin and is required for driving breast cancer cell invasion (260-263). Following Src
phosphorylation, Tks 4/5 activates NADPH oxidase to stimulate reactive oxygen species
(ROS) production, creating a possible positive feedback ROS-induced activation of Src.
Tsk 5 also recruits several key invadopodial proteins including cortactin and Nck
responsible for regulating invadopodia function (34,39,40,264-268).

In addition, Src

mediates invadopodia maturation via regulation of MMP production and secretion by
modulating PI3K, MAPK, and JAK/STAT activation (269-271). Src modulates vesicle
trafficking through phosphorylation of endophilin A2, Cdc42-interacting protein (CIP4),
and dynamin2. Src phosphorylation of CIP4 (Y471) inhibits CIP4 mediated endocytosis
of MT1-MMP, which results in elevated surface expression of MT1-MMP, increasing
invadopodia proteolytic activity (272). Src phosphorylation of Endophilin A2 tyrosine
315 functions in a similar manner, increasing invadopodia activity by inhibiting
endophilin-induced MT-MMP endocytosis (273). In addition, dynamin requires Src
phosphorylation at tyrosine sites 231/597 to mediate clathrin-coated endocytosis of
MT1-MMP (274-277).
Cortactin tyrosine phosphorylation is crucial for invadopodia maturation, where Src
regulates cortactin phosphorylation directly or indirectly via Abl/Arg family kinases
(37,41,110,111,115-119). How Src controls invadopodia disassembly is not as clear,
but Src phosphorylation of paxillin Y31 and Y118 promotes invadopodia disassembly,
providing at least one mechanism (278,279). Calpain 2 and PTP1B function together to
regulate invadopodia function, where calpain induces invadopodia turnover potentially
via Pyk2, WASP, and talin cleavage (Figure 5) (280,281).
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Figure 5. Schematic diagram of Src, activation and downstream signaling
pathways.
Overview of Src-based signaling in invasion and proliferation. Src becomes activated
as described in the main text, where it stimulates several signaling cascades including
RAS/RAF/MEK/MAPK, JAK/STAT, and PI3K/Akt cascades regulating transcription,
proliferation, cell survival and angiogensis. Src also phosphorylates several key
components involved in contractile and mesenchymal-based migration and invasion.

Src overexpression frequently occurs in HNSCC, where its activation correlates with
poor prognosis (282). Src activation can be enhanced via several mechanisms that
occur in HNSCC and other cancer types, including downregulation of CSK expression,
PTP1B overexpression, activation of receptor tyrosine kinases, or activation of integrins
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through ECM alteration (283).

Importantly, ionizing radiation, which is frequently

utilized as first line therapy in HNSCC and other cancers, stimulates Src activity due to
the generation of reactive oxygen species (ROS) increasing the potential for triggering
invasion and metastasis in radiation-resistant and recurrent tumors (284).
The inhibition of Src activity has become an important pursuit for molecular therapeutics
since Src is a key regulator of many of processes utilized in tumorigenesis. Dasatinib,
saracatinib, and bosutinib are three Src inhibitors undergoing phase I and II trials as
single agents or combination therapy with conventional chemotherapeutics.

These

inhibitors all function in a similar manner by blocking ATP binding to the SH1 catalytic
domain and have off-target effects, one of which includes serendipitous inhibition of Abl
family kinases (283,285).

Dasatinib (BM354825) treated HNSCC cell lines display

reduced activation of Akt and Erk 1/2, resulting in impaired Bcl-2 expression, growth
inhibition and increased apoptosis (286,287). In recent studies, dasatinib treatment
inhibited invasion and metastasis of pancreatic cancer cell lines (288,289). Preclinical
trials with dasatinib-treated breast cancer cell lines showed reduced proliferation,
migration and invasion (290-292). However, recent phase II trails with breast cancer
demonstrated minimal added benefit with dasatinib treatment (293-295). Our laboratory
(Study 2) and others have demonstrated that saracatinib (AZD0530) treatment inhibits
Src and FAK activity in HNSCC cell lines, causing reduction in proliferation and
migration in vitro and in vivo (296,297).

In several studies, saracatinib treatment

inhibited pancreatic tumor xenograph growth and downstream phosphorylation of the
Src substrates FAK, paxillin, and STATs (298,299). Use of saracatinib in a phase II trial
also demonstrated minimal efficacy in patients with advanced melanoma (300).
Abl: A kinase with dichotomous roles.
Abl (Abl1, c-Abl) and Arg (Abl2) are non-receptor tyrosine kinases with 90% homology
in the N-terminal region but with extremely variable C-termini (< 28% homology) (301).
The N-terminal domain, similar to Src, contains a capped region that may be posttranslationally modified by myristoylation, generating two isoforms (Abl1a and Abl1b)
(302,303). Adjacent to the capped region are highly conserved SH3 and SH2 domains
(304). Attached by a linker region to the SH2 domain, a tyrosine kinase domain targets
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substrates with (L/I/V)-Y-x-x-P consensus sequence (305). Abl family kinases have
over one hundred identified and potential substrates (306). Unlike other Src family
kinases, Abl family kinases have a C-terminal region that consists of several proline-rich
regions (Abl has four, Arg three) interspersed with three nuclear localization sequences
(Abl only) (307,308). Abl and Arg diverge structurally in the C-terminal region, where
Abl consists of a DNA binding region, a G-actin binding domain, and a F-actin binding
region with an embedded nuclear export sequence (309-312). The Arg C-terminus
includes two F-actin binding domains, a G-actin binding domain and a microtubule
binding domain (Figure 6) (313,314). These differences confer some of the divergent
functions for Abl and Arg in the cell. Arg is solely a cytoplasmic protein that functions to
regulate actin-based lamellipodia and invadopodia, but additionally bundles actin
filaments and connects actin networks with microtubules. Abl shuttles between the
cytoplasm, where it also regulates dynamic actin structures, and nucleus where it is key
in governing transcription, cell cycle progression and DNA damage response (315,316).
Abl family kinases, like Src, are tightly controlled by intramolecular interactions. Abl is
held in an inactive conformation by binding of the myristolated tail within a hydrophobic
pocket in the kinase domain (302,303,317). Interactions between the SH3 and SH2
domains with the kinase domain also help hold Abl in an inactive state (304,317). Abl
becomes weakly activated by disruption of intramolecular interactions following binding
of substrates/ adapter proteins to the SH3 and SH2 domains (302). To achieve full
kinase activity, Src phosphorylation of Abl or Abl trans-phosphorylation of Y245 in the
linker region and Y412 in the kinase domain activation loop is mandatory (165,315,318320). Additional Abl sites are phosphorylated that regulate protein stability (Y89 and
Y261), kinase inhibition (Y272), activation (Y276), generation of potential SH2-binding
sites (Y158, Y331, Y134, Y147, Y251, Y276), or are acetylated to control nuclear export
(K730) (306).
Abl family kinases are activated by several extracellular signals, EGFR, PDGFR,
insulin-like growth factor 1 receptor (IGFR), integrin signaling, bacterial invasion,
genotoxic and oxidative stress (165,308,321-323). Upon activation via RTK or integrins,
activated Abl family kinases localize to the cell periphery, where they regulate actin23

based processes including lamellipodia protrusion and invadopodia maturation
(36,37,110,111,308,315,324,325).

Abl

enhances

actin

polymerization

via

phosphorylation of the NPFs WAVE2, N-WASp and cortactin. Abl also phosphorylates
the adaptor protein Nck1 and the actin filament capping protein Ena, enhancing Enamediated actin filament elongation (37,111,307,315,326,327).
Abl kinases directly and indirectly modulate cell migration and invasion.

Arg

phosphorylates p190RhoGAP, preventing binding to p120RasGAP and subsequent
relocation of p190RhoGAP/p120RasGAP complex to cell periphery, thus preventing
Rho GTPase activation reducing myosin-induced contractility (328,328,329). PDGFR
mediated Rac activation is modulated by Abl; although the mechanism has yet to be
defined it is likely via Abl phosphorylation of SOS1 an RASGEF (330,331).

Abl-

mediated phosphorylation of CrkII (Y221) and paxillin disrupts the Crk/CAS/Paxillin/FAK
complex, resulting in disassembly of focal adhesions (308,332-337).

Abl indirectly

activates STAT3 to induce MMP1 transcription; Arg activates MT-MMP, MMP1, and
MMP3 transcription in an undefined STAT3-independent manner. Additionally, Abl/Arg
potentially mediate MT1-MMP endocytosis by directly binding and phosphorylating
MT1-MMP (324,325).

Collectively these cellular processes confer pro-invasive and

anti-invasive phenotypes dependent on the substrate and cellular localization of Abl or
Arg.
Nuclear localization of Abl occurs in response to genotoxic or oxidative stress
(321,322,338,339).

Ataxia telangiectasia mutated protein (ATM) activates Abl in

response to DNA damage (340,341).

Activated Abl phosphorylates murine double

minute 2 (MDM2) at tyrosine 394 an E3 ubiquitin ligase that targets p53 for degradation
causing the disruption of the MDM2/p53 interaction protecting p53 from degradation
(342-345). Abl stabilizes ATM/p53 complex facilitating ATM serine phosphorylation of
p53 and subsequent accumulation of p53 in the nucleus regulating cell cycle arrest
and/or apoptosis by transcription of p21 and CDK2 or BAX, BCL2, PUMA, and NOXA
(346,347).

Abl initiates DNA repair mechanisms or induces apopotosis by

phosphorylating and activating several key proteins including ATM, several RAD
proteins, damaged DNA-binding (DDB 1/2), and DNA-activated protein kinase (DNAPK)
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(348-351). Abl also regulates cell cycle progression, where phosphorylation of RNA
polymerase II induces transcription of S phase genes and cell cycle progression from S
to G2-M (342,352). Collectively, Abl is considered a pro-apoptotic regulator following
nuclear localization and activation (Figure 6) (316,353).

Figure 6. Schematic diagram of Abl structure, activation and downstream
signaling pathways.
Abl a non-receptor tyrosine kinase becomes activated via external stimuli;
phosphorylation and binding of SH3/SH2 binding partners containing proline-rich
regions or phosphorylated tyrosines. Activated Abl, in the cytoplasm, mediates
processes utilized for motility and invasion (detailed in text). In the nucleus, Abl
regulates transcription directly or indirectly via transcription factors controling cell cycle
arrest, DNA repair, and apoptosis.
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Abl activation is attenuated by several mechanisms including de-phosphorylation by
tyrosine phosphatases including PTPN1 or PTP-PEST (354). Phosphatidylinositol-4,5bisphosphate (PIP2) binds Abl preventing substrate binding; the PIP2 inhibitory
interaction is relieved by phospholipase C (PLC) hydrolysis of PIP2 (164,355). Caspasecleavage of Abl at Argine 565 or ubiquitinatation and proteosomal degradation
downregulate Abl signaling (338,356-358).
Abl has long been considered an oncogene in the context of the Philadelphia
chromosome BCR-Abl gene product. BCR-Abl an oncogenic fusion of the Abl kinase
domain with the breakpoint cluster region (BCR), giving rise to a constitutively active Abl
kinase by the removal of first exon and subsequent loss of inhibitory intramolecular
interactions within Abl. BCR-Abl is associated with the onset and progression of chronic
myelogenous leukemia (CML) (359,360). The role of Abl in solid tumors is not as well
defined, as recent work described below indicates that Abl family kinases function in a
context dependent manner, possessing pro- or anti-oncogenic functions in cancer.
Research with a panel of breast cancer cell lines suggested that kinase activation and
not expression of Abl family kinases correlates with breast cancer invasiveness
(361,362). Mader et.al. and others have shown the loss of invadopodia proteolytic
activity with imatinib-treated breast cancer and melanoma cell lines, leads to the
proposal of

an EGFR/Src/Arg/cortactin signaling pathway responsible for mediating

invadopodia regulation (36,324). The imatinib-mediated inhibition of ECM degradation
in breast cancer lines can be attributed in part to regulation of MMP 1, 3, and MT1-MMP
transcription and secretion regulated by Abl and Arg (324,325). In NSCLC, inhibition of
Abl with FUS1 or pharmacological agents reduced anchorage-independent growth,
while Abl phosphorylation of Crk correlates with tumor cell aggressiveness (363).
Collectively these studies suggest a pro-oncogenic role for Abl family kinases.
Alternately, reduction of Abl expression in HNSCC is associated with a poor patient
survival (364). Inhibition of Abl expression or activity reduces invadopodia proteolytic
function and invasion (115). Similar results were observed in work on breast cancer
lines by other groups, where Abl mediates EphrinB1/EphR4 inhibition of cell migration
and suppresses TGFβ-induced epithelial-to-mesenchymal transition (EMT) (365).
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Additionally, Frasca et al. demonstrated that HGF-simulated thyroid cancer cell lines
treated with imatinib had elevated Erk and Akt activity, increased motility and an EMTlike phenotype following long-term drug exposure (366). These results indicate an antioncogenic role for Abl.
Imatinib mesylate (Gleevac, STI571) is a competitive ATP inhibitor and first line therapy
for CML patients. This compound is extremely effective, demonstrating a 90% overall
response rate in patients following initial treatment (367). Second line therapies that
target Abl kinase in BCR-Abl containing malignancies include nilotinib, dasatinib,
bafetinib (INNO-406) and decipere (DCC-2036).

These compounds have been

developed to treat imatinib-refractory patients and are currently in pre-clinical, phase I
and II trials (368). Nilotinib and dastinib have a 50% complete response rate in phase II
trials with imatinib-resistant CML patients (368). The efficacy of Abl inhibitors in CML
and gastrointestinal stromal tumor (GIST) patients supports a pro-oncogenic role,
advocating the use of imatinib for patients with solid tumors (369). Even though preclinical studies have demonstrated efficacy with imatinib in NSCLC and breast cancer
cell lines, clinical phase I and II trials have shown no therapeutic benefits. In fact,
disease progression was observed in a phase II prostate cancer trial. Furthermore, a
combined HNSCC/NSCLC phase II trial was terminated early due to detrimental effects
in patients treated in the imabinib-containing arm (370-374,374-376). The pro- and antioncogenic impact of Abl inhibition in solid tumors necessitates further investigation to
determine the underlying molecular determinates responsible for the opposing
oncogenic roles of Abl kinases in human cancers.
As detailed in this review, EGFR, Erk 1/2, Src, and Abl have complex signaling
cascades dependent upon extracellular cues, upstream activators, cellular location, and
downstream effectors. In pre-clinical studies, EGFR, Erk 1/2, Src, and Abl have been
shown to be crucial for tumorigenesis in several cancer types, including breast and
HNSCC. Unfortunately, the various pharmacological agents targeting these kinases
(EGFR, Src, Abl) or up-stream activators (RAS, RAF for Erk1/2) typically demonstrate
negligible therapeutic benefit; in fact detrimental effects have been reported in
pancreatic, NSCLC and HNSCC cancer patients.
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Clarification and increased

understanding of the spatial and temporal molecular signaling of these key proteins is
essential for improved therapy utilizing these pharmacological agents. The specific goal
of this dissertation is to clarify the regulation of key signaling molecules that modulate
HNSCC invasion and metastasis.
In Study 1, we elucidated the regulatory hierarchy of several proteins critical for invasion
of HNSCC and breast cancer cell lines. In particular, we focused on Abl, a protein that
has opposing roles in tumorigenesis. Our results demonstrate a divergent role for Abl
function in invasion, where Abl kinase activity is pro-invasive in breast cancer and antiinvasive in HNSCC. Regardless of tumor type, the EGFR/Src pathway is crucial to
mediate invasive regardless of divergent cellular response evoked with imatinib-treated
HNSCC and breast cancer cell lines.
In Study 2, we further established the crucial role Src in HNSCC metastasis in vitro and
in vivo. In addition, we examined effects of pharmacological inhibition of Src/Abl activity
with saracatinib on downstream Src effectors and cellular processes important for
tumorigenesis. We determined that Src/Abl inhibition reduced HNSCC proliferation and
invasion in accordance with impaired invadopodia formation and MMP secretion.
Finally, in Study 3 we determined a functional role for Erk 1/2 activation and
phosphorylation of the downstream substrate cortactin in HNSCC patient samples and
cell lines, where we showed that Erk 1/2-mediated cortactin phosphorylation modulates
HNSCC adhesion and promotes migration by prolonging lamellipodia persistence.
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Abstract
Head and neck squamous cell carcinoma (HNSCC) has a proclivity for locoregional
invasion. HNSCC mediates invasion in part through invadopodia-based proteolysis of
the extracellular matrix (ECM). Activation of Src, Erk1/2, Abl and Arg downstream of
epidermal growth factor receptor (EGFR) modulates invadopodia activity through
phosphorylation of the actin regulatory protein cortactin. In MDA-MB-231 breast cancer
cells, Abl and Arg function downstream of Src to phosphorylate cortactin, promoting
invadopodia ECM degradation activity and thus assigning a pro-invasive role for
Ableson kinases. We report that Abl kinases have an opposite, negative regulatory role
in HNSCC where they suppress invadopodia and tumor invasion. Impairment of Abl
expression or Abl kinase activity with imatinib mesylate enhanced HNSCC matrix
degradation and 3D collagen invasion, functions that were impaired in MDA-MB-231.
HNSCC lines with elevated EGFR and Src activation did not contain increased Abl or
Arg kinase activity, suggesting Src could bypass Abl/Arg to phosphorylate cortactin and
promote invadopodia ECM degradation.

Src transformed Abl-/-/Arg-/- fibroblasts

produced ECM degrading invadopodia containing pY421 cortactin, indicating that
Abl/Arg are dispensable for invadopodia function in this system.

Imatinib treated

HNSCC cells had increased EGFR, Erk1/2 and Src activation, enhancing cortactin
pY421 and pS405/418 required for invadopodia function. Imatinib stimulated shedding
of the EGFR ligand heparin-binding EGF-like growth factor (HB-EGF) from HNSCC
cells, where soluble HB-EGF enhanced invadopodia ECM degradation in HNSCC but
not in MDA-MB-231. HNSCC cells treated with inhibitors of the EGFR invadopodia
pathway indicated that EGFR and Src are required for invadopodia function.
Collectively our results indicate that Abl kinases negatively regulate HNSCC invasive
processes through suppression of an HB-EGF autocrine loop responsible for activating
a EGFR-Src-cortactin cascade, in contrast to the invasion promoting functions of Abl
kinases in breast and other cancer types. Our results provide mechanistic support for
recent failed HNSCC clinical trials utilizing imatinib.
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Introduction
HNSCC is an aggressive disease characterized by extensive locoregional invasion and
cervical lymph node metastasis (1,2). Overexpression of EGFR is common in HNSCC
and correlates with enhanced invasion and nodal involvement (3-6). EGFR inhibition as
adjuvant therapy in HNSCC increases survival, highlighting the importance of
downstream EGFR signaling pathways in HNSCC progression (7). Downstream EGFR
signaling cascades in HNSCC that promote invasion and metastasis utilize Src, Erk, PI3
kinase, Akt and STATs (8-11), supporting a role for EGFR-generated signals as
important regulators of invasion promoting pathways in HNSCC.
Src kinase activation within the EGFR pathway is critical for driving tumor invasion
(12,13). Elevated Src expression and activity is frequently found in HNSCC and other
tumor types, where it has become a focus for targeted therapeutic design (14,15).
While Src targeted drugs have been developed and demonstrate anti-invasive
properties in preclinical studies (16-19), recent phase II trials demonstrate virtually no
benefit for HNSCC patients with monotherapeutic Src inhibitor treatment (19,20). While
combination therapy with receptor tyrosine kinase inhibitors increases efficacy (21-23),
a clearer mechanistic understanding of how Src-based signaling governs HNSCC
invasion is needed for the development of improved therapeutic strategies.
In carcinomas, Src activation results in the formation of invadopodia, actin-rich
membraneous protrusions responsible for extracellular matrix (ECM) proteolysis,
allowing tumor cells to infiltrate the stroma and vasculature (24,25). Src kinase activity
regulates the cyclic development of non-degradative (pre-invadopodia) and active
(mature) invadopodia (24,25). Maturation of pre-invadopodia involves recruitment and
activation of matrix metalloproteinase MMP-14 to initiate ECM degradation (26-28).
Invadopodia maturation also involves increased F-actin polymerization responsible for
driving plasma membrane protrusion (24,25,29).

A prominent component of the

invadopodia F-actin core is cortactin, an F-actin binding protein that activates the actinrelated protein (Arp)2/3 complex to stimulate branched actin polymerization (30-33).
Cortactin binds neuronal Wiskott-Aldrich Syndrome protein (N-WASp), a second
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activator of Arp2/3 complex following phosphorylation of cortactin S405 and S418 by
Erk1/2 (33-35).

Cortactin modulates shifting of pre- to mature invadopodia through

phosphorylation of two Src-targeted tyrosine residues (Y421 and Y470 in humans)
(27,28,36). Y421 and Y470 phosphorylation results in SH2-dependent recruitment of
the adaptor protein NCK1, which in turn binds and activates N-WASp to promote
additional Arp2/3 activation (28,37-39). Along with tyrosine phosphorylation, cortactin
domains that bind Arp2/3 and N-WASp are also required for invadopodia formation,
collectively highlighting the importance of cortactin in invadopodia biogenesis and
regulation (28,40,41).
The Abelson kinases Abl and Arg regulate actin cytoskeletal remodeling during motility
and invasion (42-44).

While Abl regulation of leukemic tumorigenesis is well

established (45,46), Abl activity in solid tumors promotes multiple aspects of neoplastic
progression, including increased invasion and metastasis (47-50). Activation of Abl and
Arg downstream of EGFR and Src leads to direct cortactin phosphorylation at Y421 and
Y470 responsible for invadopodia maturation in breast cancer and melanoma cell lines
(51-55). In particular, Src-mediated activation of Arg and subsequent cortactin tyrosine
phosphorylation has led to the proposal that Arg is the terminal kinase responsible for
cortactin tyrosine phosphorylation required for invadopodia maturation (51,56).
Since invasive HNSCC typically contains elevated EGFR and Src activity, we postulated
that downstream activation of Abl kinases may regulate invadopodia through cortactin
phosphorylation in this tumor type.

Paradoxically, we show that elimination of Abl

expression results in enhanced invadopodia-based gelantinase activity in multiple
HNSCC cells lines but not in MDA-MB-231 cells. Inhibition of Abl family kinase activity
with imatinib mesylate (STI571; Gleevac) in HNSCC cells resulted in enhanced
invadopodia maturation and cell invasion, whereas these processes were impaired in
MDA-MB-231.

Analysis of EGFR signaling indicates that EGFR and Src are

hyperactivated in HNSCC compared to MDA-MB-231 cells. Introduction of active Src
into Abl-/-/Arg-/- cells induced invadopodia formation, ECM matrix degradation and
cortactin tyrosine phosphorylation, suggesting that elevated Src activity can bypass the
requirement for Abl or Arg in invadopodia maturation. Imatinib treatment of HNSCC
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cells resulted in dose-dependent activation of EGFR, Src and Erk1/2, resulting in
elevated cortactin tyrosine and serine phosphorylation absent in treated MDA-MB-231
cells.

Imatinib enhanced production and shedding of the EGFR ligand HB-EGF in

HNSCC cells, where soluble HB-EGF stimulated HNSCC ECM degradation. Inhibition
of Src and Abl kinases with the dual specificity drug saracatinib suppressed EGFR
activation and ECM degradation in HNSCC, suggesting that Src is responsible for
mediating the pro-invasive signals resultant from imatinib-mediated Abl family kinase
inactivation.

Our results indicate that in HNSCC Abl kinases serve to suppress

invadopodia formation and tumor cell invasion by downregulating autocrine HB-EGF
activation of the EGFR-Src-cortactin signaling pathway, in contrast to the pro-invasive
function of Abl and Arg in breast and other solid tumors. These results suggest that Abl
kinase function in cancer invasion is context dependent, providing molecular insight into
the mechanism behind the recent failure of clinical trials with imatinib in HNSCC
patients (57).
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Results
Abl expression suppresses invadopodia activity in HNSCC cells
Since HNSCC cells form invadopodia (36,58) and Abl kinases mediate invadopodia
function in other tumor types (51,53,55), we evaluated the role of Abl in HNSCC
invadopodia formation and function. HA-tagged Abl localized within UMSCC1
invadopodia (Figure 1a) and in Src-expressing 1483 cells (Supplementary Figure 1a),
implying a functional role. This was investigated by knockdown of Abl expression using
RNA interference (RNAi).

Stable UMSCC1 clones expressing an Abl-specific short

hairpin RNA (shRNA2 and 3) reduced Abl expression by 65% compared to controls
(Ctl2 and 8) (Figure 1b).

Expression of wild-type (WT) murine Abl in shRNA cells

restored expression to endogenous levels (WT5 and 6). Abl knockdown resulted in a
44% increase in gelatin degradation compared to control (Ctl) and WT lines (Figure 1cd) without affecting the number of cells degrading ECM or the number of invadopodia
per cell (Supplementary Figure 1b-c). Abl knockdown in MDA-MB-231 cells did not
impact matrix proteolysis (Supplementary Figure 2a-c), in agreement with previous
results (51). These data suggest that Abl expression negatively regulates invadopodia
function in HNSCC cells, as opposed its invadopodia promoting role in other tumor cell
types (51,53,55).
Imatinib treatment enhances HNSCC invadopodia activity
To determine if Abl kinase activity was responsible for the negative regulatory effects
on invadopodia function in HNSCC cells, OSC19 and UMSCC1 cells were treated with
the Abl family kinase inhibitor imatinib mesylate.

Analysis of Crk phosphorylation

confirmed partial inhibition of Abl kinase activity in imatinib-treated lines (Figure 2a).
Imatinib treatment resulted in a dose-dependent increase in OSC19 and UMSCC1 ECM
degradation, demonstrating a net 2.5-3.0-fold enhancement observed at the highest
tolerated concentration (15 µM) (Figure 2b-c, 2e).

In contrast, MDA-MB-231 cells

treated with imatinib resulted in a 70% reduction in matrix proteolysis (Figure 2d-e).
The effects on treated HNSCC and MDA-MB-231 cells is likely Abl family kinase
specific, since the alternative imatinib target PDGFR is not expressed in these lines
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(Supplementary Figure 3). These data indicate that imatinib impairment of Abl family
kinase activity in HNSCC relieves the inhibitory effect of Abl on invadopodia function,
promoting ECM degradation.
Imatinib treatment stimulates HNSCC invasion
To determine if imatinib-enhanced HNSCC invadopodia activity corresponds with
increased invasive behavior, 3D invasion assays were conducted using tumor spheroids
embedded in collagen I.

OSC19 and UMSCC1 cells treated with 10 µM imatinib

resulted in enhanced invasion, whereas invasion of imatinib-treated MDA-MB-231 cells
was inhibited after 24 h (Figure 3a-c). Average invaded distances were increased by
100 µM for OSC19 and 204 µM for UMSCC1 cells, while MDA-MB-231 invasion was
suppressed by 47 µM (Figure 3d). These results indicate that imatinib treatment has
opposing effects on tumor cell invasion, enhancing HNSCC cell invasion while impairing
the invasiveness of MDA-MB-231.
Activated Src can bypass Abl and Arg to promote invadopodia formation
To address the contrasting invasive roles of Abl family kinases in HNSCC and MDAMB-231 cells, protein levels and activation of known invadopodia kinases were
evaluated. Western blotting demonstrated increased Abl expression in HNSCC lines
compared to MDA-MB-231 cells, whereas Arg protein levels were equivalent (Figure
4a).

In spite of increased Abl expression in HNSCC cells, Abl activation was not

enhanced, as evidenced by similar Crk pY221 levels between HNSCC and MDA-MB231 cells. However, OSC19 and UMSCC1 consistently displayed increased EGFR and
Src activity compared to MDA-MB-231 (Figure 4a).
The increased Src activation in HNSCC cells suggested that active Src might directly
regulate invadopodia activity independent of Abl and Arg.

To test this, Abl-/-/Arg-/-

mouse embryo fibroblasts (DKO) were used to simultaneously evaluate the role of Abl
and Arg on invadopodia function. Lack of Abl and Arg expression in DKO cells was
verified by immunoblotting (Supplementary Figure 4a). EGF stimulation of wild-type
(WT) MEFs demonstrated a threefold increase in cortactin pY421 over non-stimulated
controls, whereas stimulated DKO cells showed a 1.5 fold increase over basal levels
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(Figure 4b). While these results confirm that Abl and Arg contribute to cortactin tyrosine
phosphorylation, they also indicate that additional cortactin tyrosine kinases are utilized
downstream of EGFR. To determine if activated Src promotes invadopodia formation
independent of Abl and Arg, WT and DKO cells transfected with activated Src (527F)
were assayed for cortactin tyrosine phosphorylation, invadopodia formation and ECM
proteolysis.

DKO cells expressing 527F Src contained abundant invadopodia with

pY421 cortactin that degraded ECM, similar to 527F Src-transformed WT cells (Figure
4c). The ability of DKO cells to degrade gelatin matrix was dependent on Src kinase
activity, since kinase inactive Src (K295M) failed to promote matrix proteolysis (Figure
4d).

Expression of 527F Src in DKO cells resulted in an 86% increase in matrix

degradation area compared to 527F Src-expressing WT cells (Figure 4d-e,
Supplementary Figure 4b). The amount of gelatin degradation per cell area in DKO
527F Src cells was inhibited by 60% following re-expression of WT Abl (Figure 4d-e), in
agreement with increased matrix degradation by UMSCC1 cells with Abl knockdown
(Figure 1c-d).

Collectively these results indicate that Abl expression suppresses

invadopodia activity in Src-transformed mouse embryo fibroblasts, and that Abl and Arg
are not essential for cortactin tyrosine phosphorylation or invadopodia formation
downstream of active Src.
Imatinib treatment enhances activation of the EGFR-invadopodia signaling
pathway in HNSCC
To determine the basis for the differential regulation of invadopodia activity and invasion
when Abl/Arg activity is suppressed in HNSCC and MDA-MB-231, cells treated with
imatinib were evaluated for activation of EGFR and downstream invadopodia signaling
components. Increased EGFR activation was observed in imatinib-treated OSC19 and
UMSCC1 cells, whereas no increase was observed in MDA-MB-231 (Figure 5a,
Supplementary Figure 5a). A corresponding activation pattern was found for Src and
Erk.

Imatinib ablated Crk pY221 phosphorylation in MDA-MB-231, indicating that

Abl/Arg-based signaling was inhibited.

Crk pY221 phosphorylation was partially

impaired in imatinib-treated HNSCC lines (Figure 5a) and was further downregulated
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when combined with the Src inhibitor SU6656 (59) (Supplementary Figure 5b),
suggesting that Crk is targeted by Src and Abl kinases in HNSCC.
Since Src and Erk regulate invadopodia in part by phosphorylating cortactin (28,36,40),
cortactin tyrosine and serine phosphorylation was evaluated in imatinib-treated HNSCC
and MDA-MB-231 cells.

The Erk-targeted cortactin residues S405 and S418

demonstrated elevated phosphorylation in imatinib-treated OSC19 and UMSCC1 cells,
corresponding with increased Erk 1/2 activation, while treated MDA-MB-231 cells did
not demonstrate a substantial increase in cortactin phosphorylation (Figure 5b).
Imatinib stimulated cortactin Y421 phosphorylation in HNSCC cells (Figure 5c), likely
due to increased Src activation (Figure 5a). These data support activation of the EGFRSrc/Erk-cortactin pathway by imatinib in HNSCC cells that can bypass Abl/Arg inhibition
to promote invadopodia activity and HNSCC invasion.
Imatinib stimulates HB-EGF synthesis and promotes HNSCC invadopodia activity
Imatinib treatment of multiple HNSCC lines results in synthesis and secretion of the
EGFR ligand HB-EGF, enhancing EGFR activity (60). Lysates from imatinib treated
OSC19 and UMSCC1 cells contained increased HB-EGF compared to controls,
whereas HB-EGF levels in MDA-MB-231 cells were unaltered (Figure 6a). Conditioned
media from imatinib-treated HNSCC cells contained increased soluble HB-EGF at levels
2.5-3.0 fold higher than from MDA-MB-231 cells (Figure 6b). Addition of recombinant
HB-EGF to cells at concentrations equivalent to HB-EGF levels in imatinib-treated
conditioned media enhanced ECM degradation activity by 86% in OSC19 and 30% in
UMSCC1 cells, but did not increase invadopodia activity in MDA-MB-231 cells (Figure
6c-d). These results suggest that increased imatinib-induced HB-EGF expression and
shedding by HNSCC cells produces an autocrine loop that stimulates EGFR activation
responsible for enhancing invadopodia-mediated ECM proteolysis.
Invadopodia ECM degradation promoted by impaired Abl kinase activity requires
activation of EGFR and Src
To further confirm that Src regulates HNSCC invadopodia downstream of EGFR apart
from Abl kinases, pharmacological agents targeting EGFR, Src, or simultaneous Abl/Src
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inhibition were evaluated for their impact on gelatin degradation in HNSCC. UMSCC1
cells treated with the EGFR inhibitor gefitinib at 5 µM reduced EGFR activation by 60%
(Supplementary Figure 6a) and matrix degradation by 50% (Figure 7a). Similar results
were obtained with SU6656, where 15 µM treatment resulted in a 65% decrease of the
Src-targeted Y410 in p130CAS (Supplementary Figure 6b) and a 50% reduction in
matrix degradation (Figure 7b).

Treatment of UMSCC1 cells with the dual Abl

kinase/Src inhibitor saracatinib, (61, 62) at 1 µM inhibited EGFR activity by 55%, Src
activity by 93%, and Abl/Arg activity by 97% (Supplementary Figure 6c).
proteolysis was impaired by 80% (Figure 7c).

ECM

Furthermore, the enhanced ECM

degradation activity in UMSCC1 cells with Abl knockdown (Figure 1b-d) was abrogated
with 10 µM SU6656 (Figure 7d; Supplementary Figure 6d). These data indicate that the
enhanced matrix degradation activity promoted by targeted Abl kinase inhibition in
HNSCC requires intact EGFR-Src signaling.

Similar results were obtained with

saracatinib in OSC19 and MDA-MB-231 cells (Supplementary Figure 7a-c).
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Discussion
The effects of Abl-based signaling in solid tumors are currently controversial. Several
studies have determined that Abl family kinase activity directly contributes to enhancing
tumor proliferation, invasion and metastasis in breast and melanoma cell lines
(47,48,51,53,55). Abl family kinases also positively modulate tumorgenesis in gastric
tumors (50) and non-small cell lung carcinoma (49). On the other hand, recent reports
indicate that suppression of Abl kinase activity by imatinib increases breast tumor
growth (86), invasion (63) and inhibits epithelial-to-mesenchymal transition (64).
Imatinib also enhances thyroid cancer cell invasion (65). While these tumor stimulating
findings have been attributed to use of mutationally modified Abl constructs or nonphysiological levels of imatinib (53), our results comparing HNSCC lines with MDA-MB231 cells indicate that Abl kinase inhibition by RNAi or clinically relevant imatinib
concentrations yields opposite outcomes on tumor cell invasive events, suggesting that
Abl kinases function to suppress HNSCC invasion by reducing invadopodia matrix
degradation activity driven through the EGFR-Src-cortactin pathway.
Src

activation

is

central

to

invadopodia

formation

and

maturation,

where

phosphorylation of numerous downstream cytoskeletal proteins is required for
invadopodia biogenesis and ECM proteolytic activity (24,25). Cortactin phosphorylation
downstream of Src is involved in all stages of invadopodia formation (28,36,37,41). Src,
Abl and Arg directly phosphorylate cortactin (52,66,67), indicating that these kinases
can promote cortactin-based Arp2/3 nucleation activity indirectly via NCK1 and NWASp. Src can also phosphorylate and activate Abl and Arg downstream of EGFR and
other growth factor receptors (54,68) and recent work has shown that removal of Abl or
Arg by RNAi prevents invadopodia formation in Src transformed fibroblasts, MDA-MB231 breast cancer and melanoma cell lines (51,53,55). While these studies indicate
that Abl and Arg are the key cortactin kinases responsible for cortactin tyrosine
phosphorylation in invadopodia (Figure 8a), we show that EGF stimulation of Abl/Argnull (DKO) fibroblasts enhances cortactin tyrosine phosphorylation, indicating that Src
and/or other EGFR-activated cortactin targeting kinases phosphorylate cortactin apart
from Abl or Arg. Src-transformed Abl/Arg-null fibroblasts retain the ability to degrade
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ECM and contain tyrosine phosphorylated cortactin within invadopodia, demonstrating
that Abl family kinases are not essential in this system for invadopodia function driven
by cortactin tyrosine phosphorylation. Abl re-expression in DKO cells impaired Srcgenerated ECM degradation, confirming an inhibitory role for Abl in invadopodia
maturation similar to that observed in HNSCC cells.

These results indicate that

elevated levels of Src activity commonly present in HNSCC lines (36) or due to ectopic
expression of active Src forms can circumvent the requirement for Abl or Arg in
regulating invadopodia activity through cortactin phosphorylation (Figure 8b).
Imatinib-stimulated HNSCC invadopodia activity and invasion is likely due to increased
activation of EGFR and associated downstream signaling, since imatinib treatment
enhances EGFR, Src and Erk activation in HNSCC lines while having minimal impact
on EGFR signaling in MDA-MB-231 cells. Imatinib treatment of HNSCC cells results in
increased cortactin phosphorylation at Src-targeted Y421 and Erk-targeted S405/S418,
phosphorylation events present within invadopodia required for ECM matrix degradation
activity (40,69,70). As in other HNSCC lines (60), we observed that imatinib treatment
increases synthesis and release of the EGFR ligand HB-EGF from OSC19 and
UMSCC1 cells at concentrations 10-fold higher than MDA-MB-231 cells. Application of
HB-EGF at imatinib-treated conditioned media concentrations enhanced invadopodia
activity in HNSCC but not in MDA-MB-231 cells.

This suggests that HNSCC cells

lacking Abl or treated with imatinib generate an autocrine loop, where increased HBEGF synthesis and shedding in turn binds and activates EGFR to stimulate Src and Erk
activation, leading to elevated cortactin phosphorylation and enhanced invadopodia
ECM degradation (Figure 8b). HB-EGF induction of HNSCC invadopodia activity likely
occurs in part through stimulation and secretion of MMP9 (71,72), which localizes with
UMSCC1 invadopodia at sites of ECM degradation (73). While our data are congruent
with these findings, it is possible that other EGFR ligands may also be upregulated by
Abl kinase suppression. The increased level of EGFR overexpression in HNSCC cells
would render this tumor type more responsive to soluble HB-EGF than cell types that
contain lower EGFR levels (e.g., MDA-MB-231), which may be the underlying reason
for the differential response to Abl knockdown, imatinib and HB-EGF in our analyzed
cell lines. Whether such a scenario applies to other EGFR overexpressing cancers
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and/or tumor types that display pro-invasive behavior in response to Abl kinase
suppression will be important to determine.
How Abl kinase inhibition promotes HB-EGF synthesis and shedding in HNSCC is
unclear. In addition to cytoskeletal regulation, Abl is a nuclear kinase and work in Ablnull and imatinib-treated fibroblasts indicates that Abl functions to suppress NF-кB
(nuclear factor-кB) activity through stabilization of the NF-кB regulator HDAC1 (74).
Elevated NF-кB activity results in increased HB-EGF expression and EGFR activation
(75), providing a link between Abl activation and negative regulation of HB-EGF
expression. High HB-EGF expression is linked to poor clinical prognosis in HNSCC
(76) and low Abl expression in HNSCC correlates with late stage tumors with poor
outcome (77), supporting a potential connection between Abl activity and HB-EGF
levels in driving HNSCC progression.
Pathway analysis with inhibitors of invadopodia signaling components confirmed that
EGFR and Src activation in HNSCC is central to driving invadopodia-based ECM
degradation.

Simultaneous inhibition of Src and Abl kinases decreased matrix

degradation by UMSCC1 and OSC19 cells, reinforcing the point that the elevated
invadopodia activity in HNSCC resultant from Abl kinase inhibition requires concurrent
Src activation. While preclinical studies on HNSCC lines has shown that saracatinib
and the related inhibitor dasatinib impair cell invasion and display potent anti-tumor
effects (9,17), phase II trials in HNSCC patients with either drug as a single agent
yielded no benefit in spite of apparent Src inhibition (78,79). In contrast, a phase II trial
with imatinib administered to HNSCC and NSCLC patients was closed early due to lack
of efficacy and antagonistic effects, with a patient subset displaying a worse clinical
outcome in response to imatinib (57).

While not directly evaluated, these results

support a role for Src inhibition in counteracting the pro-invasive effects of Abl kinase
that would result in increased patient tumor progression. Although some response has
been achieved with imatinib in solid tumors with combination approaches (78,80-82),
our results further emphasize the importance of careful patient selection and exclusion
criteria for using imatinib or other Abl kinase inhibitors in HNSCC and other solid tumors
that display similar characteristics.
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We have determined that Abl kinases have a context-dependent role in regulating
invadopodia function and tumor invasion.

In HNSCC cells Abl serves to suppress

invadopodia ECM degradation and tumor invasion by preventing HB-EGF synthesis and
extracellular shedding, where it is capable of activating the EGFR/Src/cortactin signaling
pathway to accelerate invadopodia-based ECM degradation and tumor cell invasion.
This is in contrast to MDA-MB-231 cells, a cell line commonly used to analyze
invadopodia and invasive signaling, where Abl kinase inhibition prevents invadopodia
activity and impairs invasiveness. These results stress the need for further mechanistic
insight into the signaling processes that regulate the pro- and anti-oncogenic roles of
Abl in solid tumors in order to prevent detrimental affects of imatinib treatment in
ongoing and future patient trials.
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Material and Methods
Plasmid constructs
The lentiviral vector pLL5.0 (83) was used for Abl knockdown by subcloning a shRNA
targeting human Abl oligonucleotide, (5’GCTCCGGGTCTTAGGCTAT3’; (84)) with HpaI
and XhoI sites.

For Abl knockdown-rescue experiments, the resulting vector was

modified to encode a 6X-HA epitope tag using BamHI and SbfI sites. Human Abl cDNA
was PCR amplified from pMSCV-puro Abl (85) and subcloned into EcoRI and BamHI
digested pLL5.0 6X-HA. Src-GFP constructs (WT, 527F, and 295M) were used as
described (36).
Cell culture, lentiviral infection and transfection
UMSCC1, OSC19 and 1483 cells were maintained as described (36). Abl-/-/Arg-/-, wildtype MEFs, NIH3T3 and HEK 293T/17 cells were cultured as before (86). MDA-MB-231
cells were cultured in alpha Minimum Essential Media (Mediatech, Manassas, VA)
supplemented with 10% fetal bovine serum (FBS; Hyclone, Logan UT), and 1%
penicillin-streptomycin.
UMSCC1 cells stably infected with pLL5.0 6X-HA, pLL5.0 6X-HA Abl shRNA or pLL5.0
co-expressing Abl shRNA and HA-tagged Abl were generated by puromycin selection
following standard methods.

1483, Abl-/-/Arg-/- or wild-type MEF cells transiently

expressing CMV-Src or HA-Abl constructs were transfected with the Nucleofector I
device (Amaxa Biosystems, Berlin, Germany).
Western blotting, antibodies and immunoprecipitation
Western blotting of cell lysates was conducted as described (73). Antibodies used
were: anti-Src clone GD11 (1:1000; EMD Millipore, Billerica, MA), anti-pY418 Src
(1:1000; Invitrogen, Carlsbad, CA), anti-p130CAS (1:1000; BD Biosciences, San Jose,
CA), anti-pY410 p130CAS (1:1000; Cell Signaling Technology, Danvers, MA), anticortactin clone 4F11(1 μg/ml, (86)), anti-pY421 cortactin (1:500; BD Biosciences), antipS405 cortactin (1:2000; (70)), anti-pS418 cortactin (1:500; (70)), anti-ERK1/2 clone C14 (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA), anti-pERK1/2 (1:1000; Santa
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Cruz), anti-β-actin (1:10,000; EMD), anti-HA (1:200; Covance, Berkley, CA), anti-Crk
(1:1000; BD), anti-pY221 Crk (1:1000; Cell Signaling), anti-PDGFR (1:200; Cell
Signaling), anti-EGFR (1:1000, BD), anti-pY1068 EGFR (1:1000; BD), anti-Arg (1:500;
EMD), anti-HB-EGF (1:200; EMD), and anti-Abl clone 8E9 (1:500; BD). Blots were
quantified as described (73).
Immunoprecipitation was conducted from cells lysed in RIPA buffer (69).

Clarified

lysates (250 µg) were incubated with 5 µg anti-cortactin antibody 4F11 for 2 h at 4 °C.
Immune complexes were captured by incubation with 30 µL Protein A/G beads
(ThermoFisher Scientific, Rockford, IL) for 1 h, washed with RIPA and analyzed by
Western blotting.
Invadopodia matrix degradation assays and fluorescence microscopy
Cells were plated on Oregon Green 488-conjugated gelatin (Invitrogen, Grand Island,
NY) coated coverslips (27,87). In cases of inhibitor treatment, cells were allowed to
attach for 1 h, then serum starved for 12 h in the presence of 10 µM GM6001 (Sigma)
and either imatinib mesylate (LGM Pharmaceuticals, Boca Raton, FL), saracatnib
(AstraZeneca, Alderley Park, Cheshire, United Kingdom), gefitinib (AstraZeneca) or
SU6656 (EMD). Serum-free media was replaced with complete media containing 10%
FBS and kinase inhibitors for 12 h.

Cells were rinsed in PBS, fixed in fresh 4%

paraformaldehyde and labeled as described (36). Primary antibodies used were anticortactin clone 4F11 (1:500), anti-cortactin EP1922Y (1:500; Novus Biologicals,
Littleton, CO), anti-cort-pY421 (1:500), anti-Src GD11 (1:500), anti-Abl clone 8E9
(1:200), anti-GFP (1:500; Invitrogen), and anti-HA (1:200). Primary antibodies were
visualized using Alexa Fluor 405 and 647 conjugated goat anti-rabbit or anti-mouse
secondary antibodies (1:2000; Invitrogen). F-actin was visualized using rhodamineconjugated phalloidin (1:500; Invitrogen).

Cells were mounted with ProLong Gold

(Invitrogen) and images were acquired with a Zeiss LSM510 confocal microscope using
AIM software (Carl Zeiss MicroImaging, Thornwood, NY).

Gelatin degradation was

quantified as described previously (87). In brief, ≥ 90 transiently transfected and ≥ 300
lentiviral infected or inhibitor-treated cells evaluated for each condition. For therapeutic
treatments and RNAi stable cell lines, the area of degradation and cell area was
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determined by analyzing the intensity of degraded gelatin or F-actin respectively in an
entire field of view utilizing ImageJ software. For transient transfections, the area of
degradation and cell area was determined by Image J software on an individual cell
basis. The number of invadopodia per cell (n ≥ 50) and number of cells degrading
matrix (n ≥ 100) were determined or each independent experiment (n = ≥ 3) (36).
3-D spheroid invasion assays
Cells were labeled with Vybrant® DiI (Invitrogen). 96 well plates were coated with 100
µL of 1.5% noble agar (BD Biosciences, Sparks, MD) in Dulbecco’s PBS. 1 x 103
(OSC19), 5 x 103 (UMSCC1), or 2.5 x 103 (MDA-MB-231) labeled cells were plated into
individual wells for 48 h to form spheroids.

Two spheroids were transferred to a

microcentrifuge tube and centrifuged at 1000 x g for 3 min. The media was aspirated
and replaced with 500 µL of 2 mg/mL rat tail collagen I (BD). The spheroid mixture was
transferred to an individual well of 24-well plate pre-coated with 400 µL solidified 2
mg/mL collagen I. Plates were incubated for 1 h at 37 °C then overlayed with 1 mL of
complete media. Spheroid invasion was visualized by fluorescence microscopy (Zeiss,
Axiovert 200M) to establish the central z-axis (0 h) and imaged at 0 and 24 h by phase
contrast microscopy. Spheroids were pretreated for 24 h and maintained in media with
DMSO vehicle or 10 µM imatinib.

Maximal radial distances for invaded cells was

calculated using Axiovision 4.6 software (Zeiss).
HB-EGF ELISA assays
HB-EGF specific enzyme-linked immunosorbent assay (ELISA) was performed
according to the manufacturer’s protocol (Abcam, Cambridge, MA). Cells were treated
with imatinib (10µM) or DMSO for 12 h, washed with PBS and incubated for 24 h in
serum-free media with imatinib or DMSO. Conditioned media was concentrated to 500
µL, and 100 µL of media incubated overnight at 4ºC in HB-EGF antibody-coated
microplate strips. Absorbance values were obtained at 450 nm with a Biotek Synergy
H1 Hybrid Reader (Winooski, VT). Standard curves were generated and results
normalized to total cellular protein concentration for comparison across different cell
lines.
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Statistical analysis
Differences in mean values between groups were evaluated using Students t-test and
significance was determined at P < 0.05. Scale bars represent confidence intervals
(C.I.).

74

Conflict of Interest
The authors declare they have no competing financial interests in relation to the work
described.

75

Acknowledgements
We thank Bruce Mayer (University of Connecticut) for Abl constructs, Anthony Koleske
(Yale University) for Abl-/-/Arg-/- fibroblasts, Silja Wessler (Paul-Ehrlich Institute) for the
Abl shRNA construct, Elena Pugacheva (West Virginia University) for MDA-MB-231LN
cells, Jim Bear (University of North Carolina) for pLL5.0 and advice on spheroid assay
development. We thank Mark Auble and Barbara Frederick for technical assistance.
Saracatinib and gefitinib were provided by AstraZeneca. Supported by NIH grants R01
DE014578, P20 RR16440 (to SAW) and the West Virginia University Mary Babb
Randolph Cancer Center. The West Virginia University Microscopy Imaging Facility
(supported by the Mary Babb Randolph Cancer, NIH grants P20 RR16440 and P30
RR032138/GM103488) is gratefully acknowledged.

76

References
(1) Pryor DI, Solomon B, Porceddu SV. The emerging era of personalized therapy in
squamous cell carcinoma of the head and neck. Asia Pac J Clin Oncol 2011
Sep;7(3):236-251.
(2) Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and
neck cancer. Nat Rev Cancer 2011 Jan;11(1):9-22.
(3) Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and
neck cancer. J Clin Oncol 2006 Jun 10;24(17):2666-2672.
(4) Hama T, Yuza Y, Saito Y, O-uchi J, Kondo S, Okabe M, et al. Prognostic
significance of epidermal growth factor receptor phosphorylation and mutation in head
and neck squamous cell carcinoma. Oncologist 2009 Sep;14(9):900-908.
(5) Hama T, Yuza Y, Suda T, Saito Y, Norizoe C, Kato T, et al. Functional mutation
analysis of EGFR family genes and corresponding lymph node metastases in head and
neck squamous cell carcinoma. Clin Exp Metastasis 2012 Jan;29(1):19-25.
(6) Uribe P, Gonzalez S. Epidermal growth factor receptor (EGFR) and squamous cell
carcinoma of the skin: Molecular bases for EGFR-targeted therapy. Pathology Research and Practice 2011 6/15;207(6):337-342.
(7) Fung C, Grandis JR. Emerging drugs to treat squamous cell carcinomas of the head
and neck. Expert Opin Emerg Drugs 2010 Sep;15(3):355-373.
(8) Neiva KG, Zhang Z, Miyazawa M, Warner KA, Karl E, Nor JE. Cross talk initiated by
endothelial cells enhances migration and inhibits anoikis of squamous cell carcinoma
cells through STAT3/Akt/ERK signaling. Neoplasia 2009 Jun;11(6):583-593.
(9) Koppikar P, Choi SH, Egloff AM, Cai Q, Suzuki S, Freilino M, et al. Combined
inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion
of head and neck squamous cell carcinoma. Clin Cancer Res 2008 Jul 1;14(13):42844291.
(10) Yang JL, Qu XJ, Russell PJ, Goldstein D. Interferon-alpha promotes the antiproliferative effect of Erlotinib (OSI-774) on human colon cancer cell lines. Cancer Lett
2005 Jul 8;225(1):61-74.

77

(11) Huang YT, Hwang JJ, Lee LT, Liebow C, Lee PP, Ke FC, et al. Inhibitory effects of
a luteinizing hormone-releasing hormone agonist on basal and epidermal growth factorinduced cell proliferation and metastasis-associated properties in human epidermoid
carcinoma A431 cells. Int J Cancer 2002 Jun 1;99(4):505-513.
(12) Guarino M. Src signaling in cancer invasion. J Cell Physiol 2010 Apr;223(1):14-26.
(13) Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev
Clin Oncol 2009 Oct;6(10):587-595.
(14) Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis.
Cancer Metastasis Rev 2003 Dec;22(4):337-358.
(15) Shor AC, Keschman EA, Lee FY, Muro-Cacho C, Letson GD, Trent JC, et al.
Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and
induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer
Res 2007 Mar 15;67(6):2800-2808.
(16) Chen YS, Wu MJ, Huang CY, Lin SC, Chuang TH, Yu CC, et al. CD133/Src axis
mediates tumor initiating property and epithelial-mesenchymal transition of head and
neck cancer. PLoS One 2011;6(11):e28053.
(17) Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-354825) tyrosine
kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head
and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer
Res 2005 Oct 1;11(19 Pt 1):6924-6932.
(18) Sen B, Saigal B, Parikh N, Gallick G, Johnson FM. Sustained Src inhibition results
in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell
survival via altered Janus-activated kinase-STAT3 binding. Cancer Res 2009 Mar
1;69(5):1958-1965.
(19) Zhang S, Yu D. Targeting Src family kinases in anti-cancer therapies: turning
promise into triumph. Trends Pharmacol Sci 2012 3;33(3):122-128.
(20) Mayer EL, Krop IE. Advances in targeting SRC in the treatment of breast cancer
and other solid malignancies. Clin Cancer Res 2010 Jul 15;16(14):3526-3532.
(21) Wheeler DL, Iida M, Kruser TJ, Nechrebecki MM, Dunn EF, Armstrong EA, et al.
Epidermal growth factor receptor cooperates with Src family kinases in acquired
resistance to cetuximab. Cancer Biol Ther 2009 Apr;8(8):696-703.
78

(22) Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, et al.
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced
non-small-cell lung cancer. J Clin Oncol 2010 Mar 10;28(8):1387-1394.
(23) Araujo JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, et al.
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from
a phase 1-2 study. Cancer 2012 Jan 1;118(1):63-71.
(24) Murphy DA, Courtneidge SA. The 'ins' and 'outs' of podosomes and invadopodia:
characteristics, formation and function. Nat Rev Mol Cell Biol 2011 Jun 23;12(7):413426.
(25) Linder S, Wiesner C, Himmel M. Degrading devices: invadosomes in proteolytic
cell invasion. Annu Rev Cell Dev Biol 2011 Nov 10;27:185-211.
(26) Poincloux R, Lizarraga F, Chavrier P. Matrix invasion by tumour cells: a focus on
MT1-MMP trafficking to invadopodia. J Cell Sci 2009 Sep 1;122(Pt 17):3015-3024.
(27) Artym VV, Zhang Y, Seillier-Moiseiwitsch F, Yamada KM, Mueller SC. Dynamic
interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia:
defining the stages of invadopodia formation and function. Cancer Res 2006 Mar
15;66(6):3034-3043.
(28) Oser M, Yamaguchi H, Mader CC, Bravo-Cordero JJ, Arias M, Chen X, et al.
Cortactin regulates cofilin and N-WASp activities to control the stages of invadopodium
assembly and maturation. J Cell Biol 2009 Aug 24;186(4):571-587.
(29) Destaing O, Block MR, Planus E, Albiges-Rizo C. Invadosome regulation by
adhesion signaling. Curr Opin Cell Biol 2011 Oct;23(5):597-606.
(30) Ren G, Crampton MS, Yap AS. Cortactin: Coordinating adhesion and the actin
cytoskeleton at cellular protrusions. Cell Motil Cytoskeleton 2009 Oct;66(10):865-873.
(31) Buccione R, Caldieri G, Ayala I. Invadopodia: specialized tumor cell structures for
the focal degradation of the extracellular matrix. Cancer Metastasis Rev 2009 Jun;28(12):137-149.
(32) Kirkbride KC, Sung BH, Sinha S, Weaver AM. Cortactin: a multifunctional regulator
of cellular invasiveness. Cell Adh Migr 2011 Mar-Apr;5(2):187-198.

79

(33) Weaver AM, Karginov AV, Kinley AW, Weed SA, Li Y, Parsons JT, et al. Cortactin
promotes and stabilizes Arp2/3-induced actin filament network formation. Curr Biol 2001
Mar 6;11(5):370-374.
(34) Ammer AG, Weed SA. Cortactin branches out: roles in regulating protrusive actin
dynamics. Cell Motil Cytoskeleton 2008 Sep;65(9):687-707.
(35) Martinez-Quiles N, Ho HY, Kirschner MW, Ramesh N, Geha RS. Erk/Src
phosphorylation of cortactin acts as a switch on-switch off mechanism that controls its
ability to activate N-WASP. Mol Cell Biol 2004 Jun;24(12):5269-5280.
(36) Kelley LC, Ammer AG, Hayes KE, Martin KH, Machida K, Jia L, et al. Oncogenic
Src requires a wild-type counterpart to regulate invadopodia maturation. J Cell Sci 2010
Nov 15;123(Pt 22):3923-3932.
(37) Oser M, Mader CC, Gil-Henn H, Magalhaes M, Bravo-Cordero JJ, Koleske AJ, et
al. Specific tyrosine phosphorylation sites on cortactin regulate Nck1-dependent actin
polymerization in invadopodia. J Cell Sci 2010 Nov 1;123(Pt 21):3662-3673.
(38) Tehrani S, Tomasevic N, Weed S, Sakowicz R, Cooper JA. Src phosphorylation of
cortactin enhances actin assembly. Proc Natl Acad Sci U S A 2007 Jul
17;104(29):11933-11938.
(39) Yamaguchi H, Lorenz M, Kempiak S, Sarmiento C, Coniglio S, Symons M, et al.
Molecular mechanisms of invadopodium formation: the role of the N-WASP-Arp2/3
complex pathway and cofilin. J Cell Biol 2005 Jan 31;168(3):441-452.
(40) Ayala I, Baldassarre M, Giacchetti G, Caldieri G, Tete S, Luini A, et al. Multiple
regulatory inputs converge on cortactin to control invadopodia biogenesis and
extracellular matrix degradation. J Cell Sci 2008 Feb 1;121(Pt 3):369-378.
(41) Webb BA, Jia L, Eves R, Mak AS. Dissecting the functional domain requirements of
cortactin in invadopodia formation. Eur J Cell Biol 2007 Apr;86(4):189-206.
(42) Colicelli J. ABL tyrosine kinases: evolution of function, regulation, and specificity.
Sci Signal 2010 Sep 14;3(139):re6.
(43) Bradley WD, Koleske AJ. Regulation of cell migration and morphogenesis by Ablfamily kinases: emerging mechanisms and physiological contexts. J Cell Sci 2009 Oct
1;122(Pt 19):3441-3454.
80

(44) Plattner R, Pendergast AM. Activation and signaling of the Abl tyrosine kinase:
bidirectional link with phosphoinositide signaling. Cell Cycle 2003 Jul-Aug;2(4):273-274.
(45) Ernst T, Hochhaus A. Chronic myeloid leukemia: clinical impact of BCR-ABL1
mutations and other lesions associated with disease progression. Semin Oncol 2012
Feb;39(1):58-66.
(46) Wang Y, Gu M, Mi Y, Qiu L, Bian S, Wang J. Clinical characteristics and outcomes
of mixed phenotype acute leukemia with Philadelphia chromosome positive and/or bcrabl positive in adult. Int J Hematol 2011 Dec;94(6):552-555.
(47) Srinivasan D, Plattner R. Activation of Abl tyrosine kinases promotes invasion of
aggressive breast cancer cells. Cancer Res 2006 Jun 1;66(11):5648-5655.
(48) Srinivasan D, Sims JT, Plattner R. Aggressive breast cancer cells are dependent
on activated Abl kinases for proliferation, anchorage-independent growth and survival.
Oncogene 2008 Feb 14;27(8):1095-1105.
(49) Lin J, Sun T, Ji L, Deng W, Roth J, Minna J, et al. Oncogenic activation of c-Abl in
non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the
tumor suppressor gene product Fus1. Oncogene 2007 Oct 25;26(49):6989-6996.
(50) Furlan A, Stagni V, Hussain A, Richelme S, Conti F, Prodosmo A, et al. Abl
interconnects oncogenic Met and p53 core pathways in cancer cells. Cell Death Differ
2011 Oct;18(10):1608-1616.
(51) Mader CC, Oser M, Magalhaes MA, Bravo-Cordero JJ, Condeelis J, Koleske AJ, et
al. An EGFR-Src-Arg-cortactin pathway mediates functional maturation of invadopodia
and breast cancer cell invasion. Cancer Res 2011 Mar 1;71(5):1730-1741.
(52) Lapetina S, Mader CC, Machida K, Mayer BJ, Koleske AJ. Arg interacts with
cortactin to promote adhesion-dependent cell edge protrusion. J Cell Biol 2009 May
4;185(3):503-519.
(53) Ganguly SS, Fiore LS, Sims JT, Friend JW, Srinivasan D, Thacker MA, et al. c-Abl
and Arg are activated in human primary melanomas, promote melanoma cell invasion
via distinct pathways, and drive metastatic progression. Oncogene 2011 Sep 5.
(54) Plattner R, Kadlec L, DeMali KA, Kazlauskas A, Pendergast AM. c-Abl is activated
by growth factors and Src family kinases and has a role in the cellular response to
PDGF. Genes Dev 1999 Sep 15;13(18):2400-2411.
81

(55) Smith-Pearson PS, Greuber EK, Yogalingam G, Pendergast AM. Abl kinases are
required for invadopodia formation and chemokine-induced invasion. J Biol Chem 2010
Dec 17;285(51):40201-40211.
(56) Sibony-Benyamini H, Gil-Henn H. Invadopodia: The leading force. Eur J Cell Biol
2012 May 24.
(57) Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM, et al. Phase II trials of
imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer
and head and neck squamous cell carcinoma. J Thorac Oncol 2011 Dec;6(12):21042111.
(58) Clark ES, Whigham AS, Yarbrough WG, Weaver AM. Cortactin is an essential
regulator of matrix metalloproteinase secretion and extracellular matrix degradation in
invadopodia. Cancer Res 2007 May 1;67(9):4227-4235.
(59) Blake RA, Broome MA, Liu X, Wu J, Gishizky M, Sun L, et al. SU6656, a selective
src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol 2000
Dec;20(23):9018-9027.
(60) Johnson FM, Saigal B, Donato NJ. Induction of heparin-binding EGF-like growth
factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma
cells. J Cell Physiol 2005 Nov;205(2):218-227.
(61) Hennequin LF, Allen J, Breed J, Curwen J, Fennell M, Green TP, et al. N-(5-chloro1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific cSrc/Abl kinase inhibitor. J Med Chem 2006 Nov 2;49(22):6465-6488.
(62) Summy JM, Gallick GE. Treatment for advanced tumors: SRC reclaims center
stage. Clin Cancer Res 2006 Mar 1;12(5):1398-1401.
(63) Noren NK, Foos G, Hauser CA, Pasquale EB. The EphB4 receptor suppresses
breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol 2006
Aug;8(8):815-825.
(64) Allington TM, Galliher-Beckley AJ, Schiemann WP. Activated Abl kinase inhibits
oncogenic transforming growth factor-beta signaling and tumorigenesis in mammary
tumors. FASEB J 2009 Dec;23(12):4231-4243.

82

(65) Frasca F, Vigneri P, Vella V, Vigneri R, Wang JY. Tyrosine kinase inhibitor STI571
enhances thyroid cancer cell motile response to Hepatocyte Growth Factor. Oncogene
2001 Jun 28;20(29):3845-3856.
(66) Huang C, Liu J, Haudenschild CC, Zhan X. The role of tyrosine phosphorylation of
cortactin in the locomotion of endothelial cells. J Biol Chem 1998 Oct 2;273(40):2577025776.
(67) Boyle SN, Michaud GA, Schweitzer B, Predki PF, Koleske AJ. A critical role for
cortactin phosphorylation by Abl-family kinases in PDGF-induced dorsal-wave
formation. Curr Biol 2007 Mar 6;17(5):445-451.
(68) Plattner R, Koleske AJ, Kazlauskas A, Pendergast AM. Bidirectional signaling links
the Abelson kinases to the platelet-derived growth factor receptor. Mol Cell Biol 2004
Mar;24(6):2573-2583.
(69) Head JA, Jiang D, Li M, Zorn LJ, Schaefer EM, Parsons JT, et al. Cortactin tyrosine
phosphorylation requires Rac1 activity and association with the cortical actin
cytoskeleton. Mol Biol Cell 2003 Aug;14(8):3216-3229.
(70) Kelley LC, Hayes KE, Ammer AG, Martin KH, Weed SA. Cortactin phosphorylated
by ERK1/2 localizes to sites of dynamic actin regulation and is required for carcinoma
lamellipodia persistence. PLoS One 2010 Nov 4;5(11):e13847.
(71) O-charoenrat P, Modjtahedi H, Rhys-Evans P, Court WJ, Box GM, Eccles SA.
Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9
in head and neck squamous carcinoma cells. Cancer Res 2000 Feb 15;60(4):11211128.
(72) Ohnishi Y, Inoue H, Furukawa M, Kakudo K, Nozaki M. Heparin-binding epidermal
growth factor-like growth factor is a potent regulator of invasion activity in oral
squamous cell carcinoma. Oncol Rep 2012 Apr;27(4):954-958.
(73) Ammer AG, Kelley LC, Hayes KE, Evans JV, Lopez-Skinner LA, Martin KH, et al.
Saracatinib Impairs Head and Neck Squamous Cell Carcinoma Invasion by Disrupting
Invadopodia Function. J Cancer Sci Ther 2009 Nov 30;1(2):52-61.
(74) Liberatore RA, Goff SP, Nunes I. NF-kappaB activity is constitutively elevated in cAbl null fibroblasts. Proc Natl Acad Sci U S A 2009 Oct 20;106(42):17823-17828.

83

(75) Wang F, Liu R, Lee SW, Sloss CM, Couget J, Cusack JC. Heparin-binding EGFlike growth factor is an early response gene to chemotherapy and contributes to
chemotherapy resistance. Oncogene 2007 Mar 29;26(14):2006-2016.
(76) Hatakeyama H, Cheng H, Wirth P, Counsell A, Marcrom SR, Wood CB, et al.
Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired
cetuximab-resistance in head and neck squamous cell carcinoma. PLoS One 2010 Sep
13;5(9):e12702.
(77) Yanagawa T, Harada H, Iwasa S, Tabuchi K, Omura K, Suzuki H, et al. c-Abl
expression in oral squamous cell carcinomas. Oral Oncol 2000 Jan;36(1):89-94.
(78) Fury MG, Baxi S, Shen R, Kelly KW, Lipson BL, Carlson D, et al. Phase II study of
saracatinib (AZD0530) for patients with recurrent or metastatic head and neck
squamous cell carcinoma (HNSCC). Anticancer Res 2011 Jan;31(1):249-253.
(79) Brooks HD, Glisson BS, Bekele BN, Johnson FM, Ginsberg LE, El-Naggar A, et al.
Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.
Cancer 2011 May 15;117(10):2112-2119.
(80) Montero JC, Seoane S, Ocana A, Pandiella A. Inhibition of SRC family kinases and
receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin
Cancer Res 2011 Sep 1;17(17):5546-5552.
(81) Lara PN,Jr, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G, et al. A
phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castrationresistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs 2009
Mar;20(3):179-184.
(82) Gucalp A, Sparano JA, Caravelli J, Santamauro J, Patil S, Abbruzzi A, et al. Phase
II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with
hormone receptor-negative metastatic breast cancer. Clin Breast Cancer 2011
Oct;11(5):306-311.
(83) Cai L, Makhov AM, Schafer DA, Bear JE. Coronin 1B antagonizes cortactin and
remodels Arp2/3-containing actin branches in lamellipodia. Cell 2008 Sep 5;134(5):828842.
(84) Poppe M, Feller SM, Romer G, Wessler S. Phosphorylation of Helicobacter pylori
CagA by c-Abl leads to cell motility. Oncogene 2007 May 24;26(24):3462-3472.

84

(85) Antoku S, Saksela K, Rivera GM, Mayer BJ. A crucial role in cell spreading for the
interaction of Abl PxxP motifs with Crk and Nck adaptors. J Cell Sci 2008 Sep 15;121(Pt
18):3071-3082.
(86) Rothschild BL, Shim AH, Ammer AG, Kelley LC, Irby KB, Head JA, et al. Cortactin
overexpression regulates actin-related protein 2/3 complex activity, motility, and
invasion in carcinomas with chromosome 11q13 amplification. Cancer Res 2006 Aug
15;66(16):8017-8025.
(87) Martin KH, Hayes KE, Walk EL, Ammer AG, Markwell SM, Weed SA. Quantitative
Measurement of Invadopodia-mediated Extracellular Matrix Proteolysis in Single and
Multicellular Contexts. J Vis Exp 2012 Aug 27;(66). pii: 4119. doi(66):10.3791/4119.

85

Figure Legends
Figure 1 Abl expression inhibits invadopodia activity in HNSCC cells. (a) UMSCC1
cells transfected with empty vector (HA-Ctl) or HA-tagged Abl (HA-Abl) were plated on
Oregon Green 488-gelatin coated coverslips (pseudocolored white) and incubated for
24 h.

Cells were fixed and labeled with anti-HA (blue), anti-cortactin (green) and

rhodamine-phalloidin (F-Actin; red).

Boxed areas and corresponding insets denote

regions of HA-Abl localization with invadopodia markers and regions of matrix
degradation. (b) Western blot analysis of Abl expression. Cell lysates (100 µg) from
UMSCC1 control (Ctl), shRNA Abl knockdown (shRNA) and wild-type (WT) Abl rescued
shRNA cells. Parallel blots were probed for β-actin to confirm equal protein loading
across all lines. Numbers denote different independent clones. (c) Representative
confocal images of gelatin matrix degradation assays conducted with the indicated
UMSCC1 clonal cell lines described in (b). Cells were plated on Oregon Green 488gelatin coated coverslips (pseudocolored white) for 9 h, fixed and labeled with an anticortactin antibody (green) and rhodamine-phalloidin (F-Actin; red).

The amount of

gelatin degradation per cell area from four independent experiments was quantified in
(d). Data are represented as mean ± C.I.; ** P≤0.01. Scale bars: 10 µm in (a), 30 µm in
(c).
Figure 2 Targeted inhibition of Abl family kinases with imatinib has divergent effects on
invadopodia activity in HNSCC and breast cancer cells.

(a) OSC19, UMSCC1

(HNSCC) and MDA-MB-231 (breast cancer) cells were treated with the indicated
concentrations of imatinib (STI571) for 24 h, lysed and 25 µg of cell lysate analyzed by
Western blotting with anti-pY221 Crk to determine drug efficacy. The ratio of pY221 Crk
phosphorylation to total Crk levels determined by densitometry is displayed between
blots. Blots are representative from three to four independent experiments for each cell
line. (b) OSC19, (c) UMSCC1, and (d) MDA-MB-231 cells were plated on Oregon
Green 488-gelatin coated coverslips (pseudocolored white) in complete media for 1 h to
allow attachment. Cells were then serum-starved and treated with GM6001 (10µM) and
either imatinib (STI571) or DMSO vehicle (0 µM) concomitantly for 12 h. After GM6001
washout, cells were incubated with complete media containing 10% FBS for 12 h in the
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presence or absence of imatinib. Cells were fixed and labeled with an anti-cortactin
antibody (green) and rhodamine-phalloidin (F-Actin; red) and visualized using confocal
microscopy.

Representative images showing cortactin/F-Actin labeling and gelatin

degradation for each line and indicated experimental condition are shown.

Insets

denote areas of invadopodia activity indicated by the presence of overlapping
cortactin/F-Actin puncta that co-localize with dark regions of Oregon Green 488-gelatin
clearing.

Scale bars: 20 µm.

(e) Quantification of Oregon Green 488-gelatin

degradation for OSC19, UMSCC1 and MDA-MB-231 cells treated with the indicated
imatinib (STI571) concentrations.

Data from 3 independent experiments for each

experimental condition are represented as mean ± C.I.; ** P≤0.01.
Figure 3

Imatinib enhances HNSCC invasion through 3D collagen matrices.

(a)

OSC19, (b) UMSCC1 and (c) MDA-MB-231 tumor cell spheroids pre-treated with 10 µM
imatinib (STI571) or DMSO vehicle (0 µM) for 24 h were embedded in collagen I (0 h).
Spheroids were further incubated in complete media without (0 µM) or with imatinib for
an additional 24 h and invasion monitored by phase contrast microscopy. White circles
indicate the maximum radial distance traveled by invaded cells. Scale bars: 200 µm.
(d) Quantification of average invasive distance traveled by cells in each experimental
condition (n ≥12 spheroids assayed per cell line and treatment). Data are represented
as mean ± C.I.; ** P≤0.01; * P≤0.05.
Figure 4 Elevated Src activity bypasses Abl family kinase regulation of invadopodia
function. (a) UMSCC1, OSC19 and MDA-MB-231 cells grown in complete media were
analyzed by Western blotting of total cell lysates (25-50 µg) for relative basal activation
of EGFR, Src and Abl family kinases with the indicated phosphorylation-specific
antibodies. Lysates were immunoblotted in parallel for total EGFR, Src, Crk, Abl and
Arg protein levels. (b) Abl-/-/Arg-/- double knockout (DKO) and wild-type (WT) mouse
embryo fibroblasts (MEFs) were serum starved overnight, then stimulated with 100
ng/mL EGF for 15 min. Control and stimulated cells were lysed, and 50 µg of total
protein assayed by immunoblotting with phosphorylation-specific antibodies against
cortactin pY421 (Cort pY421) and total cortactin. The ratio of pY421 cortactin relative to
total cortactin levels for each cell type and treatment are shown. (c) WT and DKO cells
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transiently expressing constitutive active Src (527F) were plated on Oregon Green 488gelatin coated coverslips for 12 h, fixed, and immunolabeled with anti-cortactin-pY421
(blue), anti-cortactin (green) and rhodamine-phalloidin (F-Actin; red). Cells and matrix
were imaged by confocal microscopy. Insets show co-localization of pY421 cortactin
within invadopodia at areas corresponding with clearing of Oregon Green 488-gelatin
(pseudocolored white). DKO cells expressing GFP-tagged wild-type (WT), 527F, kinase
inactive (K295M) Src, co-expressing 527F Src and wild-type (WT) Abl or wild-type (WT)
MEFs expressing 527F Src were assayed for the percentage of cells degrading the
ECM (d) and for normalized matrix degradation per cell area (e). Data are represented
as mean ± C.I. from 3 independent experiments. ** P≤0.01.
Figure 5

Imatinib activates the invadopodia kinase pathway in HNSCC cells.

(a)

OSC19, UMSCC1 and MDA-MB-231 cells grown in complete media were treated with
DMSO vehicle (0 µM) or the indicated imatinib (STI571) concentrations for 24 h. Cells
were lysed and 25-50 µg of total cell protein were assayed by immunoblotting for
activation of EGFR (pY1068), Src (pY418), Erk (pErk) and Abl/Arg kinases (pY221 Crk).
Parallel blots were probed for corresponding levels of each assayed protein. Ratios of
phosphorylated/total protein are shown (represented as mean from ≥ 3 independent
experiments).

All blots are representative images.

(b) Western blot analysis of

cortactin S405 and S418 phosphorylation from cells treated and prepared in (a) with the
indicated phosphorylation-specific antibodies. A representative blot was stripped and
reprobed with anti-cortactin to verify equal loading. (c) OSC19, UMSCC1 and MDAMB-231 cells treated as in (a) were lysed and cortactin was immunoprecipitated from
250 µg of cell extract.

Immune complexes were assayed by Western blotting for

cortactin Y421 phosphorylation (anti-Cort-pY421). Parallel blots with anti-pan-cortactin
were conducted to verify cortactin immunoprecipitation.
Figure 6 Imatinib induced HB-EGF stimulates HNSCC invadopodia ECM degradation.
(a) OSC19, UMSCC1 and MDA-MB-231 cells treated with DMSO (0 µM) or imatinib
mesylate (STI571, 10 µM) for 24 h were lysed and 100 µg cell protein assayed by
Western blot analysis for HB-EGF. Bracketed HB-EGF shows different HB-EGF posttranslationally modified forms. Positive control (+ Ctl) recombinant HB-EGF ectodomain
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is denoted by an asterisk (*). A parallel blot was probed with anti-β-actin to confirm
equal protein loading. (b) HB-EGF ELISA analysis of conditioned media from cells
treated with the indicated imatinib (STI571) concentrations. Concentrations of cleaved,
soluble HB-EGF were adjusted in accordance with total cellular protein levels after
treatment from each cell line to allow cross-comparison. (c) Soluble HB-EGF promotes
HNSCC invadopodia ECM degradation. OSC19, UMSCC1, and MDA-MB-231 cells
were plated on Oregon Green 488-gelatin coated coverslips in complete media for 2 h
to allow attachment and stimulated with recombinant HB-EGF (0, 25, or 250 pg/mL) for
7 h.

HB-EGF concentrations were calculated from average levels present in

conditioned media of imatinib-treated cells. Cells were fixed and labeled with an anticortactin antibody (green) and rhodamine-phalloidin (F-Actin; red) and visualized using
confocal microscopy. Insets denote areas of invadopodia activity. Scale bars: 20 µm.
(d) Quantification of Oregon Green 488-gelatin degradation from OSC19, UMSCC1
and MDA-MB-231 cells treated with the indicated HB-EGF concentrations as in (c).
Data are represented as mean ± C.I.; ** P≤0.01; *P ≤ 0.05.
Figure 7 Targeted inhibition of the EGFR-Src pathway impairs HNSCC invadopodia
activity.

UMSCC1 cells treated with the indicated concentrations of gefitinib (a),

SU6656 (b) and saracatinib (c) for 24 h were fixed and evaluated for Oregon Green
488-gelatin degradation by fluorescence microscopy with rhodamine-phalloidin and anticortactin antibodies. (d) UMSCC1 control (Ctl 8), shRNA Abl knockdown (shRNA 3)
and Abl-rescued shRNA cells (WT 6) were treated with vehicle (0 µM) or SU6656 (10
µM) and assayed for effects on Oregon Green 488-gelatin proteolysis as above. Cells
and matrix were imaged by confocal microscopy and the level of matrix degradation
quantified for each treatment condition.

Data are represented as mean ± C.I.; **

P≤0.01; *P≤0.05.
Figure 8 Schematic diagram of EGFR-invadopodia signaling pathways altered by Abl
inhibition in HNSCC. (a) The current invadopodia pathway depicting EGFR activation
to cortactin phosphorylation as primarily determined in breast cancer cell lines. EGFR
activation increases Src and Erk1/2 kinase activity, where Src stimulates Abl/Arg
activation resulting in direct Abl/Arg cortactin tyrosine phosphorylation, while Erk1/2
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directly phosphorylates cortactin S405/418. (b) In HNSCC, inhibition of Abl/Arg results
in increased activation of EGFR through elevated HB-EGF synthesis and shedding,
resulting in autocrine EGFR hyperstimulation. This leads to elevated Src activity that
bypasses Abl/Arg and directly phosphorylates cortactin.

Erk1/2 activation is also

increased under these conditions, where the combined effect of enhanced Src and
Erk1/2 activation increases cortactin phosphorylation and correlates with elevated
HNSCC-mediated ECM degradation and invasion.
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Supplementary Figure Legends
Supplementary Figure 1

Abl knockdown does not impact the number of HNSCC

invadopodia. (a) Src transformed 1483 cells transiently expressing empty vector (HACtl) or HA-tagged Abl (HA-Abl) are plated on Oregon Green 488-gelatin coated
coverslips (pseudocolored white) for 24 h, fixed and immunolabeled with anti-HA (blue),
anti-cortactin (green), and rhodamine-phalloidin (F-Actin; red).

Insets demonstrate

areas of overlapping invadopodia marker localization with areas of gelatin clearing.
Scale bars: 10 µm. Quantification of Abl knockdown on percentage of UMSCC1 cells
degrading gelatin matrix (b) and invadopodia number per cell (c) from the assays
conducted in Figure 1c. Data are represented as mean ± C.I.
Supplementary Figure 2 Abl knockdown does not impact matrix degradation in MDAMB-231 cells.

(a)

MDA-MB-231 cells that were non-infected (NI) or infected with

lentivirus containing control shRNA (Ctl), Abl specific (shRNA) or Abl shRNA with WT
Abl re-expressed (WT) were plated on Oregon Green 488-gelatin coated coverslips
(pseudocolored white) for 24h, fixed and labeled with anti-HA (blue), anti-cortactin
(green) and rhodamine-phalloidin (F-Actin; red). Scale bars: 10 µm. (b) MDA-MB-231
cells infected as in (a) were lysed and 100 µg of cell lysate analyzed for Abl expression
of by Western blot analysis. Levels of β-actin were evaluated to verify equal protein
loading. (c) Quantification of Oregon Green 488-gelatin degradation from MDA-MB-231
cells transfected as in (a). Error bars indicate mean percentages of gelatin degradation
± C.I.
Supplementary Figure 3

Determination of PDGFRα expression levels in OSC19,

UMSCC1 and MDA-MB-231 cells. Total cell lysate (150 µg) from each indicated line
was assayed for PDGFRα expression by immunoblotting with anti-PDGFRα antibodies.
NIH3T3 fibroblast lysate was included as a positive control. β-actin levels were assayed
to verify equal protein loading.
Supplementary Figure 4 Abl and Arg expression levels in wild-type (WT) and Abl-//Arg-/- (DKO) mouse embryo fibroblasts (MEFs). (a) Western blot analysis of Abl and
Arg protein levels in WT and DKO MEFs with anti-Abl and -Arg antibodies. β-actin
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levels were evaluated to validate equivalent protein loading. (b) DKO cells expressing
GFP-tagged empty vector (Ctl), wild-type (WT), 527F, kinase inactive (K295M) Src, coexpressing 527F Src and wild-type (WT) Abl or wild-type (WT) MEFs expressing 527F
Src were plated on Oregon Green 488-gelatin and assayed for invadopodia formation
and matrix degradation for 12 h. Cells were fixed and imaged by confocal microscopy
for anti-GFP (3E6; blue) or anti-Abl (yellow), and co-labelled with anti-cortactin (green)
and rhodamine-phalloidin (F-Actin; red). Boxed regions and insets denote comparable
regions of invadopodia formation and gelatin degradation. Scale bars: 10 µm.
Supplementary Figure 5

Evaluation of imatinib on EGFR and Crk signaling.

(a)

Prolonged Western exposure of the EGFR pY1068 signal from the corresponding
representative panel in Figure 5a showing EGFR activation. (b) UMSCC1 cells were
treated with indicated concentration of DMSO (0 µM), SU6656 and/or STI571 for 24 h,
lysed and assayed by Western blot analysis for Crk Y221 phosphorylation. Ratios of
phosphorylated to total Crk levels are displayed. Parallel blots were probed for β-actin
to confirm equal protein loading.
Supplementary Figure 6 Targeted inhibition of the EGFR-Src pathway. UMSCC1
cells treated with the indicated concentrations of gefitinib (a), SU6656 (b) and
saracatinib (c) for 24 h were lysed and 25-50 µg total protein analyzed for drug efficacy
by Western blot analysis with the indicated phosphorylation specific antibodies. (d)
Western blot analysis of Src inhibition in UMSCC1 cells with manipulated Abl
expression. Cell lysates (50 µg) from UMSCC1 control (Ctl 8), shRNA Abl knockdown
(shRNA 3) and Abl rescued shRNA cells (WT 6) treated with DMSO (0 µM) or SU6656
(10 µM) for 24 h were immunoblotted with anti-pY418Src and anti-Src. Parallel blots
were probed for β-actin to confirm equal protein loading across all lines. Ratios of
phosphorylated to total Src levels are shown.
Supplementary Figure 7

Saracatinib impairs invadopodia activity in HNSCC and

MDA-MB-231 cells. Western blot analysis of 25-50 µg of protein from (a) OSC19 and
(b) MDA-MB-231 cells treated with DMSO (0 µM) or the indicated concentrations of
saracatinib for 24 h.

Lysates were immunblotted for activation of EGFR (pY1068

EGFR), Src (pY418 Src) and Abl family kinases (pY221 Crk).
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Parallel blots were

probed with antibodies against the non-phosphorylated protein forms as indicated.
Ratios of phosphorylated/total protein relative to control for each analyzed protein and
treatment condition are shown.

(c) Effects of saracatinib on invadopodia activity.

OSC19, UMSCC1 and MDA-MB-231 cells plated on Oregon Green 488-gelatin were
treated with either DMSO (0 µM) or the indicated saracatinib concentrations for 24 h.
Cells were fixed and labeled with rhodamine-phalloidin and anti-cortactin antibodies.
Cells and gelatin matrix were and imaged by confocal microscopy. The percentage of
gelatin degradation per cell area calculated relative to controls. Data are represented
as mean ± C.I.; ** P ≤ 0.01; *P ≤ 0.05.

101

102

103

104

105

106

107

108

Study 2: Saracatinib Impairs Head and Neck Squamous Cell
Carcinoma Invasion by Disrupting Invadopodia Function

Amanda Gatesman Ammer1,4, Laura C. Kelley1,4, Karen E. Hayes1,4, Jason V. Evans1,
Lesly Ann Lopez-Skinner1,4, Karen H. Martin1, Barbara Frederick2,4, Brian L.
Rothschild2, DavidRaben2, Paul Elvin3, Tim P. Green3 and Scott A. Weed1

1

Department of Neurobiology and Anatomy, Program in Cancer Cell Biology, Mary Babb

Randolph Cancer Center, West Virginia University, Morgantown, West Virginia, 265069300,
2

Department of Radiation Oncology, Anschutz Medical Campus, University of Colorado
Denver, Aurora, CO, 80045 and 3 AstraZeneca Pharmaceuticals, Alderley Park,
Cheshire, United Kingdom

Published in J Cancer Sci Ther. 2009 Nov 30;1(2):52-61.

Corresponding author:
Scott A. Weed
West Virginia University
Mary Babb Randolph Cancer Center
Morgantown, WV, 26508-9300
Phone: 304-293-3016
Fax: 304-293-4667
E-mail: sweed@hsc.wvu.edu
4

Note: These authors contributed equally to this manuscript

Running title: Saracatinib inhibits invadopodia activity
109

Abstract
Elevated Src kinase activity is linked to the progression of solid tumors, including head
and neck squamous cell carcinoma (HNSCC). Src regulates HNSCC proliferation and
tumor invasion, with the Src-targeted small molecule inhibitor saracatinib displaying
potent anti-invasive effects in preclinical studies. However, the pro-invasive cellular
mechanism(s) perturbed by saracatinib are unclear. The anti-proliferative and antiinvasive effects of saracatinib on HNSCC cell lines were therefore investigated in
preclinical cell and mouse model systems. Saracatinib treatment inhibited growth, cell
cycle progression and transwell Matrigel invasion in HNSCC cell lines. Dose-dependent
decreases in Src activation and phosphorylation of the invasion-associated substrates
focal adhesion kinase, p130 CAS and cortactin were also observed. While saracatinib
did not significantly impact HNSCC tumor growth in a mouse orthotopic model of tongue
squamous cell carcinoma, impaired perineural invasion and cervical lymph node
metastasis was observed. Accordingly, saracatinib treatment displayed a dosedependent inhibitory effect on invadopodia formation, extracellular matrix degradation
and matrix metalloprotease 9 activation. These results suggest that inhibition of Src
kinase by saracatinib impairs the pro-invasive activity of HNSCC by inhibiting Src
substrate phosphorylation important for invadopodia formation and associated matrix
metalloprotease activity.

Keywords: Saracatinib, Src, Head and Neck cancer, invadopodia, invasion, MMP
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Abbreviations
CAS- Crk-associated substrate
c-Src- cellular Src kinase
ECM- extracellular matrix
FACS- fluorescence-activated cell sorting
FAK- focal adhesion kinase
FITC- fluorescein isothiocyanate
HNSCC- head and neck squamous cell carcinoma
IHC- immunohistochemistry
SFK- Src family kinase
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Introduction
Tumor cell invasion and metastasis is a compounding problem in cancer management,
with therapeutic intervention of tumor invasion becoming recognized as an increasingly
relevant clinical factor (Dolgin, 2009). Increased activation of the proto-oncogene c-Src
(Src) has been established in enhancing tumor progression in human cancer and
corresponds with poor clinical outcome (Irby & Yeatman, 2000; Yeatman, 2004). Src is
responsible for governing signaling pathways that regulate proliferation, angiogenesis,
resistance to apoptosis, adhesion, motility and invasion (Summy & Gallick, 2006). High
Src expression and/or activity is observed in metastases, supporting a role for Src in
tumor progression by enhancing tumor invasion and metastatic potential (Summy &
Gallick, 2003; Yeatman, 2004). Small molecules targeting Src kinase activity suppress
proliferation, invasion and metastasis in preclinical settings (Summy & Gallick, 2006),
and are currently being evaluated in clinical trials (Kopetz et al., 2007).
Head and neck squamous cell carcinoma (HSNCC) is highly invasive, frequently
metastasizing to cervical lymph nodes and corresponds with poor prognosis (Kramer et
al., 2005). Src overexpression is common in HNSCC (van Oijen et al., 1998) and is
activated following engagement of the epidermal growth factor receptor (EGFR), where
it modulates HNSCC growth and invasion through several signaling pathways (Zhang et
al., 2004). The small molecule Src kinase inhibitor dasatinib suppresses motility and
invasion of HNSCC cells in vitro and in mouse xenografts models, corresponding with
decreased Src activation and invasion-associated substrate phosphorylation (Johnson
et al., 2005; Sen et al., 2009). Amplification and/or overexpression of Src substrates in
HNSCC correlates with poor clinical outcome, potentially serving to magnify Src
pathway effects on HNSCC invasion and metastasis (Kelley et al., 2008).
HNSCC invasion and metastatic spread is mediated in part by the action of matrix
metalloproteases (MMPs), with MMP1, MMP2, MMP9 and MT1-MMP activity
associated with poor outcome (Rosenthal & Matrisian, 2006). MT1-MMP, MMP2 and
MMP9 localize to invadopodia, actin-based ventral protrusions in invasive tumor cells
that mediate focalized proteolysis of the extracellular matrix (ECM) (Linder, 2007;
Weaver, 2006). Invadopodia formation is dependent on Src activity, which enhances
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MMP2 and MMP9 secretion (Hsia et al., 2003; Mueller et al., 1992), and matrix
degradation in HNSCC cells (Clark et al., 2007). The collective localization and action of
MMPs at invadopodia allows matrix remodeling to accommodate primary tumor growth
and to allow dissemination of encapsulated tumor cells to local and distant sites
(Gimona et al., 2008).
Saracatinib (AZD0530) is a recently developed anilinoquinazoline inhibitor designed to
disrupt Src kinase activity (Hennequin et al., 2006; Summy & Gallick, 2006). Saracatinib
exhibits inhibitory effects on tumor growth in some model systems (Herynk et al., 2006),
but several preclinical reports suggest that the primary anticancer effects of saracatinib
are impaired tumor cell migration and invasion in HNSCC and other cancer types
(Green et al., 2009; Koppikar et al., 2008; Nozawa et al., 2008). The anti-invasive
effects of saracatinib are consistent with the effects of Src kinase inhibition in HNSCC
by dasatinib, another Src-targeted inhibitor (Johnson et al., 2005). Saracatinib is
currently being evaluated in phase I/II clinical trials for efficacy against advanced stage
HNSCC and other tumor types (Kopetz et al., 2007).
Although saracatinib and other Src inhibitors are effective anti-invasive compounds, a
complete understanding of the how therapeutic Src inhibition perturbs tumor invasion at
the cellular level is lacking. We show that saracatinib inhibited Src activation and
phosphorylation of the invadopodia regulatory proteins focal adhesion kinase (FAK),
p130 Crk-associated substrate (CAS) and cortactin in HNSCC cells. Saracatinib
suppressed HNSCC growth and cell cycle progression in a subset of HNSCC cell lines.
Administration of saracatinib to nude mice containing orthotopic HNSCC tongue tumors
inhibited Src activity, cortactin phosphorylation, perineural invasion and lymph node
metastasis. We also demonstrated that saracatinib prevented invadopodia formation
and ECM degradation in invasive HNSCC cells, as well as secretion and activation of
MMP9. Collectively these results suggest that saracatinib exhibits anti-tumor effects in
HNSCC by inhibiting invasion through the prevention of invadopodia formation. The
ability of saracatinib to prevent invadopodia-mediated ECM proteolysis reveals a cellular
process perturbed by Src inhibitors that is likely utilized in the progression of HNSCC
and other invasive carcinomas containing high Src activity.
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Materials and Methods
Cell lines, antibodies and Western blotting
HNSCC cell lines 1483, HN31, UMSCC 1, UMSCC19 and MSK 921 were maintained as
described (Rothschild et al., 2006). Western blotting of cell lysates was conducted
essentially as before (Rothschild et al., 2006). Western blotting of secreted MMP2 and 9
was conducted on conditioned media, with volumes adjusted to compensate for
variations in cell numbers using dimethyl sulfoxide (DMSO)-treated cell numbers as
controls.
Antibodies for immunoblotting included anti-Src (1:1000; Santa Cruz Biotechnology,
Santa Cruz, CA, USA), anti-pY418 Src (1:1000; Invitrogen, Carlsbad, CA, USA), antip130CAS (1:1000; BD Biosciences, San Jose, CA, USA), anti-pY410 p130CAS
(1:1000; Cell Signaling Technology, Danvers, MA, USA), anti-FAK (1:1000; BD
Biosciences), anti-pY861 FAK (1:1000; Invitrogen) and anti-cortactin (1μg/ml; 4F11
(Rothschild et al., 2006)). For detection of human pY421 cortactin, a custom antibody
was developed by 21st Century Biochemicals (Marlboro, MA, USA). Briefly, a synthetic
cortactin

peptide

encompassing

the

sequence

around

tyrosine

421

(NH2-

VpYEDAASFKL-COOH) was synthesized, phosphorylated and injected into rabbits.
Immune serum was passed through a column containing agarose beads coupled to the
equivalent non-phosphorylated peptide, and then passed over a second agarose
column

containing

a

partially

overlapping

phosphorylated

peptide

(NH2-

LPSSPVpYEDAA-COOH). Bound antibodies were eluted, concentrated and screened
for specificity by Western blotting against recombinant cortactin mutant proteins
harboring phenylalanine-tyrosine point mutations at tyrosine 421 (Fig. 1, Supplemental
Material). Anti-ERK1/2 (Cell Signaling) and anti-pT202/pY204 ERK1/2 (Cell Signaling)
were used at 1:1000. Anti-MMP2 (1:500; Millipore, Billerica, MA, USA) was used to
detect cellular MMP2 levels. Secreted MMP2 was detected with antibody CA-4001
(1:100; Millipore). Cellular and secreted MMP9 was detected with monoclonal antibody
9D4.2 (1:100; Millipore). All Western blots were quantified by densitometry and ImageJ
analysis, and band intensities determined relative to non-treated controls.
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Cell proliferation and cell cycle progression assays
For cell proliferation assays, 4,000 cells were seeded overnight and treated with 0-10
µM saracatinib (AstraZeneca, Cheshire, UK) for 5d. 100 μg of 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (Sigma-Aldrich, St. Louis, MO, USA) was added to
each saracatinib treatment condition for 4h, cells were washed and the reduced dye
extracted with a 75% isopropanol/2% HCl/23% H2O mixture. Dye absorbance was read
at 490 nm with an automated plate reader.
Cell cycle distribution was determined by fluorescence activated cell sorting (FACS) as
previously described (Frederick et al., 2007).
Invasion assays
BioCoat Matrigel invasion chambers (BD Biosciences) were rehydrated with serum-free
DMEM media for 2 h. 1 X 105 cells suspended in serum-free media were plated in the
chamber insert and incubated for 2 h to allow attachment. The media in the upper and
lower chambers was replaced, with serum-free DMEM added to the upper chamber and
DMEM containing 5% FBS added to the lower chamber to generate a chemotactic
gradient. Increasing doses of saracatinib (0-1 μM) of saracatinib as indicated (Fig. 1D)
to the upper and lower chambers. Cells were allowed to invade for 12-24 h (depending
on cell line), fixed with 10% buffered formalin phosphate (Fisher Scientific, Hanover
Park, IL, USA) and rinsed with PBS. Non-invasive cells were removed from the interior
of the chamber insert with a swab and the remaining cells were stained with 0.4%
Crystal Violet solution (Fisher) for 15 min. Invasion was assessed by counting cells in
four random 20X microscopic fields.
Orthotopic xenograft assay of HNSCC invasion
An in vivo mouse model of oral tongue squamous cell carcinoma was established as
described (Myers et al., 2002) with minor modification using female athymic Foxn1nu/nu
mice 4-5 weeks of age (Harlan Laboratories, Indianapolis, IN, USA). All animal
procedures were conducted according to an approved protocol by the West Virginia
University Animal Care and Use Committee. Anesthetized mice were injected with 2.5 x
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104 UMSCC1 cells suspended in DMEM into the anterior ~1/3 of the tongue. After 10 d,
treatment was initiated by daily oral gavage of 25mg/kg saracatinib suspended in a
sterile solution of 0.5% methyl cellulose/0.1% polysorbate 80 (Tween 80, SigmaAldrich). Control animals were gavaged with the methylcellulose/Tween 80 vehicle. No
overt difficulties were encountered when gavaging mice over time as the tumor size
increased. Six mice were used for each treatment group. After 30 d of treatment, mice
were euthanized by carbon dioxide inhalation and tumor volumes determined as
described (Huang et al., 2002). Tongues, sublingual tissue containing the superficial
cervical lymph nodes and the tracheoesophageal region, deep cervical and mediastinial
lymph nodes, liver and lung were removed from each animal, rinsed, fixed and paraffin
embedded for routine histological evaluation.
Immunohistochemistry
Human HNSCC cases were obtained from the West Virginia Tissue Bank and used
under the approval of West Virginia University Institutional Review Board. Fivemicrometer sections from human HNSCC and mouse tissue blocks were processed and
immunolabeled or hematoxylin and eosin (H&E) stained using a Discovery XT
automated staining system (Ventana Medical Systems, Tucson, AZ, USA). For
immunohistochemistry, primary antibody conditions were: anti-total Src (Cell Signaling)
1:600 in Dako diluent (Dako, Carpinteria, CA, USA) for 1 h, anti-pY416 Src family
kinase (SFK) (Cell Signaling) 1:25 in phosphate saline solution (PSS) (Ventana) for 12
h, anti-total cortactin (Novus Biologicals, Littleton, CO, USA) 1:700 in PSS for 1 h,
antipY421 cortactin 1:50 in Tris-buffered saline containing 4% BSA for 1 h, and
prediluted anti-cytokeratin 14 (Abcam, Cambridge, MA, USA) for 20 min. Primary
antibodies were detected using the Omnimap antibody horseradish peroxidase kit
(Ventana) and slides were counterstained with hematoxylin. Images were acquired as
described (Rothschild et al., 2006). For quantifying pY416 Src and pY421 cortactin
staining intensities, brightfield images from at least 5 randomly selected images were
captured on an Olympus ZX70 Provis microscope (Olympus, Center Valley, PA, USA)
with a 20x/0.70 UPlanApo objective and an Optronics MicroFire 1600x1200 color CCD
camera (Optronics Inc, Goleta, CA, USA) using the StereoInvestigator imaging package
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(MBF Bioscience, Williston, VT) with the same camera settings and brightfield
correction enabled to ensure even illumination across the image. Brown 3,3'diaminobenzidine (DAB) staining was separated from blue hematoxylin staining using
the color deconvolution plug-in function of ImageJ (NIH) as described (Park et al.,
2008). The vector values for the DAB staining were determined from ROIs with brown
staining (R=0.425, G=0.600 and B=0.677 for pY421 cortactin; R=0.475, G= 0.653 and
B=0.686 for pY416 Src). Brown images were inverted and intensities were measured
inside the tumor tissue. The mean DAB intensities were averaged within the group to
calculate ratios of phosphorylation-specific staining in treated vs. control tissues.
Immunofluorescence labeling, confocal microscopy and image analysis
UMSCC1 cells were plated on fluorescein isothiocyanate (FITC)-gelatin (Sigma) coated
coverslips as described (Artym et al., 2006) for 2 h. Cells were left untreated or treated
with saracatinib for 6 h, rinsed and fixed with 4% formaldehyde. Cells were
permeabilized with 0.4% Triton-X/PBS for 4 minutes, then blocked in 5% BSA/PBS for 1
h. To identify invadopodia, cells were incubated with rhodamine-conjugated phalloidin
(1:1000; Invitrogen), anti-cortactin monoclonal antibody 4F11 (1 μg/ml) and polyclonal
pTyr-100 (1:200; BD Biosciences) in 5% BSA/PBS for 1 h. After washing, cells were
incubated in 5% BSA/PBS containing AlexaFluor 405 goat anti-rabbit and AlexaFluor
647 goat anti-mouse secondary antibodies (Invitrogen) at 1:1000. Cells were rinsed and
mounted in Fluoromount-G (SouthernBiotech, Birmingham, AL, USA).
For quantifying saracatinib effects on invadopodia incidence and matrix degradation,
eight-bit 1024x1024 pixel confocal images were acquired with a Zeiss LSM510 confocal
microscope using AIM software (Carl Zeiss MicroImaging, Thronwood, NY, USA).
Images were scanned with a 63x/1.4 NA Oil Plan-Apochromat objective at 1.3x zoom,
yielding a resolution of 10.14 pixels/μm. All images of the FITC-gelatin were taken with
the same parameters (pinhole size, laser intensity and gain) so image intensity would
be comparable between samples. For invadopodia formation, a minimum of six
independent fields comprising > 50 cells were analyzed for cells containing invadopodia
compared to total cell number. For matrix degradation, cells were analyzed using
ImageJ software. Actin images were adjusted to threshold values to include all cellular
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regions, and the resulting images were used to calculate total cell areas in µm2. For
quantifying matrix degradation, FITC-gelatin images were inverted so that regions with
increased degradation would yield higher intensity values, ensuring selection of all
areas of matrix degradation. The integrated density was reported as the amount of
degradation per total cell area. A minimum of 15 cells was analyzed for each saracatinib
concentration.
Gelatin zymography
UMSCC1 and 1483 cells were plated overnight at 5 X 106 in complete media and were
treated with saracatinib at increasing dosage for 24 h, rinsed and incubated for 24 h in
serum-free media containing the equivalent saracatinib dose. Cells were counted, and
conditioned media collected and concentrated by ultrafiltration using Amicon Ultra-4
centrifugal filter devices with a 10kDa molecular weight cutoff (Millipore). Zymography
was conducted as described (Clark et al., 2007) with minor modification. Conditioned
media (35 μl) was diluted in 2X non-reducing SDS-PAGE sample buffer and resolved on
8% SDS-PAGE gels containing 1 mg/ml bovine gelatin (Sigma). Aliquots of serum-free
DMEM and DMEM containing 10% FBS were used as negative and positive controls,
respectively. MMP activity was renatured by washing gels in 2.5% Triton X-100 for 30
min, followed by washing gels in Developing Buffer (50 mM Tris, 0.2M NaCl, 5mM
CaCl2, 0.02% Brij 35) for 30 min at room temperature. Gels were then incubated in
renewed Developing buffer for 24h at 37° C to allow MMP activity to proceed. Gels were
stained with Coomassie Brilliant Blue R-250 (0.5% w/v) for 30 min, followed by
destaining in water. Resulting gels were scanned using a FotoAnalyst Investigator
(Fotodyne Inc, Hartland, WI, USA) and areas of gelatinase activity quantified using
ImageJ. Results were adjusted relative to control DMSO treatment for gelatinase activity
and cell counts for each treatment to compensate for variations in final cell numbers.
Statistical analysis
Differences in mean values between saracatinib treatment groups for invasion,
invadopodia and gelatinase assays were evaluated using one-way ANOVA, followed by
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Student-Newman-Keuls post hoc testing. Differences were considered significant at
P<0.05, with all experimentation conducted at least in triplicate.
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Results
Saracatinib effects on HNSCC proliferation and invasion
As a first step in our work, we characterized several HNSCC cell lines previously
determined to have varying degrees of invasive and metastatic potential (Rothschild et
al., 2006; Sano & Myers, 2007; Yang et al., 2004) for their response to saracatinib. To
determine the effect of saracatinib treatment on proliferation in these lines, growth
inhibition was assessed by 5d 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assays for cells treated with increasing doses of saracatinib (Fig. 1A).
The HN31 and UMSCC1 lines were sensitive to growth inhibition by saracatinib, as
indicated by sub-micromolar IC50 values (Fig. 1A). In contrast, the 1483 line
demonstrated a marked resistance to saracatinib, with an IC50 = 7.60μM. Corresponding
effects on cell cycle progression are also observed, with increasing saracatinib
concentrations resulting in enhanced G1 checkpoint arrest in HN31 and UMSCC1 lines
determined by FACS analysis (Fig. 1B). Saracatinib treatment did not alter the
percentage of cells undergoing G2-M transition for either line. Arrest of G1 was not
evident in 1483 cells treated with saracatinib concentrations up to 1μM, in agreement
with resistance of this line in proliferation analysis (Fig. 1A). Erk1/2 activation, a potent
driver of mitogenesis, was impaired in HN31 and UMSCC1 cells at concentrations
above 0.5 μM as determined by Western blotting (Fig. 1C). Similar results were
obtained for the invasive HNSCC lines MSK921 and UMSCC19 (data not shown).
Erk1/2 activation was elevated in 1483 cells at doses up to 1μM (Fig. 1C), in agreement
with the high IC50 value for this line (Fig. 1A). These data indicate that the HNSCC lines
used in this study vary in their proliferative response to saracatinib treatment, and can
be segregated into sensitive (HN31 and UMSCC1) and resistant (1483) populations.
Next we evaluated the effect of saracatinib on HNSCC invasion in vitro using modified
Boyden chamber transwell assays. In the absence of saracatinib, UMSCC1 and HN31
cells displayed an invasive response to serum, averaging 4150 cells/aggregate field and
1719 cells/aggregate field, respectively (Fig. 1D). 1483 cells were weakly invasive, with
an average of 243 cells/aggregate field (Fig. 1D). Increased concentrations of
saracatinib resulted in dose-dependent inhibition of HNSCC invasion for all tested lines,
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with reduced invasion compared to control levels of 88% in UMSCC1, 70% in HN31,
and 78% in 1483 cells at the highest evaluated dose (1.0 μM) (Fig. 1D). These results
indicate that saracatinib directly impacts the ability of HNSCC cell lines to invade in an
in vitro setting.
Saracatinib inhibits Src activation and substrate phosphorylation in HNSCC cells
To determine the impact of saracatinib on Src activity and phosphorylation of
invadopodia-related Src substrates, dose-dependence experiments were performed on
HN31, UMSCC1 and 1483 cells (Fig. 2). Cell lines were treated with increasing doses of
saracatinib for 24 hours, lysed and assessed for phosphorylation by immunoblotting
using anti-phosphorylation site-specific antibodies to detect Src activation (pY418) and
specific Src phosphorylation sites in downstream substrates (pY410 p130 CAS, pY421
cortactin and pY861 FAK). The phosphorylation of Src at Y418 was inhibited by
saracatinib in all tested lines at concentrations between 0.5 and 1.0 μM (Fig. 2).
Phosphorylation of cortactin at tyrosine 421 and FAK at tyrosine 861 was also reduced
within the same range of saracatinib concentrations (FAK phosphorylation in 1483 cells
could not be evaluated due to the absence of detectable FAK expression in this line).
While phosphorylation of tyrosine 410 in p130 CAS was inhibited within this same dose
range in UMSCC1 cells, we observed that p130 CAS phosphorylation was consistently
inhibited at lower dose ranges (0.01-0.05 μM) in HN31 and 1483 cells (Fig. 2).
Immunoblotting with antibodies against total p130 CAS, cortactin and FAK indicate that
the expression levels of these proteins are somewhat reduced at high dose levels of
saracatinib treatment (0.5-1μM), but not at levels accountable for the resultant decrease
of tyrosine phosphorylation at the assayed sites (0.1-0.5μM).
Saracatinib inhibits Src activation, invasion and cervical lymph node metastasis
in an orthotopic mouse model of oral squamous cell carcinoma
A mouse orthotopic model of tongue squamous cell carcinoma (Myers et al., 2002) that
phenotypically mimics human HNSCC (Fig. 3) was utilized to evaluate the effects of
saracatinib on HNSCC progression and invasion in an in vivo setting. Athymic mice
with UMSCC1 tongue tumors were randomized and treated with either vehicle or daily
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with 25mg/kg saracatinib. At the end of treatment (40d), mice from both groups had
similar weight (24g) and mean tumor volumes (54.1mm3+ 2.3mm for controls;
43.7mm3+ 4.6mm with saracatinib treatment). The modest impact of saracatinib on
UMSCC1 tumor growth was not statistically significant. To determine the impact of
saracatinib on Src activity, primary tumors were evaluated for Src and cortactin
phosphorylation by immunohistochemistry.

Active Src (determined by pY416 SFK

staining) and pY421 cortactin labeling in UMSCC1 tumors displayed similar patterns
compared to human HNSCC (Fig. 3A). Saracatinib treatment reduced the ratios of
pY416 SFK and pY421 cortactin compared to control-treated mice (Figure 3A).
Human HNSCC often displays perineural invasion with regional lymph node
involvement. Given the invasive nature of UMSCC1 cells (Fig. 1D), we evaluated the
impact of saracatinib treatment on loco-regional tissue invasion and cervical lymph node
metastasis in treated mice.

Soft tissues from the submental space through the

tracheoesophageal region were evaluated for perineural invasion and cervical lymph
node metastasis by immunostaining for the epithelial marker cytokeratin 14. Similar to
human tumors, extensive perineural invasion and metastasis to the superficial cervical
lymph nodes was evident in 5/6 control treated mice (Fig. 3B). Invasion and lymph
node metastasis was found in 1/6 saracatinib-treated mice, and the remaining mice
displayed a complete absence of cytokeratin-positive cells associated with nerves,
sublingual glands, connective tissue or cervical lymph nodes (Fig. 3B). These data
demonstrate that the in vivo ability of saracatinib to down-regulate Src activity and
cortactin phosphorylation correlates with decreased invasion and local lymph node
metastasis.
Saracatinib inhibits invadopodia formation and matrix degradation in UMSCC1
cells
UMSCC1 cells plated on fluorescently-labeled gelatin formed centrally localized ventral
puncta enriched with cortactin, filamentous (F)-actin and phosphotyrosine (Fig. 4A,
DMSO), three markers that define invadopodia (Bowden et al., 2006). Spontaneous
invadopodia formation was observed in 51% of UMSCC1 cells by confocal microscopy
at a given time, corresponding with focalized areas of matrix clearing (FITC-gelatin)
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(Fig. 4B, 0μM dosage point). The gelatin matrix underneath UMSCC1 cells typically
displayed degradation encompassing ~53% of the overlying cell area, reflecting the
action of invadopodia-associated MMP activity (Fig. 4C).
UMSCC1 cells plated on FITC-coated gelatin were treated with increasing
concentrations of saracatinib, and invadopodia formation and matrix degradation was
evaluated by confocal microscopy (Fig. 4). The number of cells containing invadopodia
was significantly decreased with increasing saracatinib dosage, with < 2% of cells
having formed invadopodia at concentrations at or above 0.5 μM (Fig. 4B). Effects on
matrix degradation were more pronounced, where increased saracatinib dosage
resulted in similar incremental decreases in degradation (Fig. 4C).

UMSCC1 cells

treated with 1.0 μM saracatinib did not contain invadopodia and were incapable of
degrading matrix (Fig. 4A). These cells also lacked focal cortactin localization, had
diminished phosphotyrosine levels at focal adhesions and contained disorganized Factin puncta on the ventral membrane surface where invadopodia typically form (Fig.
4A, arrowheads).
Saracatinib inhibits MMP9 secretion from HNSCC cells
In addition to MT1-MMP, secretion and activation of MMP2 and MMP9 at invadopodia
has been reported to be partially responsible for the observed effects on matrix
degradation (Linder, 2007).

Src activity regulates MMP2 and MMP9 secretion in

fibroblasts (Hsia et al., 2003). We therefore determined the effect of saracatinib on
MMP secretion.

Confocal immunofluorescence microscopy indicated that UMSCC1

cells have MMP9-containing vesicles localized to invadopodia at sites that correspond
with gelatin degradation (Fig. 5A), indicating that MMP9 is concentrated in UMSCC1
invadopodia. To evaluate the impact of saracatinib on MMP2 and MMP9 secretion and
activity in HNSCC cells, total cell lysates and conditioned media from saracatinibtreated 1483 and UMSCC1 cells were analyzed for the presence of cellular and
secreted MMP2 and MMP9 by Western blotting (Fig. 5B).

Saracatinib treatment

resulted in modest decreases (up to 24%) in cellular MMP2 levels at concentrations to 1
μM, while cellular MMP9 levels demonstrated up to a two-fold increase under the same
concentration range. Although secreted MMP2 was not detected in the media of either
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cell line, both lines secreted detectible amounts of MMP9 (Fig. 5B). Treatment of either
line with saracatinib inhibited MMP9 secretion, and each line displayed differential drug
sensitivity. Detectible MMP9 secretion from 1483 cells was largely absent at the lowest
evaluated concentration (0.01 μM) whereas secretion from the more invasive UMSCC1
line was inhibited at concentrations of 0.5 μM and above (Fig. 5B). The secreted MMP9
from both lines displayed proteolytic activity when assayed by gelatin zymography (Fig.
5C). Saracatinib concentrations up to 0.1μM did not significantly affect MMP9 activity
as determined by ANOVA analysis for both lines, although mean values for 1483 cells
treated with these lower doses were consistently below control levels (Fig. 5C). Higher
saracatinib concentrations (0.5 μM and 1.0 μM) reduced MMP9 activity to respective
mean values of 39% and 25% for control levels in 1483 cells, and 22% and 12% in
UMSCC1 cells (Fig. 5B,C). These data indicate that saracatinib treatment of HNSCC
cells leads to selective inhibition of MMP9 secretion in 1483 and UMSCC1 cells,
preventing efficient enzymatic degradation of extracellular matrix components.
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Discussion
The present study demonstrates that inhibition of HNSCC invasion in preclinical in vitro
and in vivo settings by saracatinib directly corresponds to disruption of HNSCC
invadopodia formation and function, identifying invadopodia as a potential downstream
target of therapeutic Src kinase inhibition in HNSCC and other invasive human cancers.
Invasive HNSCC presents a difficult problem in patient care, given the proximity of most
tumors to multiple vital organ sites in the head and neck region.

Disregulation of

signaling pathways that promote and sustain invasion impinge on adhesion- and
cytoskeletal-associated proteins.

These proteins function in concert with MMPs to

enable tumor cells to degrade and protrude through an encapsulating ECM, allowing
movement into neighboring tissues. The ability of saracatinib to ablate invadopodia and
the associated invasive behavior of HNSCC cells in mice provides further evidence for a
direct link between invadopodia activity and tumor invasion, shedding light on the
specific invasion-promoting cellular processes perturbed by Src kinase inhibition.
The HNSCC lines used in this study displayed differential responses to saracatinib in
terms of anti-proliferate effects, with some lines (HN31 and UMSCC1) having
submicromolar sensitivity, cell cycle inhibition and decreased ERK1/2 activity and others
(1483) demonstrating resistance to the drug at concentrations up to 1 μM (Fig. 1A-C).
While a recent study reported IC50 saracatinib values near 1 μM for five different
HNSCC lines (Koppikar et al., 2008), our findings are in line with the wider range of IC50
values reported for different HNSCC lines treated with the non-related Src kinase
inhibitor dasatinib (Johnson et al., 2005) as well as in other tumor cell types (Boyer et
al., 2002; Johnson et al., 2005; Jones et al., 2002). These reports taken together with
our data suggest that the HNSCC lines utilized in this study fall within the typical in vitro
proliferative response profile to therapeutic Src inhibition.

While the underlying

compensatory mechanism for saracatinib resistance in 1483 cells is unknown, future
expression profiling of resistant and sensitive lines may provide insight into the
molecular nature of saracatinib resistance, as has been recently conducted for the
EGFR inhibitor gefitinib in a variety of HNSCC lines (Frederick et al., 2007).
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Saracatinib treatment resulted in in vitro anti-invasive activity, impaired Src activation
and tyrosine phosphorylation of FAK and p130 CAS in all analyzed HNSCC lines (Fig.
1D; Fig. 2).

This is in accord with other studies on other HNSCC lines utilizing

saracatinib or dasatinib as single agents (Johnson et al., 2005; Koppikar et al., 2008;
Nozawa et al., 2008). Tyrosine phosphorylation of FAK and p130 CAS have been
commonly utilized as downstream indicators for preclinical therapeutic anti-Src efficacy,
since Src-mediated phosphorylation of these proteins are critical events in enabling
tumor invasiveness (Brabek et al., 2005; Zhao & Guan, 2009). In addition, we show that
cortactin tyrosine phosphorylation was also reduced following saracatinib treatment
(Fig. 2). Cortactin is a Src substrate commonly overexpressed in invasive HNSCC and
regulates invadopodia formation (Rodrigo et al., 2000; Rothschild et al., 2006; Weaver,
2008).

Cortactin phosphorylation is important for tumor cell motility and matrix

degradation at invadopodia (Ayala et al., 2008; Oser et al., 2009; Rothschild et al.,
2006). These results suggest that cortactin tyrosine phosphorylation status can serve
as an additional downstream monitor of Src activity and invasive potential in HNSCC
cells where Src kinase function is impaired.
While saracatinib was able to modestly decrease the size of in vivo UMSCC1 tongue
tumors, the reduction in tumor size was not significant compared to untreated controls.
UMSCC1 cell growth is inhibited by saracatinib in vitro (Fig. 1A), implying that
microenvironmental

factors

such

as

inflammatory

cytokines,

growth

factors,

neoangiogenic and hypoxic aspects responsible for promoting and maintaining HNSCC
growth (Pries & Wollenberg, 2006; Timar et al., 2005) may partially circumvent the
growth-inhibitory effects of saracatinib in UMSCC1 xenografts.

On the other hand,

saracatinib displays in vivo anti-invasive properties by potently inhibiting perineural
invasion and cervical lymph node metastasis. Suppressed Src activation and cortactin
tyrosine phosphorylation in primary tumors (Fig. 4A) supports this conclusion, as
signaling through these proteins promotes invasion and metastatic spread (Weaver,
2008; Yeatman, 2004). Recent findings in a comparable xenograft system utilizing mice
treated with dasatinib demonstrated reduced Src and FAK activity (Sen et al., 2009).
EGFR overexpression is common in HNSCC, resulting in enhanced Src activity,
cortactin phosphorylation and tumor invasiveness (Koppikar et al., 2008; Rothschild et
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al., 2006).

Clinical EGFR inhibitors also display anti-invasive activity and impair

invadopodia formation in preclinical settings (Huang et al., 2002; Yamaguchi et al.,
2005; Yang et al., 2004), suggesting in light of our findings that inhibiting EGFR activity
in HNSCC impairs Src activation and substrate phosphorylation required for invasion.
This is supported by emerging rationale for dual targeting of EGFR and Src in treating
advanced HNSCC (Egloff & Grandis, 2008).
Elevated Src activity is necessary and essential for invadopodia formation (Chen et al.,
1985; Chen et al., 1984).

The ability of saracatinib to ablate invadopodia and

associated matrix degradation demonstrates that a clinically utilized Src inhibitor
disrupts a vital subcellular structure required for tumor invasion.

Src-induced

invadopodia formation in carcinoma cells first targets cortactin and F-actin formation at
matrix adhesion sites, forming a core preinvadopodia complex. Recruitment of MT1MMP to preinvadopodia initiates matrix degradation and invadopodia maturation, with
further maturation involving dissolution of the cortactin-F-actin complex, focal retention
of MT1-MMP and continued proteolytic activity (Artym et al., 2006). While rudimentary
invadopodia-like F-actin structures formed in UMSCC1 cells treated with inhibitory
concentrations of saracatinib, they do not contain cortactin (Fig. 4A), which is essential
for invadopodia formation (Artym et al., 2006), indicating that Src kinase activity is
required for cortactin localization to invadopodia.

Similar results have been shown

through the use of kinase-inactive Src constructs (Bowden et al., 2006).

Tyrosine

phosphorylation of invadopodia proteins is strongly linked with the ability to degrade
extracellular matrix (Bowden et al., 2006), with Src phosphorylation of cortactin (Ayala
et al., 2008), paxillin (Badowski et al., 2008), and ASAP1 (Bharti et al., 2007) requisite
for invadopodia formation and/or proteolytic activity.

Src kinase inhibition therefore

displays at least a two-fold effect on substrates in invadopodia by impairing proper
preinvadopodia targeting and perturbing phosphotyrosine-based signaling dynamics
involved in regulating invadopodia maturation and function. Tyrosine phosphorylation in
peripheral focal adhesions was observed in UMSCC1 cells, indicating saracatinib may
also perturb focal adhesion formation and/or function given the critical role for Src and
related kinases in these structures (Frame, 2004).
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MMP activity is essential for HNSCC invadopodia formation and function (Clark et al.,
2007). The impairment of MMP9 secretion and activation from HNSCC cells treated
with saracatinib indicates that Src kinase activity is required for targeting and secretion
of MMP9-containing vesicles at invadopodia.

This is in agreement with observed

effects of Src kinase inhibition on MMP9 secretion in other tumor types (CortesReynosa et al., 2008; Lee et al., 2005). The lack of apparent MMP2 secretion in the
HNSCC lines used in our studies precluded evaluation of this metalloproteinase, and is
likely characteristic to these lines since other HNSCC cells secrete MMP2 (Clark et al.,
2007). Localization of transmembrane and secreted MMPs to invadopodia involves
directed trafficking of vesicles emanating from the trans-Golgi network, where a
dynamin-2-N-WASp-Arp2/3-cortactin complex has been implicated in coupling cortical
actin regulation with invadopodia membrane dynamics (Buccione et al., 2004).
Cortactin has been implicated as a key regulator of MT1-MMP surface expression and
MMP2 and MMP9 secretion in HNSCC (Clark & Weaver, 2008; Clark et al., 2007).
While it is currently unknown how cortactin regulates the targeting of MMP-containing
vesicles, Src-mediated phosphorylation may play a vital role since tyrosine
phosphorylation of cortactin increases its binding to vesicle-associated proteins (Ammer
& Weed, 2008) and is required for efficient invadopodia-mediated ECM degradation
(Ayala et al., 2008; Webb et al., 2007).
Our results indicate that disruption of Src activity by saracatinib impairs HNSCC cell
invasion and lymph node metastasis by preventing invadopodia formation and function,
identifying a cellular mechanism that may be universally impacted by Src inhibition in
invasive carcinoma cells. In addition to Src and related kinases, saracatinib also inhibits
Abl kinase, an activity that has been exploited to evaluate imatinib-resistant chronic
myelogenous leukemia (CML) cases expressing the constitutively active BCR-Abl
Philadelphia chromosome gene product (Gwanmesia et al., 2009).

Along with the

tumor-promoting activities in CML, elevated Abl kinase activity has been shown to be
important in breast (Srinivasan & Plattner, 2006) and non small cell lung cancer (Lin et
al., 2007), indicating Abl kinase activity has a functional role in solid tumor progression
(Lin & Arlinghaus, 2008). Abl expression has been evaluated in oral squamous cell
carcinoma and correlates with tumor stage (Yanagawa et al., 2000), suggesting that
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elevated Abl expression may contribute to HNSCC progression. While a mechanism
pertaining to Abl function in solid tumor invasion or invadopodia function has not been
reported, Abl does bind and phosphorylate cortactin, (Boyle et al., 2007), raising the
potential for Abl kinase to play a role in cortactin-based invadopodia function in HNSCC
and other invasive Abl-expressing solid tumors. Such a role for Abl in regulating tumor
invasion would also likely be impaired by saracatinib and other dual Src/Abl inhibitory
compounds.
In addition to carcinoma invadopodia, Src-mediated processes in non-cancerous cell
types involved in promoting invasion may also be impacted by Src family kinase
inhibition.

The motility and protease remodeling ability of tumor stromal fibroblasts

involved in enabling collective HNSCC invasion could be affected by impairing Src
family kinases in vivo (Gaggioli et al., 2007), as well as the proinvasive properties of
tumor-associated macrophages (Condeelis & Pollard, 2006). The ability of saracatinib
and other Src inhibitors to impair functions of different cellular types that propagate
tumor invasion provides the opportunity for the future discovery of additional Src-based
cellular mechanisms utilized during tumor progression.
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Figure Legends
Figure 1 Effects of saracatinib on HNSCC proliferation, cell cycle progression, Erk1/2
activation and in vitro invasion. A. IC50 values for cell growth determined by 5 day MTT
assays for the indicated HNSCC lines treated with 0-10 µM saracatinib. Mean values
are shown for each line from three independent assays. B. Impact of saracatinib on
HNSCC cell cycle progression.

HNSCC cell lines were treated with the indicated

amounts of saracatinib for 24 hours, fixed labeled with propidium iodide to assess DNA
content, and analyzed for cell cycle status by fluorescence-activated cell sorting.
Results show the average percentage of cells in each cell cycle phase as indicated on
the left. Bars, SD of two independent experiments. C. Effects of saracatinib on Erk1/2
activity. HNSCC cells were treated with saracatinib for 24 hours at the indicated doses,
lysed and analyzed by Western blotting with phosphorylation-specific (pErk1/2) and total
Erk1/2 antibodies. Blots shown are representative of three different experiments, with
indicated band intensities shown relative to no treatment (0 µM) for each cell line. D.
Saracatinib inhibits in vitro HNSCC invasion. HNSCC cells (1x105) were plated in
Matrigel-coated transwells alone or with increasing concentrations of saracatinib. After
2 h, invasion was stimulated with 5% FBS and cells were allowed to invade for 12 h
(UMSCC1) or 24 h (HN31 and 1483).

Invaded cells were quantified by brightfield

microscopy. Bars, SEM of three independent experiments.
Figure 2

Saracatinib inhibits Src activity and downstream Src substrate

phosphorylation in HNSCC cell lines. HN31, UMSCC1 and 1483 cells were treated with
DMSO vehicle or saracatinib (0.01-1 μM) for 24 h. Cells were lysed and total protein
amounts were analyzed by Western blotting with total or phosphorylation site-specific
antibodies for Src and the indicated substrates. Blots shown are representative of at
least four independent experiments, with band intensities for each substrate quantified
relative to the untreated (0 µM) condition for each cell line.
Figure 3 Saracatinib inhibits Src activity, perineural invasion and cervical lymph node
metastasis in orthotopic UMSCC1 tongue tumors. A. UMSCC1 tongue tumors from
representative control-treated or saracatinib-treated mice were sectioned and stained
with hematoxylin and eosin (H&E) or by IHC with the indicated antibodies (left). A case
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of human HNSCC was evaluated in parallel as a positive control. The pY416 SFK and
pY421 cortactin ratios from saracatinib treated to control levels are indicated. Bars, 100
μm. B. Locoregional invasion and lymph node metastasis is inhibited by saracatinib.
Submental and associated tracheoesophageal tissue from control treated and
saracatinib treated mice was immunostained for cytokeratin 14 to detect cells of
epithelial origin. Magnified regions containing a single sublingual nerve and superficial
cervical lymph node are shown for clarity. Inset shows a magnified cortical region of
superficial cervical lymph nodes from control and saracatinib treated mice. Arrowheads
denote metastasized UMSCC1 cells. N; sublingual nerve, ED; excretory duct. Bars 100
μm; inset, 50 μm.
Figure 4

Saracatinib inhibits invadopodia formation and ECM degradation.

Representative

images

of

UMSCC1

cells

treated

with

different

A.

saracatinib

concentrations. UMSCC1 cells plated on FITC-gelatin coated coverslips (pseudocolored
white) for 2 h were treated with saracatinib as indicated (left) for 6 h. Cells were labeled
to visualize F-actin (red), cortactin (green) and phosphotyrosine (blue). Arrows denote
invadopodia and corresponding colocalized areas of focal matrix degradation with
invadopodia components.

Treatment with 1.0 μM saracatinib resulted in F-actin

aggregates lacking cortactin but accumulated at cytoplasmic sites where invadopodia
typically occur (arrowheads). Bar, 10 μm. B. UMSCC1 cells treated with increasing
concentrations of saracatinib were stained as in A and quantified to determine the
percentage of cells that produced functional invadopodia, presented as the mean ±
SEM. All treatment groups were significantly different from each another based on a
one-way ANOVA (p<0.05) except 0 and 0.01 μM, and 0.5 and 1.0 μM pairs.

C.

Saracatinib decreases the ability of UNSCC1 cells to degrade ECM. The percentage of
gelatin degradation per cell area for the cell population analyzed in B is shown with the
mean ± SEM.
Figure 5 MMP9 secretion and ECM degradation activity in HNSCC cells is blocked by
saracatinib.

A. Localization of MMP9-containing vesicles in UMSCC1 invadopodia.

Top: UMSCC1 cells plated on FITC-coated gelatin coverslips for 2 h were fixed and
labeled with antibodies against cortactin and MMP9.
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The merged image indicates

areas of cortactin and MMP9 co-localization (yellow; white arrows) that correspond with
sites of focal gelatin degradation (black arrows). Bar; 10 µm, Asterisk; regions of global
matrix degradation due to secreted protease activity. Bottom: Magnified view of
indicated Top region. B. Inhibition of MMP9 secretion by saracatinib. Total cell lysates
(cell) and aliquots of normalized conditioned media containing secreted MMPs (sec)
from 1483 and UMSCC1 cells treated with increasing doses of saracatinib (bottom)
were assayed for the presence of MMP2 and MMP9 by immunoblotting.

Band

intensities relative to control (0 µM) are shown for each treatment condition; secreted
MMP2 was not detected and therefore not quantified. C. Gelatin zymography of MMP9
activity. Representative zymograms from conditioned media of 1483 or UMSCC1 cells
cultured with the indicated saracatinib concentrations (bottom). DMEM was used as a
negative control (M), DMEM containing 10% FBS (FBS) was used as a positive control
for zymography. Graphs, densitometric analysis of MMP9 zymography. Percentage of
MMP9 gelatin clearing is represented and the mean ± SEM for each cell line from three
independent experiments.
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Supplementary Figure Legends
Supplementary Figure 1 Specificity of human anti-pY421 cortactin antibody. SYF
fibroblasts lacking Src, Yes and Fyn were cotransfected with a the temperaturesensitive Src allele La29 along with expression vectors encoding recombinant wild-type
human

cortactin

(WT)

or

cortactin

mutants

containing

tyrosine-phenylalanine

substitutions at the indicated Src-targeted codons and held at the non-permissive
temperature (41º) or switched to the permissive temperature (35°). TYM; triple tyrosinephenylalanine cortactin mutant lacking all three Src-targeted sites. Cells were lysed and
analyzed by Western blot analysis with anti-pY421 cortactin (left). The blot was stripped
and reprobed with anti-cortactin monoclonal antibody 4F11 (right).
molecular weight markers is noted on the left in kilodaltons.
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Abstract
Background
Tumor cell motility and invasion is governed by dynamic regulation of the cortical actin
cytoskeleton. The actin-binding protein cortactin is commonly upregulated in multiple
cancer types and is associated with increased invasion and metastasis.

Cortactin

regulates actin nucleation through the actin related protein (Arp)2/3 complex, stabilizing
the cortical actin cytoskeleton.

Cortactin is regulated by multiple phosphorylation

events, including phosphorylation of S405 and S418 by extracellular regulated kinase
(ERK)1/2. ERK1/2 phosphorylation of cortactin has emerged as an important positive
regulatory event, enabling cortactin to bind and activate the Arp2/3 regulator neuronal
Wiskott-Aldrich syndrome protein (N-WASp), promoting actin polymerization and
enhancing cell migration and tumor cell invasiveness.
Methodology/Principal Findings
In this report we have developed phosphorylation-specific antibodies against cortactin
phosphorylated at S405 and S418 to analyze the subcellular localization of this cortactin
form in tumor cells and patient samples by microscopy. We evaluated the interplay
between

cortactin

S405

and

S418

phosphorylation

with

cortactin

tyrosine

phosphorylation in regulating cortactin conformational forms by Western blotting.
Cortactin is simultaneously phosphorylated at S405/418 and Y421 in tumor cells, and
through the use of point mutant constructs we determined that serine and tyrosine
phosphorylation

events

lack

any

co-dependency.

Expression

of

S405/418

phosphorylation-null constructs impaired carcinoma motility and adhesion, and also
inhibited lamellipodia persistence monitored by live cell imaging.
Conclusions/Significance
Cortactin phosphorylated at S405/418 is localized to sites of dynamic actin assembly in
tumor cells. Concurrent phosphorylation of cortactin by ERK1/2 and tyrosine kinases
enables cells with the ability to regulate actin dynamics through N-WASp and other
effector proteins by synchronizing upstream regulatory pathways, confirming cortactin
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as an important node in actin-based signal transduction. Reduced lamellipodia
persistence in cells with S405/418A expression identifies an essential motility-based
process reliant on ERK1/2 signaling, providing additional understanding as to how this
vital signaling pathway impacts tumor cell migration.
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Introduction
Tumor cell motility and invasion is a central problem in cancer that is paramount in
contributing to metastasis [1].

Tumor cells move through successive series of

coordinated and integrated stages, with formation of protrusive membranous structures
including filopodia, invadopodia and lamellipodia required for initiation and maintenance
of invasion and migration [2,3,4,5]. Central to the movement of most carcinoma cell
types undergoing single or collective migration is the production of lamellipodia at the
leading edge of the cell. Lamellipodia are planar protrusive extensions of the plasma
membrane produced by motile cells in two- and three-dimensional settings [6].
Lamellipodia extension drives cell migration through integrin-based adhesion with the
underlying

substratum,

providing

the

necessary

traction

for

contractile-based

translocation of the cell body to generate productive movement [7].

It is generally

accepted that dynamic regulation of the cortical actin cytoskeleton through cycles of
actin polymerization and depolymerization are responsible for generating the propulsive
force needed for lamellipodia extension [8].
The actin cytoskeleton within lamellipodia is governed by the activity of numerous actinbinding proteins. One element central to the formation of lamellipodia actin networks is
activation of the actin-related (Arp) 2/3 complex, which nucleates filamentous (F-) actin
polymerization within lamellipodia [9]. Arp2/3 complex binds to the sides of pre-existing
F-actin, where upon activation the Arp2 and Arp3 subunits mimic the fast growing
(“barbed” or “+”) end of an actin filament, allowing for the rapid addition of actin
monomers to the complex and subsequent filament extension [4]. The resulting Arp2/3F-actin networks comprise an organized branched array of F-actin filaments that
contribute to lamellipodia extension, with Arp2/3 localized at filament branch points
[8,9]. Arp2/3 branch points are metastable, allowing for rapid breakdown of Arp2/3-Factin networks by filament debranching [10]. Debranched F-actin filaments are further
disassembled through the severing activity of members of the actin depolymerizing
factor/cofilin

family,

which

ultimately

dissolve

F-actin

filaments

to

promote

depolymerization, recycling actin monomers for additional rounds of polymerization and
lamellipodia extension [11].
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Arp2/3 activation is controlled by the activity of several actin nucleation promoting
factors (NPFs). The best characterized NPFs to date are members of the WiskottAldrich syndrome protein (WASp) family, which include the WASp and WAVE protein
subgroups [12,13].

In many cell types, regulation of Arp2/3 activity by the WASp

proteins N-WASp and WAVE2 are largely responsible for generating the actin network
used for creating and regulating lamellipodia, filopodia and invadopodia [4,12,14],
making these NPFs critical mediators of cell motility and invasion.
Another well-characterized NPF independent of the WASp protein family is the cortical
actin-binding protein cortactin [15,16]. Cortactin directly binds Arp2/3 complex [17,18]
and activates Arp2/3 complex nucleation activity in vitro, albeit at a lesser degree than
WASp-family proteins [18,19].

In addition to actin nucleation, a unique function of

cortactin is its ability to prevent spontaneous debranching of Arp2/3-F-actin networks by
simultaneous binding to Arp2/3 and F-actin, prolonging the lifetime of branched
filaments [19].

While the biochemical features of cortactin seem to point to a

straightforward role in lamellipodia actin regulation, studies of cortactin function in
lamellipodia have proven controversial, suggesting to a more complex role in cell
migration. For instance, RNA interference studies have yielded conflicting results in
regards to lamellipodia dynamics, with cortactin knockdown resulting in decreased
lamellipodia stability and reduced persistence [20,21,22], whereas similar studies in
different cell types suggest cortactin downregulation increases the length of extending
lamellipodia [23]. Furthermore, recent analysis of fibroblast lamellipodia dynamics in
cortactin-/- cells indicates that cortactin does not play a role in directly regulating
lamellipodia protrusion or Arp2/3-based actin dynamics, but rather is important in
mediating upstream activation of the small GTPases Rac1 and Cdc42, which in turn
regulate WAVE2 and N-WASp activity [24].

While these reported discrepancies

regarding cortactin function in lamellipodia have yet to be fully reconciled, it is clear that
cortactin is an important regulator for normal and tumor cell migration in many cell
systems [25,26]. An unambiguous role for cortactin has been shown in invadopodia,
where removal of cortactin by RNA interference ablates invadopodia formation in
multiple invasive tumor cell types [27,28,29].
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Besides regulating Arp2/3-based cortical actin networks by direct interactions, cortactin
also functions as a key mediator in several kinase-based signal transduction cascades
that serve to indirectly govern Arp2/3 activity and subsequent cell movement. Cortactin
is a well-defined target for Src kinase [30], phosphorylating human cortactin on tyrosine
residues Y421, Y470 and Y486 within the proline-rich (PR) carboxyl-terminal domain
[31]. Several other tyrosine kinases target these residues [32,33,34,35], indicating that
they collectively form a “hot spot” region as a point of convergence for multiple signaling
pathways.

Cortactin phosphorylated at tyrosines 421, 470 and/or 486 creates Src

homology (SH)2 docking sites for several phosphorylating kinases, as well as the
adaptor proteins Crk [36] and Nck1 [37]. In the case of Nck1, Nck1/cortactin complexes
interact with N-WASp or WASp interacting protein through the Nck1 SH3 domain to
stimulate Arp2/3-dependent actin nucleation [37], which in cooperation with Arg kinase
has been recently demonstrated to be important for regulating lamellipodia protrusion
and leading edge adhesion formation [38]. The cortactin/Nck1 complex is also required
to stimulate actin polymerization essential for invadopodia function in invasive breast
cancer cells [39].

These studies are in agreement with the localization of tyrosine

phosphorylated cortactin within lamellipodia and invadopodia [40], lending mechanistic
insight into the long recognized pro-migratory and pro-invasive properties associated
with cortactin tyrosine phosphorylation [29,31,41,42].
In addition to tyrosine phosphorylation, cortactin is a target for multiple serine/threonine
kinases [43]. Stimulation of tumor cells with epidermal growth factor (EGF) results in
increased serine/threonine phosphorylation of serine residues 405 and 418 within the
PR domain, coincident with a characteristic shift in cortactin electrophoretic mobility
from 80 kDa to 85 kDa in SDS-PAGE [44,45]. The mobility shift and phosphorylation of
S405/S418

are

impaired

by

pharmacologic

inhibition

of

mitogen

activated

protein/extracellular signal regulated kinase kinase (MEK)1/2, and direct biochemical
evidence indicates that the MEK effector kinases ERK1/2 directly phosphorylate
cortactin at these sites [45]. Phosphorylation of S405/S418 enhances binding of the
cortactin carboxyl-terminal SH3 domain to N-WASp and activates N-WASp NPF activity,
indicating a functional role in stimulating Arp2/3-mediated actin dynamics independent
of tyrosine phosphorylation [46].

This is supported by studies expressing
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phosphorylation-null and phosphomimetic point mutant constructs in cells, suggesting
that S405/S418 phosphorylation plays a critical role in regulating cellular actin
polymerization necessary to promote cell motility [47] and invadopodia function [29]. In
addition, p21 activated kinase 1 (PAK1) phosphorylates cortactin at S405/S418, serving
to stimulate N-WASp activity required for clathrin-independent endocytosis [48]. While
studies to date implicate a positive regulatory function for cortactin S405/418
phosphorylation in promoting N-WASp-mediated Arp2/3 actin structures, the subcellular
localization of phosphorylated S405/418 cortactin, as well as the precise role S405/418
phosphorylation plays in regulating lamellipodia dynamics have not been evaluated.
In this study, we have generated site-specific antibodies against phosphorylated
cortactin S405 and S418 to determine the spatial and temporal localization of cortactin
in dynamic actin structures and human tumors, and to evaluate signaling interplay
between cortactin tyrosine and serine phosphorylation events. We also determined the
effects of S405/418 cortactin phosphorylation on EGF-induced cell migration, adhesion
and lamellipodia dynamics in carcinoma cells.
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Materials and Methods
DNA Constructs and siRNA
For Myc-tagged human cortactin expression constructs, the wild-type human cortactin
cDNA subcloned into pcDNA FLAG2AB [49] was used as a template for producing point
mutants by site-directed mutagenesis (QuickChange; Stratagene, La Jolla, CA). Codon
alterations in human cortactin were: S405A, S418A, S405A/S418A, Y421F, Y470F,
Y486F, Y421F/Y470F/Y486F and W492K. Cortactin cDNAs were amplified by PCR as
BamHI-EcoRI fragments and subcloned into BamHI-EcoRI digested pRK5Myc [50].
Murine GFP-tagged expression constructs were produced using pcDNA3FLAG2AB
wild-type murine cortactin [17] as the template for mutagenesis, then subcloned as
EcoRI-KpnI PCR fragments into pAcGFP-C1 (Clontech, Mountain View, CA).

The

temperature-sensitive vSrc LA29 construct was previously described [51]. mCherry-βactin was obtained from D. Schafer (University of Virginia), with the parent construct
produced by R. Tsien (University of California, San Diego). Small interfering (si)RNA
targeting rodent cortactin (5’-GCTTCGAGAGAATGTCTTC-3’) was purchased from
Thermo Scientific (Waltham, MA)
Cell lines and Transfection
The HNSCC cell lines 1483 [52], UMSCC1 and UMSCC2 [53] were maintained as
described [41]. SYF cells were obtained from the American Type Culture Collection
(Manassas, VA) and maintained according to the supplied protocol. The rat mammary
adneocarcinoma line MTLn3 was maintained in aMEM supplemented with 10% fetal
bovine serum, 1% L-glutamine and 1% penicillin-streptomycin. Transient transfections
were conducted with 3 x 106 cells and 2µg of plasmid construct or siRNA using the
Nucleofector I device (Amaxa Biosystems, Berlin, Germany).
Antibodies
Antibodies against phosphorylated serine 405 (pS405) and serine 418 (pS418) of
human cortactin were produced by 21st Century Biochemicals (Marlboro, MA).
Synthetic

phosphorylated

cortactin

peptides
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containing

the

sequences

NH2-

KTQTPPV[pS]PAPQPTC-COOH (cortactin pS405) and NH2-TEERLPS[pS]PV-COOH
(cortactin pS418) were produced, conjugated to keyhole limpet cyanine and injected
into rabbits. Immune serum was screened by enzyme-linked immunosorbent assay
against the appropriate phosphorylated cortactin peptide coupled to bovine serum
albumin. High-titer bleeds were identified for each peptide, and immune serum was
passed two successive times through chromatography columns containing agarose
beads coupled to the equivalent non-phosphorylated peptide. The flow through material
for each peptide was subsequently passed twice through chromatography columns
containing beads conjugated to the matched phosphorylated cortactin peptide. After
extensive washing, bound antibodies for each phosphorylation site were eluted,
concentrated and screened for specificity by Western blotting against recombinant
cortactin mutant proteins harboring alanine-serine point mutations at serine 405 or 418,
respectively (Fig. 1A). The anti-pS405 and anti-pS418 cortactin antibodies are currently
available through Protea Biosciences (Morgantown, WV).

Anti-cortactin (4F11) was

used as described [41]. Anti-pY421 cortactin and anti-pY418 Src were from Invitrogen
(Carlsbad, CA). Anti-ERK1/2 and pERK1/2 were from Cell Signaling (Danvers, MA).
Anti-Myc epitope tag (4A6) was from Millipore (Billerica, MA). Anti-GFP (JL-8) was
fromClontech (Mountain View, CA) and anti-β-actin was from EMD4Biosciences (San
Diego, CA).
Western blotting and Immunoprecipitation
Western blotting was conducted as described [41]. Primary antibody dilutions used
were: anti-pS405 cortactin (1:4000), anti-pS418 cortactin (1:500), anti-cortactin
(1:1000), anti-pY-421 cortactin (1:2000), anti-ERK1/2 (1:2000), anti-pERK (1:2000),
anti-pY418 Src, anti-GFP (1:1000) and anti-β-actin (1:5000).

Immunoprecipitations

were performed as described [40] using 5µg of precipitating antibody captured with 40µl
of a 50% Protein A/G bead slurry (Thermo Fisher Scientific, Pittsburgh, PA). In some
cases cells were treated with selumetinib (AZD6244; ARRY-142886) or saracatinib
(AZD0530) for 24h prior to immuoprecipitation and Western blotting analysis.
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Microscopy
UMSCC2 cells were plated on fibronectin-coated coverslips (10µg/ml; Sigma, St Louis,
MO) and allowed to attach before serum starvation for 16 h. Cells were stimulated with
100ng/ml EGF (Millipore) for 1h before fixation. UMSCC1 cells plated on FITC-gelatin
(Sigma) for 8 h were processed for confocal microscopy using Zeiss LSM 510 Meta
system (Thornwood, NY) as described [49]. Anti-pS418 cortactin was used at 1:1000,
4F11 at 1:500 and rhodamine-conjugated phalloidin at 1:1000 (Invitrogen, Carlsbad,
CA).
For immunohistochemistry, HNSCC tissue blocks were obtained from the West Virginia
University Tissue Bank and used under approval of the West Virginia University
Institutional Review Board.

Five-micrometer sections from formalin-fixed, paraffin-

embedded blocks were processed for immunostaining using the Discovery XT
automated staining system (Ventana, Tucon AZ). Briefly, after deparaffinization and
antigen retrieval, sections were incubated with monoclonal rabbit anti-cortactin (Novus,
Littleton, CO) at 1:2000, anti-pS418 cortactin at 1:25 and anti-pERK1/2 at 1:100
dilutions. All primary antibodies were incubated in Dako diluent (Dako, Carpinteria, CA)
for 1 h. Primary antibodies were detected with the Omnimap antibody horseradish
peroxidase kit (Ventana).

Slides were counterstained with hematoxylin and post-

counterstained with bluing reagent (Ventana). Images were visualized with an Olympus
AX70 microscope and captured using the MicroBrightfield system (Williston, VT).
Live cell imaging was conducted using MTLn3 cells starved for 3 h with serum-free
media prior to stimulation with 100ng/ml EGF.

Cells were plated on delta-T glass

bottom dishes (Fisher) coated with 10µg/ml fibronectin (Sigma). Immediately following
EGF addition, cells were imaged by differential interference contrast using a Nikon
TE2000 inverted microscope equipped with a Roper CoolSNAP HQ charge-coupled
device camera (Photometrics, Tucson, AZ). Images were captured every 5 s for 15 min
(181 total frames). A Nikon LiveScan SFC swept field microscope was used for imaging
cells expressing mCherry-actin.

In all cases, GFP-cortactin expressing cells were

identified by fluorescence microcopy prior to imaging. Kymograms were produced by
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extracting 1 pixel-width strips from each movie frame at points of initial and maximal
lamellipodia extension, and assembled using ImageJ (v1.40).
Electric Cell Substrate Impedance Sensing
To assay cell motility and adhesion, 5 x 105 cells were plated into 8-well electric cell
substrate impedance sensing dishes (ECIS; Applied Biophysics, Troy, NY). For motility
measurements, cells were allowed to adhere overnight on 8W1E dishes to form a
monolayer. Adhesion was assayed immediately after plating cells onto 8W10E dishes.
Measurements were conducted for 24 h at 45kHz, with reading taken at 1 min intervals.
Cells treated with selumetinib were serum starved 24 h in the presence of drug prior to
ECIS.
Statistical Analysis
Differences in mean groups for migration, adhesion and kymography between control
and treated groups were evaluated using one way ANOVA, followed by StudentNewman-Keuls post hoc testing. All differences were considered significant at p< 0.05.
A minimum of three experimental groups were used for all analyses.
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Results
Localization of pS418 cortactin with dynamic cortical actin structures
We developed antibodies specific to phosphoserine 405 (pS405) and phosphoserine
418 (pS418) of human cortactin to facilitate analysis of these sites. To validate antibody
specificity, epitope (Myc)-tagged cortactin constructs containing wild-type (WT)
cortactin, cortactin with individual serine to alanine mutations at serine 405 (S405A),
418 (S418A) or with both mutated in tandem (S405,418A) were produced and
transfected into 1483 cells. Total cell lysates were blotted with anti-pS405 or antipS418 antibodies (Figure 1A). The anti-pS405 antibody recognized the WT and S418A
cortactin variants, failing to blot constructs containing the S405A mutation. Conversely,
anti-pS418 blotted WT and S405A, failing to recognize cortactin constructs with S418A
mutations.

All cortactin variants were recognized by an anti-cortactin monoclonal

antibody (Figure 1A), indicating equivalent expression of the assayed constructs.
These results indicate that the anti-pS405 and anti-pS418 antibodies specifically
recognize their cognate phosphorylated cortactin epitope, and that no interdependence
exists between phosphorylation of cortactin S405 and S418.
To determine the subcellular localization of serine phosphorylated cortactin, we
conducted indirect immunofluoresence studies on cells producing lamellipodia and
invadopodia, two actin-based structures that depend in part on N-WASp activity. While
the anti-pS405 antibody yielded non-specific staining in our hands (data not shown),
anti-pS418 specifically labeled lamellipodia and cytoplasmic puncta (presumably
vesicles) in UMSCC2 cells. In cells with a motile phenotype, anti-pS418 localized with
cortactin and F-actin in these regions (Figure 1B, top row). Labeling of UMSCC1 cells
plated on FITC-coated gelatin matrix with anti-pS418 indicated specific localization to a
subset of invadopodia that coincided with cortactin, F-actin and areas of gelatin clearing
indicative of matrix metalloproteinase mediated invadopodia activity (Figure 1B, middle
and bottom rows).
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In solid human tumors, cortactin and cortactin phosphorylated on tyrosine 421 (pY421)
localizes to invasive tumor fronts and to cell-cell junctions [41,49]. To determine the
location of pS418 cortactin in tumor tissue, head and neck squamous cell carcinoma
(HNSCC) cases were sectioned and stained with anti-pS418 (Figure 1C). Cortactin
pS418 was abundant in HNSCC cell cytoplasm and was enriched in areas of cell-cell
contact, displaying a pattern similar to sections labeled with a total cortactin antibody
(Cort).

These tumor regions also contained activated ERK1/2, as evidenced by

pronounced cytoplasmic and nuclear staining of phosphorylated ERK1/2 in serial
sections (Figure 1C).

Growth factor mediated phosphorylation of cortactin S405/418 is MEK dependent
Previous biochemical work has implicated chemical inhibition of MEK and subsequent
blocking of ERK1/2 activation as a major pathway responsible for cortactin S405/418
phosphorylation [45].

To further evaluate the role of the MEK-ERK1/2 pathway on

cortactin phosphorylation, we utilized the anti-pS405 and pS418 cortactin antibodies to
directly test the effects of MEK inhibition on cortactin pS405/418. Western blot analysis
of cell extracts from EGF- and serum-stimulated UMSCC1 cells with anti-pS405 and
pS418 antibodies displayed similar phosphorylation kinetics of S405 and S418, with
phosphorylation of both sites first evident 10 min after stimulation (Figure 2A) and
remaining phosphorylated up to 2 h (data not shown). Treatment of UMSCC1 or 1483
cells with the small molecule MEK inhibitor selumetinib [54] reduced EGF-stimulated
cortactin S405/418 phosphorylation in a dose-dependent manner, where near
elimination of phosphorylation at both serine residues occurred at doses > 1µM (Figure
2B).

ERK1/2 activity was also reduced under similar dose conditions, although

complete ablation of ERK1/2 phosphorylation was observed at doses > 5µM (Figure
2B). These data suggest that the MEK-ERK pathway is largely responsible for growthfactor induced cortactin S405/418 phosphorylation in HNSCC cells, in agreement with
previous findings in other cell types [45].
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The 80kDa to 85kDa cortactin conformational shift is associated with serine and
tyrosine phosphorylation
Based on sequence analysis, the largest and most prominent cortactin isoform
(cortactin “A” or “SV1”) encodes a 61.5kDa protein [55,56].

This cortactin form

frequently migrates as an 80/85kDa doublet in SDS-PAGE [30,57] that has been
attributed to conformational alterations within the polypeptide chain [15,45]. Shifting
from the 80kDa to 85kDa form is seen in response to EGF, with the resulting 85kDa
band associated with S405/418 phosphorylation [44,45].

To directly assess the

presence of pS405/418 in the two cortactin conformational isomers, serum-starved
UMSCC2 (Figure 3A) and 1483 (Figure 3B) cells were stimulated with EGF and the
cortactin forms in cell lysates were analyzed at successive time points with anti-pS405
and anti-pS418 antibodies. S405/418 phosphorylation was maintained in the 85kDa
cortactin form in both cell lines following serum starvation, despite of the lack of ERK1/2
activity (0 min, Figure 3A and Figure 3B).

EGF stimulation resulted in complete

conversion of the 80kDa to the 85kDa cortactin form by 1 h after EGF treatment in both
cell lines (Figure 3A and Figure 3B).

Cortactin pS405 and pS418 was observed

primarily in the 85kDa form and increased at both sites during the entire time course,
whereas ERK1/2 activity peaked at 15 min and rapidly declined afterwards (Figure 3A
and Figure 3B). Interestingly, the phosphorylation of S405 was also associated with an
increase appearance of cortactin degradation in UMSCC2 cells (Figure 3A).

It is

uncertain whether these products represent increased overall cortactin degradation, or if
the net cortactin degradation is constant but is selectively identified by the pS405
antibody in response to EGF treatment and phosphorylation.

EGF-induced Src

activation and cortactin pY421 phosphorylation was sustained throughout the entire
time course in UMSCC2 cells (Figure 3A), indicating that cortactin can be
simultaneously phosphorylated by ERK1/2 and Src or potentially other EGF-stimulated
cortactin tyrosine kinases. Pretreatment of UMSCC2 cells with the Src family kinase
inhibitor saracatinib at 10µM or selumetinib at 1µM completely impaired the cortactin
shift from 80kDa to 85kDa (Figure 3C). The exclusive presence of pS405 and pS418 in
the EGF-induced 85kDa cortactin form, as well as the ability of MEK inhibition to impair
the cortactin shift is consistent with results obtained from previous work [45].
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Our

results also identified EGF-induced Src-mediated phosphorylation of cortactin at
tyrosine 421 as a necessary mediator of the cortactin shift.
Cortactin

serine

phosphorylation

in

vivo

is

independent

from

tyrosine

phosphorylation
EGF treatment of UMSCC2 cells resulted in phosphorylation of cortactin S405/418 and
cortactin pY421 (Figure 3A). A previous in vitro study evaluating the impact of cortactin
phosphorylation on N-WASp activation determined that S405/418 phosphorylation by
ERK1/2 enables the cortactin SH3 domain to stimulate N-WASp Arp2/3 activation, while
Src phosphorylation downregulates N-WASp activity and counteracts the effects of
S405/418 phosphorylation [46]. This proposed “on-off switch” postulates that cortactin
serine and tyrosine phosphorylation are mutually exclusive events governing the ability
of cortactin to regulate N-WASp activity and downstream actin reorganization [58].
Using the available antibodies reactive against cortactin pS405 and pY421, we sought
to determine if these two different classes of phosphorylation events are interdependent
in any manner.

Cortactin depleted SYF fibroblasts (null for the Src, Yes and Fyn

kinases) were co-transfected with the temperature-sensitive vSrc construct tsLa29-GFP
[51] to activate the Src and ERK1/2 signaling pathways, along with constructs encoding
wild-type cortactin or the following Myc-tagged cortactin mutants: Y421F, Y470F,
Y486F, Y421/Y470/Y486F (TPM), S405A, S418A, S405/418A (Figure 4A). A W492K
cortactin mutant was also included, as this mutant abolishes the ability of the cortactin
SH3 domain to interact with corresponding SH3 binding proteins [59]. After shifting to
35ºC for 2 h to activate tsLa29-GFP, the serine and tyrosine cortactin mutants were
analyzed for phosphorylation at Y421 and S405 by SDS-PAGE and Western blotting
(Figure 4B). Mutations to S405 and S418 alone and in combination did not impact the
ability of these constructs to be phosphorylated on Y421, as indicated by their
recognition with the anti-pY421 antibody (Figure 4B).

Similarly, mutations to Y421,

Y470, and Y486, alone and in combination (TYM) did not affect the ability of these
constructs to be phosphorylated on S405.

These data indicate that cortactin is

simultaneously phosphorylated at S405 and Y421 downstream of vSrc activation,
suggesting in this system that phospho-regulation of cortactin SH3 domain function is
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not governed in vivo by the serine-tyrosine “on-off switch” mechanism proposed from
previous in vitro experimentation [46,58].
S405/418 phosphorylation is required for efficient tumor cell motility and
adhesion
To evaluate the role of cortactin S405/418 phosphorylation on carcinoma cell migration,
1483 and UMSCC1 cells were treated with selumetinib and assayed for effects on
motility by ECIS (Figure 5). Selumetinib treatment impaired the motility of both cell
types in a dose-dependent manner, corresponding to the observed decreases in
S405/418 phosphorylation (Figure 2B).

Since MEK inhibition likely impaired the

phosphorylation of other proteins involved in motility in addition to cortactin, we directly
assessed the impact of cortactin S405/418 phosphorylation on cell migration using
phosphorylation-null

cortactin

expression

constructs.

MTLn3

rat

mammary

adneocarcinoma cells were initially transfected with a siRNA targeted against rodent
cortactin, followed by transfection with GFP-tagged human wild-type (WT), S405A,
S418A and S405/418A cortactin constructs.

Cortactin siRNA reduced endogenous

cortactin levels to > 90%, having no impact on expression of the human GFP-labeled
variants (Figure 6A).

MTLn3 cells with cortactin knockdown (si) displayed a 29%

reduction in motility compared to control (Ctl) (Figure 6B).

Expression of wild-type

human GFP-cortactin (WT) led to a 2-fold increase in motility, presumably due to
increased expression of this variant over endogenous (Ctl) levels (Figure 6A).
Expression of S405A, S418A or S405,418A cortactin resulted in an 49% average
decrease in cell migration for each cortactin mutant, indicating that phosphorylation of
S405 and S418 are both vital in maintaining optimal carcinoma cell motility (Figure 6B).
Since lamellipodia formation is required for detached cells to adhere to the ECM, we
conducted ECIS assays to determine the effects of cortactin S405/418 phosphorylation
on cell adhesion.

MTLn3 cells lacking cortactin expression (si) exhibited a 50%

decrease in cell adhesion compared to control (Ctl) cells. Expression of wild type (WT)
GFP-cortactin restored adhesion to levels similar to Ctl, whereas expression of S405A,
S418A or S405/418A cortactin mutants all reduced adhesion to levels 42-58% of Ctl,
failing to restore adhesion to levels above cortactin si cells (Figure 6C). These results
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suggest that S405/418 phosphorylation is critical for carcinoma cell motility and
adhesion, representing an important pro-migratory substrate targeted by the MEKERK1/2 pathway.
Cortactin S405/418 phosphorylation is required for carcinoma cell lamellipodia
persistence
Given the localization of pS418 cortactin within lamellipodia (Figure 1B) and the effects
of cortactin S405/418A expression on cell motility, we evaluated the impact of cortactin
S405/418 phosphorylation on lamellipodia dynamics using live-cell imaging and
kymographic analysis.

Serum-starved MTLn3 cells expressing mCherry-β-actin and

containing endogenous cortactin knockdown alone (si), rescued with human GFP- wildtype cortactin (si+WT) or with GFP-cortactin S405/418A (si+S405,418) were stimulated
with EGF for 15 min.

Lamellipodia dynamics were monitored by time lapse video

microscopy (Figures S1-S4) and assayed by kymography (Figure 7A). EGF-stimulated
MTLn3 cells produced an initial dominant lamellipodia that reached maximal extension
between 1.5 and 3 min, and retracted to the point of origin between 5-7 min [60,61].
Control MTLn3 cells containing mCherry-β-actin displayed similar extension-retraction
kinetics when assayed by kymography (Figure 7B and Figure S1). While no differences
were observed in lamellipodia protrusion rates in any of the assayed cellular conditions
(Figure 7A), cortactin knockdown (si) increased lamellipodia extension by an average of
5.8 µm over the maximum extension length observed in control cells (Figure 7A and B).
Lamellipodia formed in cortactin si cells failed to effectively retract lamellipodia,
demonstrating a ~2-fold increase in average lamellipodia persistence over control levels
(Figure 7A and Figure S2). These results are consistent with the observed increase in
lamellipodia extension and persistence observed when MTLn3 cells contact EGFcoated bead matrices [23].

These effects are fully rescued to control levels upon

expression of WT GFP-cortactin (si+WT; Figure 7A and B). Although expression of
GFP-cortactin S405/418A in cortactin si cells did not impact EGF-induced lamellipodia
extension, average lamellipodia persistence was reduced by 46%, from 195 sec in
si+WT cells to 106 sec in si+405,418 cells (Figure 7A). The lamellipodia in si+405,418
cells displayed series of multiple short extensions and retractions, had enhanced ruffling
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and appeared more labile than control or si+WT cells (Figure 7B: Figures S1 and S2
compared to Figure S4). These results suggest that S405/418 phosphorylation is vital
in regulating lamellipodia actin dynamics responsible for proper protrusive behavior.
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Discussion
While the effects of cortactin phosphorylation at S405 and S418 by ERK1/2 have been
studied at the biochemical and functional level in several systems [29,45,46,47], the
spatial and temporal evaluation of S405 and S418 phosphorylation have been
hampered due to the lack of suitable reagents to directly study these sites in cellular
and tissue contexts. Our development of anti-pS405 and anti-p418 cortactin antibodies
has allowed us to examine the localization and signaling pathways regulating these
cortactin phosphorylation events.

These antibodies, coupled with the use of

phosphorylation-null mutant constructs, allowed us to validate and extend previous
findings implicating these sites in the regulation of carcinoma cell motility and
associated lamellipodia dynamics.
The localization of pS418 cortactin in carcinoma lamellipodia and invadopodia is
consistent with the defined and emerging roles cortactin plays in regulating actin
dynamics within these structures [26,62]. To date, all studies designed to evaluate the
cellular effects of pS405/418 phosphorylation have relied on the use of phosphorylation
null or phosphomimetic (S405/418D) constructs. In pancreatic tumor cells, S405/418A
and S405/418D both promote lamellipodia protrusion over control levels, whereas
S405/418A inhibits and S405/418D promotes cell motility [47].

While the ability of

S405/418A to promote lamellipodia protrusion in these studies is unclear, the remaining
results are consistent with an activating role for S405/418 phosphorylation in
lamellipodia dynamics and motility. Similar results were obtained in the analysis of
S405/418 on invadopodia function, with S405/418A expression impairing and
S405/418D promoting ECM degradation activity [29]. Phosphorylation of cortactin S418
within lamellipodia and invadopodia (Figure 1B) supports these results. Precisely where
cortactin is phosphorylated on S405/418 in carcinoma cells remains to be determined,
although the phosphorylating kinases ERK1/2 and PAK1 have been localized within
lamellipodia [63,64] and invadopodia [65]. This could suggest that cortactin is initially
localized to lamellipodia or invadopodia, where it is subsequently phosphorylated on
S405/418 when associated with the cortical actin networks within these structures. An
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analogous mechanism is employed for cortactin tyrosine phosphorylation within
lamellipodia [40].
In HNSCC and several other tumor types, cortactin is present in the cytoplasm and is
enriched at cell-cell junctions [41,66,67]. The localization of pS418 cortactin at regions
of HNSCC cellular contact within tumors resembles the localization pattern of pY421
cortactin in this tumor type [68].

The staining pattern of cortactin and its tyrosine

phosphorylated form is reminiscent of that found in two-dimensional epithelial
monolayers, where cortactin has been shown to be essential for Arp2/3-mediated actin
remodeling resultant from E-cadherin homoligation and subsequent Src activity [69,70].
While the presence of pS418 cortactin at these sites suggests additional functional roles
for cortactin in E-cadherin-mediated actin regulation within tumors, whether or not
cortactin S405/418 phosphorylation impacts elements of E-cadherin-based regulation of
solid tumor behavior (such as tumor cell cohesion, motility or dissemination) remains to
be examined.
Selumetinib inhibition of cortactin S405/S418 phosphorylation is consistent with results
obtained with non-clinical MEK inhibitors [29,45], reinforcing the MEK-ERK1/2 pathway
as the main signaling route responsible for phosphorylating these cortactin sites in
tumor cells. This is supported by direct phosphorylation of cortactin by ERK1/2 in vitro
[45] along with our data demonstrating concomitant downregulation of active ERK1/2
resultant of selumetinib treatment. In addition to MEK, PAK1 has recently been shown
to phosphorylate cortactin at S405/418, regulating N-WASp actin dynamics responsible
for clathrin- and caveolin-independent endocytosis [48]. PAK1 is activated primarily by
binding to active Cdc42 or Rac1 [71], although alternative modes of activation have also
been described [72].

Activated PAK1 also binds and activates MEK, stimulating

ERK1/2 activation [73]. Since MEK inhibition largely ablates S405/418 phosphorylation
in most cell types, the impact of PAK1 activity on S405/418 phosphorylation may be
context dependent, with direct PAK1 phosphorylation of cortactin S405/418 regulating
actin

polymerization

required

for

endosomal

trafficking,

while

MEK-mediated

phosphorylation (activated by Raf or other MEK activators) may be primarily responsible
for governing motility-based actin dynamics. In addition, the related kinase PAK3
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phosphorylates cortactin at S113, an event that downregulates the ability of cortactin to
bind F-actin and is important in modulating invadopodia function [29,74]. While our
understanding regarding the interrelationship and regulation between PAK and MEK in
governing cortactin S405/418 phosphorylation is currently incomplete, it is clear that the
PAK- MEK-ERK1/2 signaling nexus impinges at multiple levels on cortactin to regulate
actin dynamics involved in several membrane-based cellular processes.
Consistent with other reports [44,45], we observed the MEK-dependent EGF-induced
shifting of cortactin from the 80kDa to 85kDa form by Western blotting. Direct analysis
with anti-pS405 and anti-pS418 antibodies indicates that the 85kDa form is almost
exclusively phosphorylated on these residues, as was determined by
tryptic peptide analysis [44,45].
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P labeling and

The shift in cortactin Mr is not attributable to bulk

addition of phosphate, since phosphatase treatment of cortactin immunoprecipitates
from EGF-treated cells failed to reconvert the 85kDa form to 80kDa (data not shown).
While the distinct 80kDa and 85kDa bands represent different post-translationally
modified cortactin forms associated with pS405/418 phosphorylation, mutations at these
sites have no effect on 80/85kDa cortactin ratios, with the S405/418A mutant displaying
a similar cortactin electrophoretic pattern to wild type cortactin (Figure 4). This suggests
that S405/418 cortactin phosphorylation, while associated with the shift from 80 to
85kDa, is not necessary for generation of the 85kDa cortactin form. This is supported
by the presence of 80kDa and 85kDa cortactin forms produced in kinase-free systems
[30,75] and by the existence of a single 85kDa form when analyzed by urea denaturing
SDS-PAGE [75].
The lack of detailed structural data for cortactin derived by nuclear magnetic resonance
spectroscopy or X-ray crystallography has hindered the field in understanding
conformational changes cortactin undertakes in response to post-translational modifying
events.

The existence of cortactin in a “closed” versus “open” form regulated by

S405/418 phosphorylation has been proposed to explain the observed 80 to 85kDa shift
[45]. Support for this is derived from biochemical studies on N-WASp activation by the
cortactin SH3 domain, where S405/418 phosphorylation enhances N-WASp activation
and Arp2/3 actin nucleation activity [46].

These studies propose that the “closed”
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cortactin form undergoes an autoinhibitory conformational state where the carboxyl
terminal helical proline-rich (HP) domain containing S405 and S418 is altered to render
the SH3 domain inaccessible to binding N-WASp or other proteins. Phosphorylation of
S405/418 results in liberating the SH3 domain, where it in turn is capable of binding and
stimulating N-WASp activation.

Expression of cortactin S405/418D phosphomimetic

forms in cells increases branched actin networks in actin tails associated with
cytoplasmic vesicles, providing support for this model in promoting cellular actin
polymerization [47]. Initial assessments of cortactin structure by rotary shadow electron
microscopy revealed cortactin to exist as a rod shaped monomer 220Å in length [76].
However, a recent biophysical analysis utilizing chemical crosslinking and small angle xray scattering suggests that cortactin exists in a more globular form, with the carboxyl
terminal HP and SH3 domains folding back onto the amino terminal actin binding region
[77].

Such a structure would support a “closed” conformation, although “open”

structures were not observed, nor were the effects of ERK1/2 phosphorylation
evaluated. Additional evidence for an inhibitory function of the amino terminus can be
inferred from the ability of the cortactin carboxyl terminal domain to promote N-WASPdependent cell motility as effectively as wild type cortactin [78], as well as the
prevalence of the 85kDa form in invasive colorectal cancer [66].
In

the

ERK-Src

“switch”

model

proposed

for

cortactin

regulation,

cortactin

phosphorylation by Src at Y421, 470 and 486 serves to downregulate N-WASp activity
promoted by S405/418 phosphorylation [46]. This model therefore suggests that serine
and tyrosine phosphorylation of cortactin function in a reciprocal manner to govern NWASp activation [58]. Our data with site-specific phosphorylation antibodies on lysates
from EGF-stimulated cells indicates that S405/418 and Y421 are co-phosphorylated,
and analysis of point mutant cortactin constructs does not indicate a reciprocal influence
between cortactin serine and tyrosine phosphorylation events. These data suggest that
cortactin function is not exclusively regulated by a serine-tyrosine “switch” mechanism.
This view is additionally reinforced by the presence of pS418 and pY421 cortactin within
lamellipodia and invadopodia. While our data do not rule out scenarios where such a
mechanism may be employed at the cellular level, they are consistent with biochemical
and cellular evidence indicating that tyrosine phosphorylation promotes N-WASp activity
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through binding of the adaptor Nck1 [37,39], a component that was not present in the
original assays where the “switch” mechanism was defined. The ability of cortactin to
be simultaneously phosphorylated at S405/418 and Y421/470/486 may therefore
provide cells with the ability to fine-tune the level of N-WASp activation and subsequent
actin remodeling in response to diverse upstream stimulatory input that triggers motility
and invasion.
Consistent with the mechanistic descriptions above, inhibition of carcinoma cell motility
by MEK inhibition and S405/418A expression indicates that S405/418 cortactin
phosphorylation is important in promoting and maintaining cell migration. While similar
results were observed in wound healing assays with pancreatic cancer cells [47], our
work extends these findings by evaluating the effects of pS405/418 on lamellipodia
dynamics. The inability of MTLn3 cells expressing S405/418A cortactin to maintain
EGF-stimulated dominant lamellipodia persistence implies that the actin networks within
these cells fail to maintain proper Arp2/3 nucleation, or are more labile following
lamellipodia extension.

While N-WASp activation and Arp2/3-mediated actin

polymerization resultant of cortactin SH3 domain binding has been shown to be
important in governing motility in multiple cell types [47,78], a detailed study of EGFinduced lamellipodia protrusion in this cell type has recently shown that WAVE2 and
formin proteins, not N-WASp, are responsible for lamellipodia protrusion [14]. These
results would therefore rule out a role for direct N-WASp activation by pS405/418
cortactin in MTLn3 lamellipodia extension. In addition to N-WASp, the cortactin SH3
domain interacts with several other proteins that have the potential to directly or
indirectly regulate lamellipodia actin dynamics (reviewed in [62]). In particular, cortactin
binds and activates the Dbl family guanine nucleotide exchange factor faciogenital
dysplasia protein 1 (FGD1) [79,80], a potent activator of Cdc42 [50]. Cdc42 activity is
required for localization of WAVE2 and its activator IRSp53 to the cell membrane,
where it mediates lamellipodia extension [81]. FGD1 also activates the MEK-ERK1/2
pathway [50], allowing the potential of a positive feedback loop in stimulating cortactin
S405/418 phosphorylation through continuous cortactin SH3-mediated FGD1 activity.
FGD1 binding represents just one possible cortactin SH3 domain ligand with the
capability to influence WAVE2 localization and lamellipodia dynamics. Whether such an
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FGD1-based regulatory circuit or other modes of potential pS405/418 cortactin
regulation of WAVE2 activity exist in MTLn3 cells remains to be confirmed.
Previous studies on lamellipodia dynamics in other cells types indicate that cortactin
removal decreases lamellipodia persistence, which can be rescued by re-expression of
a cortactin amino terminal fragment lacking the carboxyl terminal region [20], eliminating
contributions from pS405/418 in this system. These results differ from our work in
MTLn3 cells, where cortactin removal results in enhanced persistence that can be
rescued by re-expression of wild type cortactin.

It is likely that these observed

differences are due to a combination of different cell types, chemotactic cues, and
analysis of dominant, initial lamellipodia versus steady-state lamellipodia dynamics [62].
Interestingly, inhibition of ERK1/2 signaling during macrophage lamellipodia extension
results in decreased lamellipodia stability, with similar kymograph profiles to EGFstimulated MTLn3 cells with S405/418A expression [64].

These studies provide

supporting evidence for our observations.
Through the use of phosphorylation-specific antibodies, we have analyzed the
localization of cortactin pS405 and pS418 in tumor cells and tissue, as well as the
signaling pathways regulating pS405/418 phosphorylation. Through the use of these
reagents, we have been able to validate and further clarify the role of pS405/418 in
cortactin-based signaling. Our functional studies of carcinoma motility and lamellipodia
dynamics with phosphorylation-null constructs have shed additional light on the role
these phosphorylation events play in regulating lamellipodia function involved in tumor
cell movement.
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Figure Legends
Figure 1 Specificity and validation of pS405 and pS418 phospho-specific cortactin
antibodies.

(A) Phospho-specific recognition of anti-cortactin pS405 and pS418

antibodies. Clarified lysates (50μg) from 1483 cells transfected with Myc-tagged wildtype cortactin (WT), Myc-cortactin S405A, Myc-cortactin S418A or Myc-cortactin
S405A,S418A point mutants were immunoblotted with affinity purified anti-Cort-pS418
(left) and anti-Cort-pS405 (right) antibodies. (B) Localization of pS418 cortactin in areas
of motile and invasive actin dynamics. UMSCC2 cells (top row) were serum starved for
16h prior to stimulation with 100ng/ml EGF for 1 h to induce lamellipodia formation,
while UMSCC1 cells (middle row) were plated on FITC-conjugated gelatin coated
coverslips (pseudocolored white) for 6 h to promote invadopodia formation. Cells were
fixed, permeablized, and labeled with TRITC-phalloidin (Actin), anti-cortactin (Cort) and
anti-cortactin-pS418 antibodies. Arrows denote localization of pS418 cortactin with total
cortactin and F-actin in lamellipodia (top) and to invadopodia (middle) coinciding with
areas of active matrix degradation. Bottom panels are magnified views of the indicated
cellular region.

Bars, 10μm.

(C) Localization of pS418 cortactin in HNSCC tumor

tissue. Serial sections from a patient with invasive HNSCC were processed for
immunohistochemistry with control IgG (Ctl), pS418 cortactin (pS418), total cortactin
(Cort) and phospho-ERK1/2 (pERK) antibodies.

Sections were counterstained with

hematoxylin. Arrowheads indicate areas of peripheral pS418 cortactin and total cortactin
enrichment. Bar, 100μm.
Figure 2

Growth factor-stimulated Erk 1/2 activation mediates phosphorylation of

cortactin at serine 405 and 418. (A) Growth factor-induced phosphorylation of cortactin
S405 and S418. Serum starved UMSCC1 cells were stimulated with EGF (left) or FBS
(right) for the indicated times. Cells were lysed and analyzed by Western blotting with
anti-Cort-pS418 and anti-Cort-pS405 antibodies. Blots were stripped and reprobed with
a pan-cortactin antibody to confirm equal loading (bottom). (B) Pharmacologic MEK
inhibition inhibits cortactin S405 and S418 phosphorylation. UMSSC1 (left) and 1483
(right) cells were serum starved in the presence of the indicated selumetinib
concentrations prior to stimulation with EGF for 20 min. Cortactin immunoprecipitated
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from cell extracts was assayed by Western blotting with anti-Cort- pS418 and anti-CortpS405 antibodies. Blots were stripped and reprobed with pan- cortactin antibody as in
(A) (bottom panels). Selumetinib efficacy was verified by the blotting of lyastes from
selected timepoints with phospho-ERK1/2 (pERK1/2) and pan ERK1/2 antibodies
(bottom). All blots are representative images from 3-4 independent experiments.
Figure 3 EGF-induced conversion of cortactin from 80kDa to 85kDa is impaired by Src
and MEK1/2 inhibition.

EGF induces the p80kDa to p85kDa shift in HNSCC cells.

Serum starved UMSCC2 (A) and 1483 (B) cells were treated with 100ng/ml EGF for the
indicated times. Clarified lysates were assayed by Western blotting with anti- cortactin,
anti-Cort-pS418, anti-cort-pS405, anti-Cort-pY421, anti-Src-pY418, anti-pErk1/2 and
total Erk1/2 antibodies as indicated.

Red bars denote the position of the 85 kDa

cortactin form; black bars denote the 80 kDa form. (C) Inhibition of Src and MEK1/2
kinase activity inhibits the cortactin “shift”. UMSCC2 cells were treated with vehicle
(DMSO), saracatinib, or selumetinib for 16 h in serum free media. Cells were stimulated
with 100ng/ml EGF for 1 h, lysed and analyzed by Western blot analysis with an anticortactin antibody.
Figure 4 Cortactin tyrosine and serine phosphorylation resultant of v-Src activation are
not interdependent. (A) Schematic diagram of the cortactin point mutant constructs
assayed for phosphorylation. Mutated codons are denoted on the left and displayed
with the corresponding mutant amino acid at the appropriate position within cortactin in
red.

(B) Murine fibroblasts lacking endogenous Src, Yes and Fyn (SYF) were

transfected with murine-specific cortactin siRNA and cultured for 48 h to deplete
endogenous cortactin. Cells were subsequently co-transected with the temperaturesensitive v-Src construct La29 (tsLa29) and wild-type or the indicated myc- tagged
human cortactin point-mutant constructs at 41°C (non-permissive temperature). TPM;
triple point mutant consisting of Y-F mutations at positions 421, 470 and 486. After
transfection, cells were cultured at 41°C, then shifted to 35°C (permissive temperature)
for 2 h to promote v-Src activation. Recombinant cortactin proteins were assayed by
immunoblotting with anti-cortactin-pY421, anti-cortactin-pS405, anti-myc, anti-cortactin,
and anti-β-actin antibodies. Note that the inability of cortactin to be phosphorylated on
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Y421 does not impact its ability to be phosphorylated on S405, nor does lack of S405
phosphorylation impact Y421 phosphorylation.
Figure 5

Targeted inhibition of MEK1/2 inhibits HNSCC cell motility.

1483 and

UMSCC1 cells (5x105) were starved for 24 h in the presence of vehicle (DMSO) or
increasing concentrations of selumetinib as indicated. Cells were assayed for motility
by electric substrate impedance sensing (ECIS) following stimulation with complete
media containing the matched selumetinib concentration for 24 h. Data is displayed as
slope values calculated from the linear part of ECIS tracings. Bars represent mean ±
SE. *, p < 0.05 compared to DMSO treated control cells.
Figure 6 Cortactin phosphorylation at serine 405 and 418 regulates carcinoma cell
migration and adhesion. (A) Expression of GFP-cortactin constructs in MTLn3 cells.
MTLn3 cells were transfected with murine-specific cortactin siRNA (Si) for 48 h to
silence endogenous cortactin expression. Cells were subsequently transfected with the
indicated

human

GFP-tagged

cortactin

wild-type

and

the

various

Erk1/2

phosphorylation-null point mutant constructs. Following transfection, cell lysates were
immunoblotted with anti-cortactin, anti-GFP and anti-β-actin antibodies.

Solid

arrowheads indicate the position of GFP-tagged cortactin variants; open arrowheads
denote the position of endogenous cortactin. (B) Serine 405 and 418 phosphorylation is
required for efficient carcinoma cell motility. MTLn3 cells transfected as in (A) were
analyzed for cell migration by ECIS.

Cell impedance versus time plots for each

transfected line are shown on the left; slope values calculated from the linear region of
each plot are displayed on the right.

(C) Carcinoma cell spreading requires

phosphorylation of cortactin S405 and S418. Transfected MTLn3 cells were plated, with
rates of spreading were monitored by ECIS tracings over time left. Slope values from
the linear regions are shown on the right. Bars represent mean ± SE for 3 independent
experiments. *, P < 0.05 compared to control (ctl) cells.
Figure 7 Cortactin phosphorylation at serine 405 and 418 is required for lamellipodia
persistence. (A) Kymographic analysis of MTLn3 lamellipodia. Serum starved MTLn3
cells (Ctl) or cells transfected with the indicated cortactin siRNA and cortactin constructs
were monitored for dominant lamellipodia formation by live cell imaging following EGF
183

stimulation. Quantification of lamellipodia protrusion rates, length of extension, and time
of lamellipodia persistence are shown for each experimental condition. > 10 cells were
analyzed for each group from > 3 independent experiments.

(B) Representative

kymograms of each cell type. Kymograms were constructed from 1-pixel wide lines
drawn from the initial leading edge and in the direction of the dominant lamellipodia.
Cells were visualized by fluorescent microscopy using mCherry-β-actin as the
lamellipodia marker. Images were captured every 5 sec for a period of 15 min. Black
lines denote the baseline position of the leading edge prior to EGF stimulation. Bar; 5
µm.
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General Discussion
The successful treatment of CML and GIST patients with imatinib makes it an attractive
chemotherapeutic agent for solid tumor types with elevated Abl activity (1-5).
Unfortunately, single agent imatinib phase I and II trials have demonstrated little benefit
for breast or pancreatic cancer patients. Furthermore, imatinib treatment of prostate,
NSCLC, and HNSCC patients in clinical trials had deleterious effects, resulting in
enhanced tumor progression (6-10,10-12). The poor response rate for chemotherapy
targeting Abl in solid tumors may be attributed to the consequential oncogenic effects of
Abl inhibition in these specific diseases.
On one hand, Abl family kinases enhance tumor proliferation and invasion in breast,
melanoma, gastric and NSCLC (1,1-5,13-16). Conversely, Abl family kinases have also
been shown to inhibit TGFβ induced EMT, tumor growth, and/or motility in breast
cancer. Moreover, thyroid cancer cells treated with imatinib results in enhanced cell
migration. In vivo, imatinib treatment increases breast cancer tumor size in xenograft
mouse models, and; in vitro analysis of imatinib treated MA-11 breast cancer cells
demonstrated enhanced migration, elevated Erk 1/2 and Wnt signaling (17-20). Study 1
provides additional insight into the divergent roles of Abl in tumor invasion by showing
that Abl regulates invasive signaling in a tumor type specific manner (21). This work
confirmed the published pro-invasive Abl family kinases activity in breast cancer
invadopodia formation and 3-D collagen invasion utilizing the common MDA-MB-231
cell line (4,5), as well as demonstrating an opposing role for Abl in HNSCC invasion
where Abl functions an invasion suppressor.
Study 1 demonstrates elevated basal activation of Src and EGFR in HNSCC compared
to MDA-MB-231 cells.

Elevated Src activation in HNSCC can regulate ECM

degradation and invasion by bypassing Abl family kinase regulation, contrary to the
proposed EGFR/Src/Arg/Cortactin-mediated regulation of invadopodia maturation
published by the Koleske group (4).

In HNSCC, Src activity is responsible for the

increased ECM-degradative activity of invadopodia induced by inhibition of Abl kinase
activation by imatinib or RNAi.
examined in Study 2.

The regulatory role of Src in HNSCC was further

The efficacy of the dual Src/Abl inhibitor saracatinib was
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demonstrated in HNSCC cell lines by Western blot analysis of Src substrate
phosphorylation sites in FAK, p130Cas and cortactin. Study 2 confirmed the regulatory
role of Src by the inhibition of invadopodia formation and activity, matrigel invasion and
metastasis in vivo. Interestingly, analysis of CML cell lines resistant to the Abl-specific
inhibitor nilotinib with overexpression of the Src-family member Lyn regained sensitivity
to nilotinib when Lyn was removed by RNAi (22,23). Similar results were observed with
imatinib-resistant human GIST xenograph models, where resistant tumors had integrinmediated elevated Src and Lyn activation (24). Collectively, these reports and the
studies herein indicate that elevated Src kinase activity supersedes any pro- or antiinvasive role governed by Abl. In addition, these studies suggest the activation of Src
resultant from Abl inhibition observed in Study 1 is not specific to HNSCC.
To determine the molecular mechanism for imatinib-mediated activation of Src in
HNSCC and subsequent enhanced invadopodia proteolytic activity and invasion, we
examined the activation of EGFR and Erk 1/2, two key components of invadopodia
regulation. In Study 1, EGFR and Erk 1/2 activity were elevated in imatinib-treated
HNSCC, but not in MDA-MB-231 cells. The increased Erk1/2 phosphorylation achieved
with Abl family kinase inhibition is contrary to current dogma, where the
RAS/RAF/MEK/Erk signaling pathway is activated by either BCR-Abl or integrinmediated c-Abl activity (25-27). Unexpectedly, increased phosphorylation of Erk 1/2 is
frequently observed in imatinib-resistant CML cells and other tumor types. CD34+,BCRAbl+ progenitor leukemic cells treated with imatinib or nilotinib results in enhanced Erk
1/2 activation (28).

Imatinib also stimulates elevated phosphorylation of Erk 1/2,

PI3K/Akt, and Stat3 in PDGFRβ expressing glioblastoma cells (29).

Conversely,

imatinib treated colon adenocarcinoma cells display apoptosis and disrupted F-actin
cytoskeletal networks (30). Such studies further highlight the need for better insight into
the mechanisms utilized by tumors to acquire imatinib or nilotinib resistance if these
compounds are to be considered for widespread use in solid tumors, as well as for
current treatment of CML and GIST patients where imatinib and nilotinib forms an
important part of the standard of care for these individuals.
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Along these lines, Packer et. al. have examined all known components of the
RAS/RAF/MEK/Erk1/2 signaling pathway in an imatinib-resistant CML cell line,
determining that imatinib induces activation of RAF and MEK in addition to Erk1/2.
Cells lines from solid tumors were compared that contained constitutive inactivation of
this pathway due to upstream KRAS mutation. When treated with imatinib, nilotinib or
dasatinib, the RAF isoform BRAF was inhibited, but the related form CRAF was partially
activated by heterodimerization with inactive BRAF, presenting a possible mechanism
for imatinib activation of Erk1/2 (31). This is supported by the observation of CRAF
hyperactivation in melanoma and thyroid cancer patients containing inactivating BRAF
V600E mutations (32). MDA-MB-231 cells contain an activating KRAS mutation that
hyperactivates KRAS/RAF/MEK/Erk1/2 and potentially diminishes the effect of imatinibinduced CRAF activation. This creates a plausible explanation for divergent effects
observed with imatinib treatment between our HNSCC cell lines (UMSCC1 and OSC19)
and MDA-MB-231. However, this mechanism does not explain the increased ECM
degradation observed in UMSCC1 cells with Abl knocked-down seen in Study 1.
Elevated expression and secretion of HB-EGF in imatinib-treated HNSCC cell lines was
shown by our laboratory (Study 1) and others (33), presenting an alternate mechanism
for imatinib-mediated induction of EGFR, Src, and Erk 1/2 activity. Nevertheless, HBEGF is likely not the only cytokine up-regulated in HNSCC with imatinib treatment.
Imatinib exposure enhanced ephrin and osteonectin in BCR-Abl+ leukemic cell lines
(34,35).
Cortactin is overexpressed in HNSCC and other cancers and correlates with poor
prognosis (36-40).

Elevated cortactin tyrosine phosphorylation is associated with

increased invasion and metastasis (13,14,21,41-46). Cortactin is also phosphorylated
by Erk 1/2 at serine sites 405 and 418, but little was known of the effects of cortactin
serine phosphorylation on invasion and metastasis (47).

Martinez-Quiles et al

demonstrated cortactin serine phosphorylation increased N-WASp binding to the SH3
domain of cortactin, enhancing cortactin-mediated activation of Arp 2/3 actin
polymerization (48). Study 3 further elucidated the effect of cortactin phosphorylation by
Erk 1/2 on cancer cell motility and lamellipodia function.
194

Serine 405/418

phosphorylation resulted in increased adhesion and motility with in EGF-stimulated
HNSCC cells. This motility enhancement can be attributed in part to an increase in
lamellipodia persistence. Our laboratory (Study 3) and others have shown that cortactin
serine phosphorylation and interaction with p120 catenin are essential for lamellipodia
persistence and lamellipodial-mediated ECM recycling (49,50).

Cortactin serine

phosphorylation by Erk 1/2 also modulates invadopodia formation and proteolytic
activity (51). These results collectively support a role for Erk 1/2 phosphorylation of
cortactin in regulating motility structures utilized for amoeboid, mesenchymal and
collective cell motility and invasion (52).
Imatinib treatment enhances Erk 1/2, Src, and/or EGFR phosphorylation in HNSCC,
CML and other tumor types. Our laboratory and others have demonstrated that imatinib
can increase or decrease invasion and metastasis by activating or inhibiting key
components of these processes- namely Erk1/2, Src, and EGFR. Abl appears to be a
key component in mediating these divergent effects and can function as an anti- or prooncogenic protein dependent on cellular context. The regulating mechanism(s) that
modulate the dichotomous roles of Abl in tumor motility are currently unknown. An
understanding of this complex process is crucial as the use of imatinib expands to solid
tumors in the clinic in order to prevent detrimental effects to patients undergoing
imatinib treatment.
Imatinib is the first successful targeted kinase inhibitor that moved from the bench to the
clinic, ushering in the era of modern targeted therapeutic intervention in cancer. The
efficacy of these targeted therapies has been mixed, from the success of imatinib to the
puzzling lack of response with dasatinib in phase II and III trials where preclinical work
showed great promise. Why certain targets are more effective than others when
therapeutically inhibited is not fully understood, nor are the compensatory mechanisms
tumor cells utilize to overcome targeted therapies in developing drug resistance.
Drug resistance has been attributed to three main reasons; the heterogeneity of tumors
that enable a subset of tumors cells (likely tumor initiating stem cells) to survive
chemotherapeutic agents, the complexity of the microenvironment (cellular and noncellular) providing a protective niche for the tumor cells; and tumor cell plasticity (53).
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Tumor plasticity allows the tumor to reversibly change and adapt their phenotype to
intrinsic and external cues without permanently altering genomic DNA. EMT confers
stem cell like properties and chemoresistance in tumor cells. Transcription factors such
as Zeb1, Twist, and Snail are key components that regulate EMT and are current areas
of intense focus in efforts to reverse molecular and phenotypic elements of
transformation (54). However, it is clear that EMT is not the sole factor regulating tumor
plasticity (55), as our work and others indicates that adaptive kinase responses play
important roles in mediating drug resistance (21,28,29).

Duncan et. al. utilized an

innovative multiplexed inhibitor beads (MIBs) system that binds over 60% of the kinase
kinome to examine the rapid kinome reprogramming induced by MEK inhibitor treatment
of triple negative breast cancer (56). MIBs are generated by immobilizing several broad
kinase inhibitors to sepharose beads. MIBs selectively bind active kinases due to the
general mechanism utilized by kinase inhibitors, blocking the ATP binding sites; this
allows the monitoring of altered activity of over a hundred kinases simultaneously (56).
Our work demonstrates kinase “reprogramming” within hours after drug treatment
enhances HNSCC metastasis and invasion making imatinib an interesting candidate for
this process. The dichotomous functions of Abl in different cancer types suggest that it
may play a key regulatory role in governing tumor plasticity responsible for facilitating
drug resistance.
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Supplemental Figure 1 Confocal imaging of additional HNSCC cell lines
assayed for Src activity and invadopodia-forming capability in Fig 1A. (A) The
FADU and MSK921 HNSCC cell lines were incubated on FITC-coated gelatin
(white) coverslips for 12 hours, then fixed and labeled with TRITC−phalloidin
(red), and cortactin (green) (top panels). Both lines fail to make endogenous
invadopodia or degrade matrix. (B) FADU and MSK921 cells transfected with
Src527F−mCh (red) were incubated on FITC-coated gelatin (white) coverslips for
12 hours, then fixed and labeled with cortactin (green) (top panels). Src-induced
invadopodia are present and identified by the cortactin aggregates (white arrows)
that localize with Src527F and the dark holes in the FITC-gelatin (black arrows).
Scale bars: 10 µm.
Kelley LC, et al. J Cell Sci 2010 Nov 15;123(Pt 22):3923-3932.
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Supplemental Figure 2 Src regulates invadopodia maturation in OSC19 cells.
(A) Src protein levels in OSC19 cells treated with with Src shRNA (SrcSh) or a
shRNA vector control (Ctl). Expression SrcWT (WT) or Src527F (527) in Ctl and
SrcSh cells evaluated by immunoblotting (B) and confocal microscopy (C). Cells
were plated on FITC−gelatin-coated (pseudocolored white) coverslips for 10
hours and immunolabeled with TRITC−phalloidin (red). Scale bars: 10 µm. (D)
The effect of Src expression on percentage of cells displaying invadopodia, the
number of invadopodia per cell, and the amount of matrix degradation per cell
were examined. Data are represented as mean ± s.e.m., groups are statically
different (*P&λτ;0.01, **P&λτ;0.05).
Kelley LC, et al. J Cell Sci 2010 Nov 15;123(Pt 22):3923-3932.
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Supplemental Figure 3 (A) Invadopodia are formed in cells expressing tsLa29−GFP at
the permissive temperature. SYF cells transfected with empty GFP vector (EV) or with
tsLa29 tagged with GFP on the C-terminus (tsLa29−GFP) were incubated at 41°C or
35°C. Cells were fixed, permeabilized, and dual-labeled with TRITC-phalloidin and a
phospho-specific antibody for cortactin Tyr421. Cells were visualized by confocal
microscopy through 2D and 3D (z-stack) sectioning. (B) Silencing of cortactin with
siRNA prevents invadopodia formation. SYF cells were transfected with cortactintargeted or control siRNA (Ctl) and incubated at 37°C for 2 days. Cells were then
transfected with tsLa29−GFP and the experiment proceeded as described in A. Cells
were fixed, permeabilized, and immunolabeled with TRITC-phalloidin and an anticortactin (4F11) antibody. Invadopodia fail to form in cells treated with cortactin siRNA.
(C) Clarified cell lysates (30µg) from cells transfected with mock siRNA or siRNA to
knock down cortactin, alone or in combination with tsLa29−GFP, were incubated at
41°C or 35°C, resolved by SDS-PAGE and immunoblotted with anti-Src-pY418, anti-Src
(EC10), anti-cortactin (4F11), anti-cortactin-pY421, anti-GFP (JL8) and anti-β-actin
antibodies. Scale bars: 10 µm.
Kelley LC, et al. J Cell Sci 2010 Nov 15;123(Pt 22):3923-3932.
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Supplemental Figure 4 Characterization of fluorescent protein-tagged Src constructs.
(A) Determination of relative Src kinase activity. SYF cells expressing Src-GFP, Srccerulean, Src527F-GFP, Src527F-mCherry, Src295M−GFP, or Src295M-cerulean were
lysed, resolved by SDS-PAGE and immunoblotted with anti-Src-pY418, anti-Src, and
anti-β-actin antibodies. Quantification of the relative Src phospohorylation in transfected
SYF cells was conducted using densitometry. Src-pY18 protein expression was
normalized to total Src protein levels. (B) Swept-field imaging of fluorescently labeled
Src constructs. Fixed cells were imaged for expression and localization of GFP,
mCherry, and cerulean-tagged Src fluorescent proteins by direct fluorescence. GFP,
green fluorescent protein; CerFP, cerulean fluorescent protein; mChFP, mCherry
fluorescent protein. (C) Confocal imaging of GFP-tagged SrcWT, Src295M, and
Src527F. Transfected cells expressing the indicated Src constructs were fixed,
permeabilized and immunolabeled with TRITC-phalloidin and the anti-cortactin (4F11)
antibody. Arrows indicate invadopodia in cells expressing Src527F. Scale bars: 10 µm.
Kelley LC, et al. J Cell Sci 2010 Nov 15;123(Pt 22):3923-3932.
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Supplemental Figure 5
Cotransfection and localization of
fluorescent protein tagged Src
constructs. (A) Representative
images of non-transfected SYF
cells (left) and SYF cells coexpressing WT Src tagged with
Cerulean fluorescent protein
(Src-Cer)
and
GFP-tagged
Src527F (527F−GFP) (right).
Cells were fixed, permeabilized
and
immunolabeled
with
TRITC−phalloidin
and
anticortactin
(4F11)
antibody.
Arrows denote invadopodia in
the
527F−GFP-transfected
cells. Scale bar: 20µm. (B) SYF
and SYF+/+ cells expressing
cSrc527F−mCherry alone or in
combination with Src−cerulean
or Src295M−cerulean, were
lysed and resolved by SDSPAGE and immunoblotted with
anti-Src-pY418, anti-Src, antiGFP or anti-cerulean (JL8, does
not recognize mCherry), antiactin, anti-cortactin-pY421 and
anti-cortactin (4F11) antibodies.
Kelley LC, et al. J Cell Sci 2010 Nov 15;123(Pt 22):3923-3932.

243

Supplemental Figure 6
Comprehensive SH2 and PTB
binding assay. An in vitro binding
assay was performed using 91 GST
SH2 domains and three GST PTB
domains, representing nearly the full
complement
of
human
phosphotyrosine-binding domains.
GST and mutated Abl SH2 domain
(Abl R>K) were used as negative
controls. SH2 binding to SYF cell
lysate
was
determined
by
densitometric
quantification
of
digitally
captured
chemiluminescence images. The
mean raw binding intensities with
s.e.m. from two independent
experiments are shown. Domains
are ordered from left to right by their
binding intensity to SYF+/+ cells
expressing Src527F to reflect rank
order relevance for invadopodia
maturation.
Kelley LC, et al. J Cell Sci 2010 Nov
15;123(Pt 22):3923-3932.
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